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Abstract 
This study aimed to investigate the pharmacology of selected pyrrolobenzodiazepine 
(PBD) compounds shown to have cytotoxic activity with predicted DNA sequence 
selectivity.  Research focused upon the PBD dimer, SJG-136, selected for clinical trials, 
and the novel PBD monomer compounds D709119, MMY-SJG and SJG-303. 
SJG-136, a novel sequence-selective DNA minor groove cross-linking agent, was 
shown to have potent tumour cell type selective cytotoxicity in in vitro assays. 
Pharmacokinetic studies in mice via both the i.p. and i.v. route (dosed at the maximum 
tolerated dose (MTD)) showed that SJG-136 reaches concentrations in plasma well in 
excess of the in vitro IC50 values for 1 h exposure, and was detected in tumour and brain 
samples also above the in vitro IC50 values.  Furthermore, SJG-136 showed linear 
pharmacokinetics over a 3-fold drug dose range.  Metabolism studies showed SJG-136 
is readily metabolised in vitro by hepatic microsomes, predominantly to a 
monodemethylated metabolite; this metabolite could be detected in vivo.  Analytical 
method development work was also conducted for the imminent Phase I clinical trial of 
SJG-136 resulting in a sensitive and selective bio-analytical detection protocol.  Comet 
analysis showed that SJG-136 dosed at the MTD and ⅓MTD causes significant 
interstrand DNA cross-linking in lymphocytes in vivo.  In vitro studies demonstrated 
that SJG-136 localises within the cell nucleus, and acts to disrupt cell division via a 
G2/M block in the cell cycle at realistic concentrations and exposure times that are 
achievable in vivo. 
In vivo pharmacokinetic studies of D709119 showed the compound is easily detectable 
in mouse plasma following i.p. dosing at the MTD, but could not be detected in either 
tumour or brain samples.  In vitro cytotoxicity studies revealed D709119 to have potent 
activity across a selection of tumour cell lines. 
SJG-136, D709119, MMY-SJG, SJG-303 and DC-81 demonstrated a non-enzyme-
catalysed reactivity with the biologically relevant thiol, reduced glutathione (GSH). 
Studies demonstrated that reactivity of the PBD compounds toward GSH was dependent 
on GSH concentrations.  At levels of GSH found in plasma, the PBD compounds 
showed considerably lower reactivity with GSH than at intracellular GSH levels. 
SJG-136 and D709119 also showed favourable pharmacokinetic profiles in mice, and 
warrant further study for anti-tumour activity in vivo and progression to use in patients.  
Keywords: Pyrrolobenzodiazepine (PBD), anti-cancer, SJG-136, D709119, DNA-
interactive agent, pharmacokinetics, pharmacodynamics, HPLC, glutathione, pre-
clinical 
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1 What is Cancer? 
 
1.1 The history of cancer 
Cancer has become an increasingly prominent disease and is one of the leading causes 
of death in the western world, although the disease itself has ancient roots. 
 
The Greek physician Hippocrates is thought to have originated the word “cancer” used 
today, due to his usage of the terms “carcinos” and “carcinoma”, to describe non-ulcer 
forming and ulcer-forming tumours.  These words refer to a crab in Greek, and were 
used to describe the finger-like projections formed by the tumour.  Hippocrates believed 
the body contained four humours or body fluids, blood, phlegm, yellow bile, and black 
bile.  Good health was thought to depend upon a balance of these fluids, and imbalance 
was considered to cause illness and disease.  Cancer was thought to arise from an excess 
of black bile.  This theory was widely accepted and held sway for over 1300 years, 
perhaps a result of religious prohibitions preventing the study of the body and thereby 
disallowing practices such as autopsy (Diamandopoulos, 1996). 
 
One of the theories that replaced the humoral theory proposed by Hippocrates suggested 
the formation of cancer from another body fluid, lymph.  At this point in time (18th 
century), life was thought to consist of the continuous movement of fluids through 
solids; blood and lymph were thought to be the most important of these fluids.  
Proposed by Stahl and Hofman, it was believed that cancer was composed of 
fermenting and degenerating lymph, varying in density, acidity and alkalinity 
(Diamandopoulos, 1996). 
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An investigation by Sir Percival Pott in 1775 provided one of the first scientific studies 
into the cause of cancer (Shindell & Goldberg, 1981).  This linked the high incidence of 
death from cancer of the scrotum in males in their twenties to earlier occupation as 
chimneysweeps, and suggested that the causative agent responsible was soot.  This 
study identified both a suspected carcinogen, and further characterised cancer as a 
disease with a notable latent period. 
 
Johannes Muller, a German pathologist, demonstrated in 1838 that cancer is composed 
of cells, not lymph.  However, he believed that cancer cells did not originate from 
normal cells, but from budding elements (blastema) between normal tissue.  It was his 
student, Rudolf Virchow, who determined that all cells (including cancer cells) are 
derived from other cells (Diamandopoulos, 1996). 
 
The recognition of cancer as a condition arising from the uncontrolled proliferation of 
cells was not possible until the advent of the microscope.  Examination by the eminent 
19th century pathologist Rudolf Virchow, prompted the declaration that “every cell is 
born from another cell”.  Consequently cancer became established as a cellular disease, 
and the science of oncology was born.  This enhanced the ability and usefulness of 
surgery for cancer treatment, as body tissues removed by the surgeon could now be 
microscopically examined and a precise diagnosis could be made (Ackerknecht, 1953).  
Virchow proposed that cancer is caused by chronic irritation.  He also believed that 
cancers could spread “like a liquid”.  It was shown later by a German surgeon, Karl 
Thiersch, that cancers metastasise through the spread of malignant cells in the 
bloodstream. 
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A theory that was entertained for much of the 17th and 18th centuries was that cancer 
may be contagious.  This manifested itself predominantly in France; the first cancer 
hospital there was forced to move out of Paris in 1779 as a result of fears that cancer 
may spread through the city.  In a similar vein, a Nobel Prize was mistakenly awarded 
in 1926 for work which indicated that cancer could be caused by a parasitic worm (e-
Museum, 1926).  The parasite theory was not confirmed, and rapidly fell out of favour. 
 
1.2 Cancer – the problem 
Despite numerous medical advances in the treatment of cancer, it remains a significant 
health problem.  During 2001, in the UK alone malignant neoplasm (excluding benign, 
in situ, other and unspecified neoplasms) was responsible for 154,460 deaths.  This 
places cancer as the cause of a quarter (26%) of all deaths in the UK (Cancer Research 
UK, 2003).  Additionally, more than 262,000 new cases of cancer were diagnosed in the 
UK in 1998 (Cancer Research UK, 2002).  Excluding non-melanoma skin cancers, the 
three most common cancers are responsible for the largest number of deaths; 22% of 
deaths are attributed to lung cancer, cancers of the large bowel (colon and rectum) are 
responsible for 10%, and breast cancer (despite a very low incidence in men) is 
responsible for 8% of all cancer deaths (Cancer Research UK, 2002; 2003).  While there 
are over 200 different types of cancer only a few occur frequently, and of these lung, 
breast, large bowel (colorectal) and prostate account for over half of new cases (Cancer 
Research UK, 2002). 
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1.3 The biology of cancer 
 
1.3.1 What is cancer? 
Cancer is a broad umbrella term used to describe any of over a hundred different 
diseases characterised by uncontrolled cell proliferation.  It is important to be aware of 
the distinction between different types of cancer, as the clinical implication and 
outcome for a patient can be vastly different depending on the type and location of 
cancer manifested.  This is further complicated as cancers arising from the same cell-
type can behave differently. 
 
There are somewhere in the region of 5 x 1013 cells which make up the component parts 
of the human body, and each of these cells is carefully controlled and regulated in order 
to meet the needs of the body as a whole.  Bearing in mind that the entire body 
originates from the formation of one cell from the fusion of two gametes, there are a 
vast number of cell divisions occurring to form the final organism.  This system is 
subjected to tight and rigorous control to ensure that the rate at which cells are formed 
matches that at which cells are removed (Ruddon, 1995). 
 
Cancer results from a defect in the regulation of cell growth and proliferation.  A single 
cancerous cell can divide to form two cells; the two cancerous cells can further split to 
form four, and the rate of growth can continue onwards exponentially.  Thus a tumour 
can be formed from the malfunction of a single cell.  If this cancerous growth goes 
unchecked, it can progress to invade surrounding tissue, enter the circulation and 
spread, and interfere with the normal functions of the body ultimately leading to the 
death of the individual (Ruddon, 1995). 
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1.3.2 Types of cancer / cancer classification 
There is a major distinction between types of neoplasm: benign (non-cancerous) or 
malignant (cancerous).  The primary characteristic of a benign neoplasm is the 
confinement of the growth to its original location.  It is generally enclosed in a fibrous 
capsule, and does not invade surrounding tissue or metastasise to other parts of the 
body.  The common skin wart is an example of a benign growth and, as it is localised, it 
is almost invariably treatable by surgery resulting in the total removal of neoplastic 
cells.  The complete removal of the neoplastic tissue and lack of invasive characteristics 
mean that this type of tumour is generally not life-threatening unless it occurs in an 
inoperable location.  Benign growths tend to grow relatively slowly, and more closely 
resemble their tissue of origin than their malignant counterparts (Ruddon, 1995). 
 
Alternatively the growth may be malignant; this can both invade adjacent tissue, and 
can spread to become established in other parts of the body via metastasis.  Malignant 
neoplasms are growths generally considered to be cancers.  It is the ability of these 
tumours to invade normal non-neoplastic tissue, and to spread to other parts of the body 
(metastasise) that makes this growth highly dangerous and difficult to treat.  Once 
metastases (secondary growths that have travelled to other parts of the body) have 
become established in other areas of the body the option to completely remove the 
cancer by localised surgery is no longer possible, and alternative modes of treatment 
become necessary (Ruddon, 1995). 
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1.3.3 Cancer classification 
Neoplasms are classified according to the type of cell and tissue from which they 
originate.  There is a subdivision into three types of malignant tumour: the carcinomas, 
sarcomas, lymphomas and leukaemias.  Approximately 90% of human cancers fall into 
the carcinoma classification, and are a result of malignancies formed from epithelial 
cells.  Sarcomas are formed from connective tissues such as muscle and bone, and are 
rare in humans.  Lymphomas and leukaemias constitute about 8% of human cancers, 
and are cancers derived from cells of the lymphatic and blood systems, respectively 
(Franks & Teich, 1997). 
 
The diversity of cancers and the complexity of classification has resulted in the 
development of clinical staging systems in order to describe the extent of tumour 
progression.  One of the most common techniques for classifying cancers is known as 
the TNM (Tumour, Node, Metastasis) system.  This system can be used to describe the 
size of a primary tumour, whether the cancer has spread to the lymph nodes, and 
whether the cancer has metastasised to other parts of the body.  An example of this 
staging system can be seen in Table 1.1. 
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Classification Description 
Primary Tumour  
Tis Means ‘in situ’ – cancerous cells have been found but they have 
not yet begun to move into surrounding tissues in the testicle. 
T1 Means the tumour is contained within the testicle and epididymis. 
T2 Means there are signs that the tumour has grown into blood or 
lymphatic vessels. 
T3 Means the tumour has grown as far as the spermatic cord (and 
there are may also be blood or lymphatic vessel involvement). 
T4 Means the tumour has grown into the scrotum. 
Regional Lymph 
Nodes 
 
N0 There are no lymph nodes containing cancer cells. 
N1 The lymph nodes are all smaller than 2 cm across. 
N2 At least one of the lymph nodes is bigger than 2 cm, but smaller 
than 5 cm across. 
N3 At least one of the lymph nodes is bigger than 5 cm across. 
Distant 
Metastases 
 
M0 Means there are no signs of spread to other body organs. 
M1a Means there is cancer spread to the lungs OR there are lymph 
nodes a long way from the testicles, for example near the collar 
bone. 
M1b Means there is spread to other body organs such as the liver or 
brain. 
Table 1.1  The TNM system of tumour classification for testicular cancer (adapted 
from the Cancer Research UK website, www.cancerhelp.co.uk). 
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1.4 Causes of cancer 
 
1.4.1 What leads to tumour formation? 
In normal continually renewing tissue there are two types of cell: (i) the stem cell, 
which has a high capacity for proliferation (although normally the rate of division is 
slow), and (ii) the differentiated cell, which arises from a stem cell but has progressed 
through a process of maturation and differentiation to become a particular type of cell.  
A stem cell normally divides asymmetrically producing two daughter cells, one of 
which retains its growth potential and remains a stem cell (a copy of the mother cell), 
whereas the other becomes a differentiated cell.  In most cases tumours arise from a 
single transformed stem cell, rather than from a differentiated cell. 
 
There is an extensive amount of evidence that genetic mutation can cause cancer.  This 
can include changes within the genome such as insertions, deletions, point mutations, 
translocations or amplifications.  It was observed by Ames (Ames, 1983) that the 
majority of carcinogens are also mutagens.  There are findings that show that 
genetically determined traits associated with a deficiency in DNA repair enzymes can 
be linked with incidence of cancer.  This led to the general acceptance of a genetic 
component to cancer formation, and therefore the link that damage to genetic material 
could lead to tumour formation. 
 
Initiation of tumour formation can occur in several ways.  The mechanisms by which 
this may transpire are: 
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• Activation of oncogenes.  Often this involves the conversion of a proto-oncogene 
into an activated oncogene.  Oncogenes can be activated by mutations, viral 
oncogenesis (insertion of an oncogene by a viral vector), gene amplification, or by 
chromosomal abnormalities.  Viral oncogenesis is relatively rare and results from 
either the incorporation of viral sequences (normally modified versions of proto-
oncogenes) into the host genome, from insertional mutagenesis (viral integration 
into host DNA causing the disruption of a host growth control factor), or by 
transactivation of an unrelated growth regulatory protein by a virally encoded 
protein (Hodgson & Maher, 1999). 
• Inactivation of tumour suppressor genes.  Tumour suppressor genes act in a 
recessive manner as the loss of a tumour suppressor gene may lead to tumour 
formation.  An example of this is the tumour suppressor gene, p53.  p53 has been 
shown to initiate apoptosis in cells that have been subjected to DNA-damaging 
agents, such as ionising γ radiation and various chemotherapy agents (Canman & 
Kastan, 1995).  Hence loss of the p53 gene can result in the survival of cells with 
DNA damage, and the potential for the accumulation of mutations may result in the 
activation of oncogenic factors.  The mechanisms by which p53 elicits its effects are 
still not fully understood, although it is widely agreed that p53 plays an important 
role in the cellular response to DNA damage. 
• Heritable cancer.  This type of cancer is usually caused by inheritance of a 
defective DNA repair mechanism, a metabolism that is overly efficient at 
metabolising chemicals into carcinogens, or an inappropriate immune response.  A 
defect in DNA repair mechanisms can lead to conditions such as retinoblastoma (a 
tumour of the eye) and familial adenomatous polyposis (a predisposition to 
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colorectal cancer), both of which are dominantly inherited (Hodgson & Maher, 
1999). 
 
1.4.2 Environmental aspects of cancer 
A high proportion of cancer is attributed to environmental factors, with categories 
ranging from the use of substances such as tobacco and alcohol, to the more general 
categories of diet and exposure to solar radiation.  In the USA, there is evidence that 
over 70% of cancers are linked to environmental factors, and therefore are potentially 
avoidable (Doll & Peto, 1981). 
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2 Treatment of Cancer 
 
2.1 Surgery 
Surgery is the primary and most preferred method of treating cancer.  Correctly used, 
surgery can often eradicate primary or localised disease.  Even in a situation where a 
cancer is not confined to one region of the body the removal of a large focal tumour 
mass may help by lowering the overall tumour burden.  For the removal of easily 
operable neoplasms, such as the basal cell carcinoma (the commonest form of skin 
cancer), surgical procedures such as curettage and cautery, surgical excision or 
cryotherapy, are commonly used procedures that result in a high cure rate.  In more 
complicated situations, where the tumour has begun to invade surrounding tissue, it is 
common for surgical excision of the growth to be combined with either radiotherapy or 
chemotherapy to increase the likelihood of removing all of the cancerous cells. 
 
2.2 Radiotherapy 
Radiotherapy is similar to surgery as it is primarily useful in the treatment of localised 
cancers, but has the advantage that it can be used to treat cancers that have grown out of 
reach of the surgeons' knife, and have become inoperable.  As radiotherapy is less 
invasive some localised tumours are treated solely with radiation.  Other tumours are 
treated with a combination of surgery and radiation in order to remove the bulk of the 
tumour surgically and eliminate any cancerous cells that may have invaded the 
surrounding tissue with radiotherapy.  As some types of tumour are particularly 
sensitive to radiation, this can be a highly effective tool. 
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Damage by radiation is a noted cause of cancer due to the genetic damage that can occur 
as a result of exposure to non-lethal doses, resulting in random mutations to the host 
DNA.  Used in high doses radiation can result in cell death; this is the main principle of 
radiotherapy.  This method of treatment is similar to surgery, as it is not specific for 
cancerous cells and will also kill normal cells.  This limits the usefulness of radiation 
therapy, as it can pose a highly toxic threat to the patient. Lack of specificity is one of 
the main problems with current treatments for cancer. 
 
There are several types of radiation in use for the treatment of cancer: X-rays or γ 
radiation are used to excite electrons within the biological matter and cause the further 
ionisation of other atoms, and electrons (produced by a particle accelerator) are used to 
directly interact with the atoms of molecules present in the target cells, are two 
examples.  Generally, radiotherapy uses an external radiation source and beams of 
radiation are directed at the tumour in order to destroy the cancerous cells. 
 
In order to control tumour growth by the use of radiotherapy, it is important to consider 
the concept that tumours contain a fraction of cells that have unlimited proliferative 
capacity.  Therefore, in order to control tumour growth all of the tumour stem cells need 
to be killed.  Thus the dose of radiation required to control a tumour depends on both 
the sensitivity of the cells to radiation and the number of cells present.  Many different 
factors can influence the effectiveness of radiotherapy.  This includes the type of 
radiation used, factors that can influence the effectiveness of the radiotherapy such as 
the presence or absence of oxygen (which can alter the dose of low-LET (linear energy 
transfer – X or γ rays) radiation needed by up to 3 times) (Chapman et al., 1974; 
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Cheong et al., 1993; Bristow & Hill, 1998).  Types of radiation used include UV 
radiation, X-rays, β-rays, or γ-rays. 
 
2.3 Chemotherapy 
Chemotherapy is the concept of treating cancer with drugs.  Treatment of cancer in this 
way is thought to be at least 500 years old, when preparations of zinc, mercury and 
silver were used, although the first documented treatment was in 1865 when potassium 
arsenite was used to treat a patient with leukaemia where a positive effect was noted 
(Lissauer, 1865).  However, it was not until some 80 years later that the first successful 
systemic cancer treatment emerged as a spin-off from the development of nitrogen 
mustard for warfare use.  Nitrogen mustard was used in a clinical trial for the treatment 
of lymphosarcoma in 1942, and a review of its effectiveness in the treatment of cancer 
was published in 1946 when it became more widely known.  This publication is 
regarded as marking the beginning of modern cancer chemotherapy (Gilman & Philips, 
1946).  Mechlorethamine, one of the first nitrogen mustards to be shown to be clinically 
effective, is still used today in the treatment of cancer. 
 
2.3.1 Principles and practice 
Currently, chemotherapy is used in clinical practice in one of three roles: 
• As the major curative agent for a few selected malignancies, e.g. Hodgkins 
disease (and other lymphomas), acute leukaemia in children, and testicular 
cancer in males. 
• As a palliative treatment for many types of advanced cancers. 
• As an adjuvant treatment before, during, or after localised treatments (such as 
surgery or radiotherapy) to enhance cell kill and eliminate possible metastases. 
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In addition to the desired antitumour effects, all current anticancer drugs are toxic to 
normal tissue, so there is a limited dose that may be given to a patient before the benefit 
of tumour cytotoxicity develops into the detrimental effects of systemic toxicity.  This 
places a constraint on the clinical efficacy of the drugs.  The overall goal in the 
development and design of antitumour drugs is to widen the therapeutic window and 
allow large doses of drug to be given, without causing major toxicity to normal tissue.  
This has led to many different strategies for enhancing toxicity to tumour cells while 
reducing toxicity to normal tissues, including strategies such as using pro-drugs, 
chemotherapeutic drugs which are not activated until they reach the tumour site, as well 
as the currently used drug therapies. 
 
Chemotherapeutic agents are divided into separate classes based upon their mechanism 
of action or the cellular target upon which they act: 
 
• Antimetabolites.  Interfere with production of nucleic acids.  There are several 
distinct subclasses: 
o Folate antagonists.  Competitive inhibitors of dihydrofolate reductase 
prevent regeneration of reduced folate and lead to diminished DNA 
synthesis due to lack of purines and thymidine monophosphate (Pratt et 
al., 1994). 
o Pyrimidine antagonists.  Inhibitors of thymidylate synthase decrease 
thymidine production resulting in decreased DNA synthesis (Ivanetich & 
Santi, 1988). 
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o Purine antagonists.  Inhibit nucleotide production (at PRPP 
amidotransferase and IMP dehydrogenase) and act as pseudonucleotides 
(Pratt et al., 1994; Moore & Erlichman, 1998). 
o Ribonucleoside reductase inhibitors.  Hydroxyurea destabilises the haem 
centre of ribonucleoside reductase disrupting deoxyribonucleoside 
synthesis (Pratt et al., 1994). 
• Alkylating agents.  Transfer an alkyl group to an intracellular molecule 
(typically an amine, phosphate, sulfhydryl or hydroxyl moiety), forming a 
covalent bond.  Monofunctional (one reactive alkyl group) or bifunctional (two 
reactive alkyl groups and capacity for crosslink formation).  Effects believed to 
be elicited from interaction with DNA bases, causing strand-breakage (Kohn, 
1979; Garcia et al., 1988).  There are several classes: 
o Nitrogen mustards.  N-7 position on guanine is most susceptible position 
for alkylation; form covalent cross-links.  Several in current clinical use. 
o Nitrosoureas.  Bifunctional alkylating agents.  Single clinically useful 
agent (streptozotocin).  Able to cross blood-brain barrier (Moertel et al., 
1992). 
o Alkanesulfonates.  Bifunctional alkylating agents that react with N-7 
position of guanine.  Shown to form interstrand DNA crosslinks (Tong & 
Ludlum, 1980; Bedford & Fox, 1983; Farmer, 1987). 
o Aziridines.  Bifunctional alkylating agents.  Can form DNA crosslinks. 
• Platinum compounds.  Similar mechanism of action to alkylating agents.  
Preferred binding sites at N-7 of guanine and adenine (Roberts et al., 1988).  
Can form interstrand crosslinks and adducts (DNA-DNA binding and DNA-
protein binding) (Fichtinger-Schepman et al., 1987). 
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• DNA-intercalating drugs: 
o Anthracyclines.  Act by intercalating non-covalently and disrupting DNA 
structure and synthesis.  Induce protein-linked double-strand breaks in 
DNA (Glisson et al., 1986; Myers et al., 1988). 
o Mitoxantrone.  Interferes with topoisomerase II function preventing 
reannealing  of DNA strands and causing double-strand protein-linked 
breaks (Harker et al., 1989). 
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3 Anticancer drug development 
 
3.1 A brief history of anticancer drug development 
There have been many different approaches to the development and testing of 
anticancer drugs over the years.  The majority of historic and current drug development 
systems revolve around the use of in vivo screens.  These screens have the advantage 
that the effects of a potential agent can be observed in a whole-body environment, 
taking into account distribution of the drug, metabolic processes and rate of excretion of 
the drug as well as the effect of the drug on the tumour. 
 
The idea of a primary in vivo screen was initially formalised in 1934 at the National 
Cancer Institutes of the USA (NCI) (Zubrod, 1979).  This screen used randomly bred 
mice and the implantation of sarcoma-37.  From the 1940s onwards many other tumours 
of various rodents came into use across the international scientific community, although 
again this used randomly bred animals, and thus rendered the systems highly 
immunogenic.  In 1955, with the establishment of the Cancer Chemotherapy National 
Service Centre, the L1210 leukaemia became the primary screen, which was later 
superseded by the P388 leukaemia.  Approximately 700,000 compounds were put 
through this screen (Frei, 1982).  This practice of in vivo primary screening fell out of 
favour in 1985 with the initiation of the NCI human tumour cell line screen, and 
increasing pressure from ethical issues on the use of animals for a screen showing such 
a low hit-rate for new compounds (less than 0.1% at that time), coupled with the 
significantly lower amount of novel compound needed for evaluation in the in vitro 
system. 
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The advent of modern chemotherapy in the 1940s gave way to the serious usage of in 
vitro chemosensitivity assays for use in the prediction of in vivo cytotoxicity.  Human 
tumour explants were used to assess the cytotoxicity of compounds.  However, many 
factors were uncontrolled in these experiments as chemically defined cell culture 
medium was not available, and purely qualitative measurement was used, factors which 
made assessment of the data difficult.  Improvements to cell culture techniques occurred 
during subsequent years helping to make this type of assay easier and more viable as a 
screening test.  However, it was not until the implementation of the NCI human tumour 
cell line screen that this type of technique was elevated from a pre-screen to a primary 
screen. 
 
While the progression of drugs from synthesis to clinical trials is still evolving, the 
actual clinical phase of drug development has remained relatively consistent.  Phase I 
trials define basic parameters such as maximum tolerated dose (MTD) in a patient (to 
estimate an efficacious dose for use in phase II trials), toxicity of the compound, and 
study the clinical pharmacology of the drug.  Phase II trials are designed to investigate 
therapeutic value of the compound, using information determined in phase I.  Phase III 
trials are used to compare the new therapy to an existing standard to assess whether the 
new therapy has a significant advantage over current treatments. 
 
3.2 The process of drug development 
Much of current anticancer drug development preclinical work revolves around the 
practices put in place by the NCI.  The NCI has a comprehensive human tumour cell 
line screening procedure in place, to which organisations have open access, and 
subsequent in vivo studies (such as hollow fibre and tumour xenograft) as used by the 
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NCI also tend to be used across the board. Thus, current preclinical work tends to 
follow the pattern described in Figure 3.1, with phase II and III trials following on.  The 
usage of a panel of tumour cells has resulted in a shift of drug discovery from the 
previous “compound-oriented” approach to a “disease-oriented” approach, as 
compounds are now tested from the outset with the aim of finding out which tumour 
cell line the compound will be most effective against. 
 
 
Figure 3.1 The preclinical drug development process. 
 
3.2.1 Human tumour cell screening 
Measurement of cytotoxicity in human tumour cell lines as an indicator of anticancer 
agent efficacy has become a fairly common practice over recent years.  One of the most 
valuable resources for the testing of new chemical entities is the 60-cell-line based In 
Vitro Cell Line Screening Project (IVCLSP) run by the NCI.  Fully operational as a 
primary screen in 1990 after five years of development, this project was set up with the 
intention of screening up to 20,000 compounds a year through a panel of 60 human 
In vitro 3 cell line prescreen
In vitro 60 cell line screening panel 
In vivo hollow fibre assay 
In vivo tumour xenograft testing in nude mice 
Toxicology and formulation
Phase I trials
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tumour cells lines representing different tumour types (leukaemia, melanoma, cancers of 
the lung, colon, brain, ovary, breast, prostate and kidney), and generating dose-response 
curves for the compound in each cell line.  The aim of this type of screen is to enable a 
ranking of compounds as to which is most likely to possess biological activity, and thus 
prioritise which compounds should progress to further stages in development for 
evaluation in more complex tumour models.  Due to the nature of the screen and the 
broad spectrum of cancer cells involved in the screen, it is also thought that this would 
enable an indication as to which type of cancer the potential drug may be useful in 
treating, as bias in the cell type killed may point to tumour selectivity (NCI, 2001). 
 
In 1995, the NCI cell screening process was further streamlined, due to a large number 
of inactive compounds finding their way into the system.  This resulted in the 
development of a 3-cell line pre-screen (MCF-7, NCI-H460, and SF-268 cell lines), 
which is significantly less labour intensive and costly than the 60 cell-line screen.  This 
was designed to filter out as many of the inactive compounds as possible, without 
missing any of the active compounds, and involved a relatively high concentration (10-4 
M), single-dose regimen to detect any cytotoxicity elicited by the test drugs.  It is 
estimated that up to 50% of compounds can be eliminated from the full screen using this 
process (NCI, 2001). 
 
The actual screen itself generates a 5 point dose-response curve for each compound in 
each cell line, using sulforhodamine B (SRB) protein binding stain to assess growth and 
viability after incubation with the test drug over a 48 h period (Skehan et al., 1990).  
Results obtained from this assay are used to generate a “fingerprint” or mean-graph 
display, and their profile can then be compared by use of the COMPARE pattern-
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recognition algorithm to relate the novel compound to other compounds in the NCI 
database.  It has been stated that the profiles for drugs acting by similar mechanisms of 
action have been shown to correlate using the COMPARE function.  Therefore, it is 
considered that use of the algorithm to look for compounds that show profiles that do 
not correlate well to other drugs in the database, and yet still show cytotoxicity in some 
cell lines, may result in the discovery of compounds acting by novel pathways (Boyd, 
1997). 
 
This first-line level of cell-based screening of compounds tends to now constitute what 
would be considered the “discovery” level of the drug research process.  Complemented 
by rational drug design processes and in silico modelling of compounds, this should 
allow a significant streamlining of compounds that progress to the more resource-
intensive levels of research involving whole animal models. 
 
3.2.2 In vivo secondary screens 
The time and expense involved in the in vivo screening of potential anticancer agents, 
has split the process of in vivo screening into two parts.  The current NCI drug 
development programme uses a “hollow fibre assay” as the initial in vivo exposure stage 
of a drug, as it allows a quantitative assessment of drug efficacy, while using a minimal 
level of resources, and compounds proving to be of continued interest are then 
investigated in a tumour xenograft model. 
 
3.2.2.1 The hollow fibre assay 
The hollow fibre assay involves the culturing of cells within a polyvinylidene fluoride 
membrane hollow fibre, and subsequent implantation in vivo.  The fibres used have a 
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molecular weight cut-off of 500 kDa, which allows the interaction of host and tumour 
cell soluble factors (including proteins) across the membrane, without allowing the 
tumour cells to leave the fibre, or host cells to penetrate.  The fibres are implanted both 
i.p. (intraperitoneal) and s.c. (subcutaneous), and the animals are exposed to the drug 
continuously for 4 days.  After the final dosing, the fibres are collected from the animal 
and the cells removed from the fibres and subjected to the MTT assay to determine 
viability, and hence efficacy of the compound (Hollingshead et al., 1995).  The main 
advantage of this technique is that several fibres can be implanted per animal, allowing 
assessment of the activity of the compound on many more tumour cell lines in a much 
shorter time period than a xenograft study would (see section 3.2.2.2).  Used in 
conjunction with the cell-line screen, this further facilitates the decision as to what 
tumours the compound should be aimed at in later stages of development. 
 
3.2.2.2 Tumour xenograft studies 
Human tumour xenografts are used in order to better assess the tumour-specific 
cytotoxic effects of a potential anticancer agent.  This involves the implantation of a 
human-derived tumour (derived from a human tumour cell line) onto, most commonly, 
the congenitally athymic nude mouse (immunocompromised, and thus less likely to 
react to the implanted foreign material).  The xenograft has advantages over the assays 
used earlier in the drug discovery process in that it provides an intact tumour model, 
which means that it is closer to how the tumour would appear in humans and may 
express similar levels of enzyme activity or detoxifying molecules as would be 
observed in situ.  However, this technique is very time-consuming compared to the 
methods described earlier, as it may take up to 8 weeks in total to perform the 
experiment for slower-growing tumours and is expensive in numbers of mice, as often 
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50-100% more than the required number of mice must be used in order to compensate 
for mice in which the tumours do not take (Plowman et al., 1997).  Hence the wisdom 
in using the faster and cheaper methods mentioned earlier to both screen out inactive 
compounds and to select for which tumour type the potential drug should be tested in 
when at the xenograft stage, should increase the chances of finding a positive response 
and possible tumour selectivity in a shorter time. 
 
3.2.3 Preclinical toxicology 
Having reached this point, there is sufficient confidence in the drug for it to be 
considered for use in man; therefore, appropriate toxicology studies must be carried out 
in animals to determine a safe starting dose before the drug can progress to the clinic.  It 
has been established that preclinical studies in rodent species, specifically the mouse, 
are sufficient for prediction of toxicity in humans, a conclusion based on extensive data 
comparing toxicity in animals to that in humans (Newell et al., 1999).  Thus toxicity 
studies are performed in the mouse to establish a safe starting dose, typically defined as 
one tenth of the mouse MTD, and this is confirmed by testing in a second species, often 
rat or dog before the drug advances to phase I clinical trials (Toppmeyer, 1997). 
 
3.3 Clinical evaluation 
 
3.3.1 Phase I trials 
Once a candidate compound has shown favourable characteristics in non-human 
models, and appropriate parameters for the drug have been established, such as the 
tumour type for which the drug is to be indicated and safe starting dose, the drug can 
progress to phase I trials. 
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Due to the nature of anticancer drugs, their inherent toxicity, narrow therapeutic 
window and often non-linear pharmacokinetics, it is considered unethical for an 
anticancer compound to be tested in a normal healthy volunteer, as therapy could prove 
life-threatening or harmful at efficacious doses.  Thus, the first line of testing of 
anticancer drugs is generally in cancer patients for whom all other therapeutic options 
have been exhausted.  However, recent trends moving away from conventional 
cytotoxic agents to biological agents that manipulate the host response or perturb cell 
signalling mechanisms is altering this approach. 
 
The principle aim of phase I trials is to establish the maximum tolerated dose (MTD), 
which is defined as the highest dose that can be safely administered to a patient.  With 
conventional cytotoxic agents, this is typically achieved by beginning dosing at one-
tenth of the murine equivalent LD10, and incrementing dose levels using a modified 
Fibonacci dose escalation scheme (dose levels incremented as sequential 67%, 50%, 
40%, and 33% increases) until an MTD is seen (Collins et al., 1986).  Usually 2-3 
patients are used per dose escalation (Simon et al., 1997).  If none of the patients 
experiences dose limiting toxicity (DLT), dose is escalated to the next level.  If one of 
the three patients experiences a DLT, three additional patients are treated at the same 
dose.  If two or more out of the total of six patients this dose level experience DLTs, 
then the MTD is considered to have been exceeded and additional patients are treated at 
the previous dose level to confirm the safety of that dose for future studies. 
 
With newer biological agents the compound is not designed as a cytotoxic agent and 
often does not need to be dosed at the MTD to achieve optimum efficacy; therefore 
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conventional trial design is inappropriate.  These trials have evolved to identify an 
optimum biological dose (or pharmacodynamic endpoint), to combine maximum 
efficacy with minimum adverse effects (Blackledge & Averbuch, 2004). 
 
Phase I studies enable the setting of a safe dose level for further studies in phase II.  
Other purposes of the phase I trial are to characterise the toxicity profile of the drug 
(expected and unexpected toxicities), and to examine the clinical pharmacology of the 
compound.  While phase I trials are not designed to characterise the efficacy of 
compounds, any antitumour effect will be noted.  The sample size for this phase of 
investigation is often small, and several sources quote differing sample sizes, however a 
range of 15 -60 patients depending on compound and study design appears typical 
(Lewis & Weiner, 2002; Voorhees et al., 2003; Blackledge & Averbuch, 2004; Harris, 
2004). 
 
3.3.2 Phase II trials 
The purpose of a phase II trial is to determine if a compound is having a therapeutic 
effect against a tumour or cancer to a degree that is worthy of further study.  This type 
of study usually includes patients that have been selected based upon the type of cancer 
they are suffering, so that it is matched to the cancer that the drug is considered to be 
efficacious against, and rely on tumour response to the therapy as the primary measure 
of effectiveness.  This trial is generally conducted on a larger scale than phase I trials, 
and the number of patients needed in the trial is calculated beforehand and decided upon 
the basis necessary to achieve statistical significance (Teicher, 1997; Lewis & Weiner, 
2002). 
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3.3.3 Phase III trials 
Phase III trials are aimed at proving the value of a novel drug over an existing therapy.  
At this stage the activity of the drug has been proven, but for the drug to become 
routinely used in the clinic there is a requirement for evidence of an advantage of the 
novel therapy, due to either a reduced side-effect profile or an increase in potency 
against a tumour (Teicher, 1997; Lewis & Weiner, 2002). 
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4 New targets in cancer research 
Current chemotherapeutic approaches to cancer are nowhere near ideal, as treatment 
often results in an incomplete cure, and toxicity of anticancer drugs is an accepted norm.  
Chemotherapy has improved dramatically since its inception, with improvements in 
survival being the most notable landmark by which to judge this advance (McVie, 
1999).  The difficulty in finding an effective treatment arises mainly from the incredibly 
difficult task of designing or finding a treatment that is able to distinguish normal cells 
from cancerous cells.  Therefore, there is still tremendous scope for development of 
cancer therapies to enable the selective elimination of cancerous cells, with minimal or 
no tissue toxicity. 
 
Strategies for the development of new therapies have involved the synthesis of 
analogues in the hope of finding a better drug based on the efficacy of an existing lead 
compound or agent, i.e. improving the cytotoxicity or maintaining the same levels of 
cytotoxicity and reducing toxicity.  However, this “handle turning” technique has not 
been particularly successful, producing only a relative few useful agents (Verweij & de 
Jonge, 2000). 
 
In an attempt to produce drugs more intelligently, research has evolved to look at the 
processes involved in cellular division and differentiation to see what makes a cancer 
cell different from a normal cell.  Efforts are underway to characterise these differences 
and to exploit these anomalies in order to use the machinery of cancer against itself. 
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4.1 p53 
p53 is a tumour suppressor gene found to be mutated in over 50% of human cancers, 
and as such is one of the genes most commonly altered in tumours (Hollstein et al., 
1999; Soussi et al., 2000).  The central role of p53, the product of which is a nuclear 
transcription factor, is to act in response to DNA damage and to induce cell cycle arrest 
or apoptosis.  This helps to ensure the integrity of the genome in that if a cell is able to 
repair its DNA, it can do so before undergoing division; if not, it is eliminated.  The role 
of p53 is thus to act to prevent the division of cells with an altered genome.  Cells with 
damaged or mutated forms of p53 do not have this mechanism; this can result in 
increased genetic instability and increased chance of damaged cells progressing to a 
cancerous state.  Furthermore, mutated p53 is associated with increased resistance to 
chemotherapy believed to arise from interference in the normal apoptotic pathway by 
mutated p53.  Such mutants are thought to confer "gain of function" characteristics upon 
tumour cells, bestowing additional properties upon the cell over and above simply the 
loss of wild-type p53 function and potentially affecting the sensitivity of the cell to 
anticancer agents (Wattel et al., 1994; Rusch et al., 1995; Gasco & Crook, 2003; Soussi, 
2003). 
 
The major cellular role of p53 and its involvement in the occurrence of such a large 
number of cancers [estimated to be involved in over 35% of world-wide new cancer 
cases (Harris, 1996)] have presented it as an attractive target for the design of new 
therapies to specifically target p53-mutated/deficient tumours. 
 
One of the strategies used to attempt to target tumours lacking p53 is to replace the 
damaged copy of the p53 gene with a working copy, through the use of gene therapy.  
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Gene therapy as a technique itself poses significant problems, as currently there is no 
regular use of gene therapy due to a combination of ethical and practical problems.  
However, several attempts have been made using both viral and non-viral means of 
delivery to insert working copies of p53 into tumour cells. 
 
Phase I clinical trials have indicated that the use of a viral vector for the p53 gene has 
potential for success.  Both retroviral and adenoviral methods have been shown to work, 
although adenoviral vectors are preferred, as this confers only a transient expression of 
the transfected p53 gene as the viral DNA is not integrated into the host genome (Roth 
et al., 1996; Clayman et al., 1999).  Transient expression should be all that is necessary, 
as damaged cells should undergo apoptosis almost immediately upon the expression of 
p53, and this avoids ethical issues arising such as the germline transmission of 
transfected DNA.  It has also been observed that this affords a higher level of efficiency 
of transfection and resultant higher levels of expression over retroviral vectors.  
However, it has become apparent from these experiments that transfection with p53 is 
not enough to completely abolish an established tumour.  Transfection with p53 appears 
to sensitise cells to other anticancer agents, such as ionising radiation and 
chemotherapeutic agents.  However, transfection of p53 via a viral vector has 
drawbacks, as immunological complications arise and there is a lack of specificity for 
tumour cells. 
 
Non-viral transfer of an undamaged copy of the p53 gene has also been considered, and 
presents fewer problems than a viral delivery system.  Cationic liposomes have been 
used to this end (Chene, 2001).  The cationic lipids bind to the anionic DNA, and can 
then be injected.  However, this method is currently relatively inefficient as interactions 
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with plasma constituents and the immune system can have a drastic effect on the 
amount of DNA delivered to the tumour site.  This is coupled with a lack of tumour 
specificity, and as a transfection technique cationic liposomes produce poor transfection 
efficiencies. 
 
Other techniques are also being developed in pursuit of p53 as an antitumour target.  
There is interest in using p53 deficiency as a target at which to aim adenoviruses; in this 
case, p53 acts by binding to a section of the adenovirus and to cause its inactivation.  
Thus cells are protected from the cellularly lethal effects of the virus by p53, but cells 
possessing either no p53 or a mutated form are not (Heise et al., 1997).  There is also 
interest in the fixing or reactivation of aberrant p53.  It is thought that it may be possible 
in some cases to alter the mutated p53, shifting it into an active or more stable form, 
thus allowing stimulation of apoptosis in tumour cells (Chene, 2001). 
 
4.2 Angiogenesis 
It is well established that the formation of new blood vessels is critical for tumour 
progression and metastasis.  Therefore, inhibition of this blood vessel formation 
(angiogenesis) as a method of disrupting tumour growth presents an attractive target.  
There have been many targets identified to this end.  Among these are the growth 
factors (foremost of these is VEGF or vascular endothelial growth factor), the MMPs 
(matrix metalloproteinases), and the integrins. 
 
VEGF is instrumental in the induction of angiogenesis.  It is currently understood that 
the process of angiogenesis in tumours is primarily mediated by VEGF, driving 
endothelial cell proliferation, migration and tubule formation.  In association with 
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VEGF, Ang-1 (angioprotein-1) causes vessel maturation and stabilisation in vivo, 
although this can be destabilised by Ang-2 and another cycle of angiogenesis can 
proceed if VEGF is present.  In the absence of VEGF, the vessels will degenerate 
(Matter, 2001).  In addition to this, although separate from the regulatory systems 
involved in controlling VEGF levels, the matrix metalloproteinases (MMPs) have been 
shown to exert considerable influence over angiogenesis.  MMPs are involved in the 
tissue remodelling that occurs during angiogenesis, and are therefore also implicated in 
modulating tumour invasiveness and metastatic potential of tumours, as tissue 
remodelling is vital for vessel formation and tumour spread. 
 
There are surface receptors implicated in the processes of angiogenesis, as well as 
metastatic progression: these are the integrins.  This association arises from the 
observation of an anti-angiogenic effect of αv-integrin antagonists.  Further 
observations of factors interacting with integrins and resulting in anti-angiogenic 
effects, have supported their role in angiogenesis (e.g. endostatin, tumstatin and 
thrombospondin) (Eliceiri & Cheresh, 2001). 
 
These numerous targets have led to a wealth of research into agents to exploit 
angiogenesis as an anticancer key.  VEGF tyrosine kinase receptor inhibitors have 
proved popular, as the target has been validated by use of anti-VEGF antibodies (Kim et 
al., 1993).  This area has now resulted in drugs in clinical trials: SU5416 (semaxanib), a 
VEGF-R2 inhibitor, reached phase III trials but has recently been found ineffective in 
colorectal cancer (Peapack, 2004), and PTK787/ZK222584, a general VEGF receptor 
kinase inhibitor, is in phase I trials. 
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MMPs are a large family of zinc-binding proteins, of which there are several subtypes 
(MMPs 1, 2, 3, 7, 8, 9, 11, 12 & 13) expressing differing substrate specificities.  MMPs 
come into the classifications of collegenases, stromelysins, elastases and membrane 
type MMPs (Buolamwini, 1999).  MMP inhibitors targeted at these enzymes have been 
reasonably successful as a therapeutic target, resulting in several potential drugs.  One 
such drug is marimastat, a broad-spectrum MMP inhibitor with activity against many of 
the major enzymatic subtypes.  A competitive, reversible substrate inhibitor, marimastat 
has reached phase III clinical trials as a cytostatic agent.  There are several other 
compounds in various stages of development for inhibition of MMPs. 
 
The integrins are transmembrane proteins that function as receptors for matrix proteins 
such as fibronectin, collagen, laminin and vitronectin.  This has led to attempts to 
exploit this role in angiogenesis for cancer chemotherapy, and has prompted the use of 
synthetic peptides to antagonise integrin interactions, providing a degree of success (El-
Hariry & Pignatelli, 1997).  It is thought that this area has special value in the 
prevention of metastatic disease, although present knowledge of the interactions and 
functions of the cell adhesion molecules is not sufficient to allow a rational approach to 
therapy design. 
 
The epidermal growth factor receptor (EGFR) and its downstream signalling pathway 
has become the target of much interest over recent years (Woodburn, 1999).  EGFR 
mediated signalling has been linked to the production of increased amounts of 
angiogenic factors such as VEGF.  Several novel strategies have been attempted to 
modulate this pathway.  Small molecule inhibitors have been developed for the 
inhibition of EGFR tyrosine kinase.  Gefitinib has recently received approval for 
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clinical use, and is the first EGFR directed agent to achieve this status; erlotinib is 
following closely behind and is in follow-up stage of phase III trials (Blackledge & 
Averbuch, 2004).  Monoclonal antibodies have also become successful and reached the 
clinic as anticancer therapies.  The chimeric monoclonal antibody Cetuximab, is 
directed against EGFR and has been approved for use against metastatic colorectal 
cancer (Harris, 2004).  Similarly, Trastuzumab is a monoclonal antibody directed 
against another member of the ErbB family, Her2/neu, and has shown positive clinical 
benefit in breast cancer and is approved for use in the clinic (Harris, 2004). 
 
4.3 Ras farnesyltransferase 
There has been much effort into the development of Ras-targeted drugs for anticancer 
therapy, stimulated by the fact that Ras mutations occur in up to 30% of human cancers.  
Oncogenic mutation of the Ras gene, can lead to constitutive activation of the protein, 
resulting in continuous activation of its downstream effectors irrespective of growth 
signals, and mitotic activity where none is required.  Activated Ras triggers the 
mitogen-activated protein kinase (MAPK) cascade, ultimately resulting in the activation 
of extracellular-signal-regulated kinase (ERK), which enters the nucleus and stimulates 
mitosis by phosphorylating and activating appropriate transcription factors.  Ras 
farnesyltransferase (FTase), is instrumental in the transfer of a farnesyl moiety to the 
newly transcribed Ras protein (Buolamwini, 1999).  The farnesyl group is needed to 
anchor Ras to the cell membrane and allow it to perform its signalling function.  Thus, 
the inhibition of FTase would potentially provide a target that may have anticancer 
properties via inactivation (or lack of activation) of Ras.  Thus far, FTase inhibitors 
have proven effective in animal models, and have progressed to clinical trials (Lobell & 
Kohl, 1998). 
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4.4 Telomerase 
At the end of chromosomes are caps of repeating DNA base sequences called telomeres.  
In humans, this repeating sequence is a 6 base-pair (bp) sequence 5'-(TTAGGG), 
typically 5-15 kb pairs long.  Telomeres are often referred to as a mitotic clock, as with 
each cell division the length of the telomeres are shortened by some 50-200 bp as a 
result of a mitotic DNA synthesis aberration, termed the ‘end replication problem’, and 
when telomeres reach a critical length the cell undergoes growth arrest (cellular 
senescence).  This confers a limited number of replications on any given cell.  When a 
cell reaches senescence, it has effectively entered a stable state where further cell 
division does not occur; however, senescence does not result in cell death.  Should a cell 
continue to divide beyond senescence, the telomere will reach a critical length and 
undergo crisis, a condition in which the telomeres are so short that end-to-end fusion 
and chromosome breakage and fusion can occur, leading to chromosomal abnormalities 
and apoptosis (White et al., 2001).  In occasional cases, the cell can escape senescence 
or crisis (and therefore death), by regenerating its telomere, and this phenomenon has 
been associated with the enzyme telomerase (Wright & Shay, 1992; Kim et al., 1994). 
 
Telomerase is a ribonucleoprotein consisting of two main components, hTR (the human 
RNA component, the template for the 6 base pair repeat) and the hTERT (the human 
telomerase reverse transcriptase) catalytic subunit.  The limiting factor for telomerase 
activity in normal cells is the expression of hTERT, as hTR is constitutively expressed 
in all human somatic cells, whereas hTERT is not expressed in normal somatic tissues 
(Feng et al., 1995).  Telomerase has been found to be expressed in around 85% of 
human tumours, and thus it is believed that for a cancerous cell to continue proliferating 
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beyond its normal life span, telomerase must be reactivated to maintain the telomere and 
prevent senescence or crisis occurring (White et al., 2001).  Hence inhibition of 
telomerase presents an attractive target for potential anticancer therapy as a mechanism 
of removing the immortality of the cancerous cells, thus allowing them to divide and 
senesce or apoptose.  Telomerase inhibitors have shown remarkable activity in 
preclinical tests, but have yet to progress to clinical trial. 
 
 
4.5 Proteasome 
The proteasome is a proteinase complex crucial to cell cycle regulation and apoptosis 
and is responsible for the degradation of most intracellular proteins.  It was discovered 
that the caspases, part of the protease family, are involved in the apoptotic pathway and 
garnered interest in the potential role of the proteasome in this process.  Inhibition of the 
proteasome has been shown to induce apoptosis of cancer cells and have in vivo efficacy 
against tumours (Fujita et al., 1996; Orlowski et al., 1998).  Bortezomib, a proteasome 
inhibitor, has demonstrated a broad spectrum of antitumour activity in the NCI tumour 
cell line screen and antitumour activity in several murine tumour xenograft models.  It is 
thought that proteasome inhibitors act in a synergistic manner with DNA damaging 
agents by preventing transcription of genes involved in DNA repair by inhibiting 
translocation of nuclear factor κB, and also by interfering with P-glycoprotein 
maturation thus inhibiting one of the best characterised mechanisms of chemotherapy 
resistance (Loo & Clarke, 1999; Orlowski & Baldwin, 2002; Mitsiades et al., 2003).  
Bortezomib has been approved for use in the clinic as part of combination therapy, and 
is the only such proteasome inhibitor thus far to have entered clinical trials. 
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4.6 BCR-ABL 
BCR-ABL is a tyrosine kinase implicated in chronic myeloid leukaemia (CML).  In 
CML, there is a genetic abnormality caused by reciprocal translocation of chromosomes 
9 and 22, and this results in the expression of the constitutively active tyrosine kinase, 
BCR-ABL.  It has been shown that expression of this kinase alone is sufficient to cause 
CML, and as such it presents an attractive and selective target for anticancer 
agents(Druker et al., 2001).  The BCR-ABL inhibitor, Imatinib (STI571), acts by 
competitive inhibition of the ATP-binding site of BCR-ABL, resulting in inhibition of 
the tyrosine phosphorylation of proteins involved in the BCR-ABL mediated signal 
transduction pathway.  Imatinib is approved for use in the clinic, and is the first of the 
molecular targeting drugs to directly act on a protein known to be implicated 
carcinogenesis. 
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5 DNA repair mechanisms and cancer 
Many of the successful chemotherapeutic agents, such as the nitrogen mustards and 
platinum-containing compounds, target DNA in order to produce cytotoxic effects.  
This often results in the alkylation of DNA and may subsequently produce strand breaks 
and possibly inter-strand cross-links.  Damage to DNA by these agents is seldom 
limited to cancerous cells, and the often seen side-effects of chemotherapy arise as a 
direct result of damage to normal cells (Ferber, 1999).  As early as the 1960’s, reports 
appeared examining the effects of chemotherapeutic agents on bone marrow and 
peripheral blood cells, touting the gross chromosomal damage inflicted on these normal 
cells by therapeutic doses of chemotherapeutic agents (Bell et al., 1966; Whang-Peng et 
al., 1969).  From a current perspective, it seems obvious that this damage arose from the 
inability of cellular DNA repair mechanisms to cope with the damage inflicted by the 
chemotherapy used.  Knowledge of the apoptotic events that occur in a normal cell 
when DNA becomes damaged beyond repair allows explanation of why the induced 
chromosomal damage did not itself result in secondary tumours. 
 
Nuclear DNA is constantly under attack from environmental stresses, and DNA repair 
mechanisms have evolved to combat these cellular insults.  These mechanisms consist 
of base-excision repair, nucleotide-excision repair, recombinational repair and mismatch 
repair.  Repair mechanisms most important in relation to chemotherapy are excision 
repair and recombinational repair, as these processes are responsible for repair of single 
strand breaks and alkylation events, and double-strand breaks and inter-strand cross-
links, respectively.  These types of damage are often induced by chemotherapeutic 
agents.  Among other mechanisms resistance to chemotherapy has been linked with an 
increase in the activity of cellular DNA repair mechanisms possibly acting to prevent 
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sufficient damage to cause cell death (Masuda et al., 1988; Wang et al., 2001).  It is 
suggested that certain pyrrolobenzodiazepine (PBD) compounds may bind to DNA in a 
manner that allows circumvention of the DNA repair pathways that act to provide 
resistance to conventional anticancer drugs. 
 
5.1 Base excision repair 
The base excision repair (BER) pathway is a critical repair mechanism for dealing with 
single-strand breaks, and is involved in the removal of chemically altered bases.  The 
repair pathway consists of four key stages at which individual enzymes performs tasks 
imperative to the complete pathway (Figure 5.1). 
 
Figure 5.1 DNA base excision repair pathway.  1) Glycosylase enzyme removes 
damaged base, 2) endonuclease cleaves sugar phosphate backbone 5' to the AP 
site, 3) DNA polymerase removes sugar phosphate and fills resulting gap, 4) 
DNA ligase seals remaining nick and repair is complete.  Red X markers 
denote bonds broken in the processes.  Adapted from (Parikh et al., 1997). 
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5.1.1 DNA glycosylases and damage detection 
The DNA glycosylases are key enzymes involved in the detection and instigation of 
BER.  These enzymes are responsible for recognising distinct forms of DNA damage, 
and removing the damaged and/or inappropriate bases by hydrolysis of the glycosyl 
bond (Krokan et al., 1997).  This results in the generation of a non-coding 
apurinic/apyrimidinic (AP) sites.  There are a number of different DNA glycosylases, 
each thought to be responsible for the recognition of different types of DNA damage 
(Mol et al., 1999).  DNA glycosylases fall into two categories: the pure glycosylases 
and the AP lyase/glycosylases.  The pure glycosylases leave an abasic site in the DNA 
strand whereas the AP lyase/glycosylases leave an AP site with a 3' nick. 
 
It is currently believed that there are distinct enzymes involved in the recognition of 
lesions that are repaired via the BER pathway.  A brief description follows for the 
enzymes thought to be involved in repair of these lesions and their proposed mechanism 
of action: 
• Deamination: 
o Uracil-DNA glycosylase (UDG).  Cleaves the N-C1' glycosyl bond between 
a target uracil and the deoxyribose sugar.  Acts to remove uracil from single-
stranded DNA and from U-G or U-A pairings in double-stranded DNA, but 
will not act on RNA (Slupphaug et al., 1995).  Thought to act by flipping out 
target base from DNA base stack. 
o G-T/U mismatch-specific DNA glycosylase (MUG).  Cellular cytosine is 
often methylated at its 5' position, and this can result in deamination to form 
5-methyluracil or thymine and result in G-T mismatches in DNA.  MUG 
cleaves thymine or uracil mismatches with G, C and T, but will not act on A-
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T/U pairs or single strand DNA (Neddermann & Jiricny, 1993).  This 
enzyme is also thought to act by flipping out the target base. 
• Oxidation: 
o MutY mismatched-adenine glycosylase.  MutY specifically acts to remove 
adenine mispaired with 8-oxoguanine, guanine or cytosine (Gogos et al., 
1996; Manuel et al., 1996).  It is 1000-fold more active towards an 8-
oxoguanine mismatch than for A-C mispairs (Bulychev et al., 1996).  This 
enzyme belongs to the Helix-hairpin-Helix (HhH) superfamily of DNA 
repair enzymes.  This enzyme is also thought to act by flipping out the target 
base. 
o Endonuclease III oxidised-pyrimidine glycosylase/lyase.  Endo III has broad 
specificity, and acts to cleave oxidised pyrimidine bases.  It also acts as an 
AP lyase to nick DNA at abasic sites (Katcher & Wallace, 1983; Doetsch & 
Cunningham, 1990).  This enzyme also belongs to the HhH superfamily and 
is believed to act by flipping the damaged base out of the DNA base stack. 
• Alkylation: 
o AlkA 3-methyladenine DNA glycosylase.  AlkA has broad range of 
substrate activity, recognising and excising not only 3-methyladenine, but 
also alkylated purines and pyrimidines, oxidative lesions, and even 
undamaged normal bases (Berdal et al., 1998).  This enzyme also belongs to 
the HhH superfamily and is believed to act by flipping the damaged base out 
of the DNA base stack. 
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5.1.2 AP endonucleases and AP site recognition 
The second stage of the BER cascade involves AP endonuclease enzymes.  This enzyme 
is responsible for recognition of AP sites.  After generation of an AP site by the 
glycosylase enzyme, AP endonuclease recognises the non-coding site and cleaves the 
phosphodiester backbone of DNA 5' to the AP site.  This acts to prime the section of 
DNA for repair by leaving a 3'-hydroxyl group (Parikh et al., 1997; Wilson & Barsky, 
2001).  The predominant AP endonuclease present in mammalian cells is human AP 
endonuclease (HAP1, also called APE1 or APEX), and is thought to comprise ~95% of 
total cellular AP site-cleaving activity (Chen et al., 1991). 
 
5.1.3 DNA polymerase and damage repair 
The DNA polymerase enzyme, DNA polymerase β, acts in BER to bind to the nicked 
DNA produced by endonuclease activity and cleaves out the abasic site (Matsumoto & 
Kim, 1995).  The enzyme then proceeds to bind dNTP, move the dNTP into the gap site 
and subsequently catalyse nucleotidyl transfer (Parikh et al., 1997). 
 
5.1.4 DNA ligase finish 
DNA ligase joins up the remaining nick left after the activity of DNA polymerase β, 
completing the repair.  This is done by the catalysed annealing of the 5' phosphate-
terminated donor strand to the 3' hydroxyl terminated acceptor.  DNA ligases I and III 
have been implicated in mammalian BER (Parikh et al., 1997). 
 
5.2 Nucleotide excision repair 
Nucleotide excision repair (NER) is principally responsible for the repair of DNA 
adducts that result in large, helix-distorting lesions.  Dipyrimidine lesions such as those 
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resulting from exposure to UV light are an example of this type of damage (Friedberg et 
al., 1995; Batty & Wood, 2000). 
 
 
Figure 5.2  Nucleotide excision repair.  Damage is recognised by XPC-hHR23B 
and/or XPA-RPA.  DNA is unwound by the TFIIH complex using helicases 
XPB and XPD; the structure created is a target for the endonucelases XPG and 
XPF-ERCC1 which cleave DNA and release the damaged section of DNA.  
The gap remaining is subsequently filled and ligated. 
 
NER is a multi-step process (Figure 5.1) thought to involve in the region of 20 proteins 
in the repair pathway (Wood, 1997).  The initial step is the recognition of DNA damage.  
This is currently believed to involve the XPC-hHR23B and XPA-RPA proteins, 
although the order in which the proteins bind is unclear (Batty & Wood, 2000).  The 
TFIIH transcription factor is then enrolled, which contains the helicases XPB and XPD 
which are vital in the unwinding of DNA in the region of the lesion (Evans et al., 1997).  
The protein complex clustered around the lesion then provides a landmark for the 
nucleolytic incisions of XPG (3' of the lesion) and XPF-ERCC1 (5' of the lesion), which 
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leads to the release of a nucleotide containing the lesion, of approximately 30 
nucleotides in length (Huang et al., 1992).  This is followed by DNA synthesis across 
the gap left by oligonucleotide excision, thought to be by DNA polymerase δ / ε (Wood, 
1997).  The double helix is finally restored by ligation, thought to be performed by 
DNA ligase I (Barnes et al., 1992). 
 
5.3 Double-strand break repair 
Events that cause double-strand breaks (DSB) in DNA are especially cytotoxic.  DSBs 
if left unrepaired are generally lethal to cells, and if repaired erroneously can result in 
chromosomal abnormalities such as translocation and subsequent alterations in gene 
function.  Cells have evolved two key mechanisms for the repair of DSBs: homologous 
recombination (HR) and non-homologous end-joining (NHEJ). 
 
HR repairs DNA using an undamaged sister chromatid as a repair template, this 
removes damage in an error free process.  The Rad52 epistasis group of proteins are 
implicated in the HR-mediated repair of DSBs, although it is unclear in the literature as 
to which enzyme mediates each part of the reparation process.  HR proceeds (Kanaar et 
al., 1998; Braithwaite et al., 1999; Fojo, 2001; Martin, 2001; McHugh et al., 2001; 
Pierce et al., 2001) by: 
1. Recognition of the damaged DNA ends. 
2. Nucleolytic processing of the DNA ends to give a single-stranded 3' overhang at 
each broken end. 
3. Searching for the homologous template on the sister chromatid. 
4. Formation of a complex between the 3' end on the broken DNA and the 
complementary sequence on the homologous strand. 
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5. Extension of the 3' ends by synthesis of DNA complementary to the template. 
6. Dissociation of the recombination complex and ligation of repaired DNA. 
 
NHEJ is a more error-prone mechanism of DSB repair as it relies on pasting the broken 
ends of DNA together, and there is no homologous template required to ensure 
sequence fidelity.  This somewhat simplifies the process of DSB repair as there are less 
proteins involved.  The human Ku (derived from the first two letters of the family name 
of a Japanese patient in which it was recognised) protein is a heterodimeric complex 
composed of two protein subunits Ku70 and Ku80 (also termed Ku86).  The binding of 
Ku to the broken ends of DSBs is believed to initiate the process of NHEJ.  Ku is 
thought to stabilise the ends of DNA in order to allow rejoining by DNA ligase IV in 
association with XRCC4.  NHEJ appears to be the main form of DSB repair in 
mammalian cells (Kanaar et al., 1998; Braithwaite et al., 1999; Fojo, 2001; Martin, 
2001; McHugh et al., 2001; Pierce et al., 2001). 
 
5.4 Repair of interstrand crosslinks 
Current understanding of the mammalian mechanisms of DNA interstrand crosslink 
(ICL) repair is poorly understood.  Repair of ICLs have been characterised in bacterial 
cells in more detail and suggest that there is interplay between NER and HR.  This 
model suggests an initial incision either side of the lesion on one strand of the DNA 
duplex releasing an oligonucleotide (still linked via the crosslink to the complimentary 
strand) as with NER, considered an ‘unhooking’ of the crosslink.  This is followed by 
an HR event, replacing the missing oligonucleotide and repairing that strand of the 
DNA duplex.  To complete the repair, a second NER process takes place to excise the 
remaining lesion and is followed by completion of the NER process to fill in the 
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remaining gap.  It was found that although there was potential for ‘unhooking’ of both 
strands simultaneously, and subsequent DSB formation, this was not observed to occur. 
 
Studies in yeast showed a different story for eukaryotic cells: DSBs were seen to form 
in yeast cells treated with DNA crosslinking agents.  However, the proposed double-
NER reaction was not found to account for all DSBs formed.  It was observed that there 
was a high proportion of DSBs formed in rapidly-dividing cells, whereas virtually no 
DSB formation was seen in non-dividing cells (McHugh et al., 2000).  This led to the 
proposal that the formation of DSBs was as a result of DNA replication forks running 
into an ICL, which is likely an impassable block.  The following collapse of the 
replication fork is believed to result in the formation of a DSB. 
 
In mammals, the mechanisms by which ICLs are repaired are somewhat less well 
understood.  It has been shown that a combined NER + HR mechanism, as proposed for 
bacteria (Cole, 1973), is not likely to be a major contributor to repair of ICLs, as 
mutation studies aimed to remove key proteins involved in the NER process did not 
cause the increase in sensitivity to crosslinking agents that would be expected if this 
was the main mechanism of repair.  It has been shown however, that mutation of XPF 
(also ERCC-4) or ERCC-1 (both required for nicking DNA 5' of the lesion) results in 
extreme sensitivity to crosslinking agents versus other proteins in the NER pathway 
(Damia et al., 1996; De Silva et al., 2000).  Further studies have shown a role for Xrcc3, 
a protein linked to the HR repair pathway, in the repair of ICLs via its apparent 
influence on Rad51 foci formation (Wang et al., 2001). 
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Therefore current understanding of ICL repair in mammals and humans appears to 
indicate a role for ERCC1, XPF and Xrcc3 and Rad51 foci in the repair pathway.  The 
current diversity of opinion would perhaps also indicate the possibility of several 
differing repair mechanisms, as differing reports indicate implication of HR, NER and 
NHEJ in ICL repair, and indeed several reports appear to implicate a combination of 
individual elements of each repair pathway. 
 
5.5 DNA repair mechanisms and cancer chemotherapy 
Many of the more effective chemotherapeutic treatments for cancers centre on actions 
on DNA, directly or indirectly.  These include the alkylating or platinating agents 
(nitrogen mustards, cisplatin, carboplatin), inhibitors of DNA topsimerases I (topotecan, 
camptothecin) and II (mitoxantrone) and antimetabolites (methotrexate, capecitabine, 
fluorouracil, mercaptopurine).  Despite the proven efficacy of these DNA active drugs, 
DNA as a target has in many circles now lost favour, largely as a result of the perceived 
lack of specificity afforded by this mechanism of cytotoxicity.  Furthermore cancers can 
often become resistant to these DNA-directed therapies.  Obvious culprits for the noted 
resistance to DNA directed drugs are DNA-damage repair mechanisms.  It has been 
noted in several tumour lines that resistance to drugs acting on DNA is associated with 
the upregulation or overexpression of proteins linked to DNA repair.  This has led to the 
development of therapies designed to circumvent these repair mechanisms such as drug-
based inactivation of aspects of DNA repair mechanisms (Middleton & Margison, 
2003), and it has been suggested that modulation of DNA repair proteins may be 
achieved using gene therapy strategies (Wang et al., 2001).  Other approaches have 
centred on attempting to increase the cytotoxicity and therefore yield of ICLs induced 
by drugs in order to overwhelm DNA repair pathways.  However, it is likely that this 
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increased cytotoxicity to tumour cells would have implications on side-effects, and thus 
prodrug approaches have also become popular in attempting to deliver enhanced 
cytotoxicity compounds to the tumour.  Another approach is to design drugs that have 
minimal effect on the structure of DNA and thus evade the repair mechanisms 
employed by the cell.  The pyrrolobenzodiazepine class of agents has been engineered 
to behave in this fashion through DNA minor groove-mediated events. 
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6 The pyrrolobenzodiazepines 
 
6.1 Background to the compound family 
The PBDs or pyrrolobenzodiazepines (also termed pyrrolo[2,1-c][1,4]benzodiazepines) 
are a group of antitumour antibiotics first discovered in 1963.  Prior to their discovery, 
many [1,4]benzodiazepines had been developed as potential antianxiety drugs, but it 
had not been thought that fusion of a pyrrole ring to this system would evoke 
antitumour activity.  There has been a high level of interest in the biological activity of 
this group of compounds, but as yet there have been no PBDs accepted as therapeutic 
agents, despite compounds progressing to clinical trials, although some anticancer 
activity for this class of compound has been documented. 
 
The first of the PBD compounds to be studied was anthramycin.  It was discovered in 
1963 that the addition of ammonium sulfate to a fermentation broth derived from 
Streptomyces refuineus resulted in a precipitate that showed activity against a spectrum 
of Gram-positive bacteria.  It was also shown to be active against sarcoma 180 in mice 
and carcinoma 755 in rats.  This active precipitate was denoted refuin, and was assumed 
at that point to be a protein.  Further work resulted in the development of an extraction 
and purification method to isolate the active molecules in this broth.  It was discovered 
that the active element was not a protein, but the heterocyclic compound anthramycin, 
so named due to the presence of anthranilic acid as part of its structure.  Comparisons 
between refuin and anthramycin indicated that refuin contained only 0.5% anthramycin.  
Pure anthramycin is highly active against Gram-positive bacteria and active to a lesser 
extent against Gram-negative bacteria and fungi. 
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Further PBDs were discovered over later years with the advent of sibiromycin (derived 
from extracts from Streptosporangium sibiricum in 1969), tomaymycin (derived from 
Streptomyces achromogenes in 1972), and neothramycin (derived from Streptomyces 
No. MC916-C4 in 1976).  All were shown to have activity against bacteria, and some 
degree of antitumour activity.  There are now 12 known naturally occurring PBDs, in 
addition to numerous synthetic analogues (Thurston, 1999). 
 
 
Figure 6.1  The PBD monomer DC-81 showing the numbering system and ring 
lettering of the PBD nucleus. 
 
The PBD molecule consists of a fused tricyclic system (see structure 2 in Figure 6.1), 
namely an aromatic A-ring, a pyrrolidine C-ring, and a 1,4-diazepin-5-one B-ring 
bearing a N10-C11 imine carbinolamine moiety (Baraldi et al., 1999).  All naturally-
occurring forms of this compound possess the (S) configuration at C11a, which provides 
the molecules with a right-handed twist when viewed from the C-ring towards the A-
ring.  This provides the isohelicity with the DNA minor groove needed for an effective 
interaction with the nucleic acid, and hence biological efficacy. 
 
 
6.2 Mechanism of action 
Pyrrolobenzodiazepines elicit their antitumour effects through strong covalent binding 
with DNA, the result of this being interference with DNA and RNA synthesis.  This 
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interference is a function of their ability to form adducts in the minor groove of B-form 
DNA.  The mechanism involved in the binding of a PBD molecule to DNA is believed 
to be a two-stage process with the initial interaction being non-covalent.  The shape of 
the drug molecule allows a snug fit into the minor groove, followed by the formation of 
a covalent bond with the C11 of the drug and the exocyclic 2-amino group of a guanine 
residue (Remers, 1988; Thurston, 1993). 
 
Anthramycin, the first discovered PBD, has had its mode of DNA interaction well 
studied.  Shown to bind to DNA, and to result in the formation of a strongly bound 
drug-DNA complex (Kohn et al., 1974), anthramycin displays a marked preference for 
double-stranded DNA over single-strand DNA, but shows no reactivity with RNA 
(Kohn & Spears, 1970).  Interestingly, the time taken to reach saturation binding of 
DNA with anthramycin has been shown to be significantly longer than that of typical 
intercalating drugs such as actinomycin, taking minutes to hours rather than the 
milliseconds to seconds of the intercalating drugs (Konishi et al., 1984).  Initially the 
anthramycin-DNA adduct was shown to be covalent in nature by the use of UV 
spectroscopy, thermal denaturation, dialysis, gel filtration and alcohol precipitation 
techniques (Kohn & Spears, 1970; Kohn et al., 1974; Kohn, 1975).  Further 
investigation using enzymatic (S1-nuclease) and chemical (BND-cellulose 
chromatography) probes indicated that the bonding of the drug causes little or no 
distortion of local DNA structure (Petrusek et al., 1981).  However, these studies were 
not able to identify the finer details of the binding, such as the orientation in the minor 
groove, or the configuration at the C11 position.  Further work was able to identify the 
C11 position of the PBD as the point of adduct formation, in support of earlier 
suggestions that this was the point of bond formation (Kohn & Spears, 1970).  Other 
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possible sites for alkylation were identified as C6, C7, C8, and N3 and were 
subsequently eliminated (Petrusek et al., 1981).  Direct evidence for the involvement of 
C11 was provided by the use of NMR comparing the 13C spectra of [11-13C]-
anthramycin methyl ether and the [11-13C]-anthramycin adduct formed with calf thymus 
DNA (Graves et al., 1984). 
 
The interaction of PBD compounds with DNA is proposed to be in a relatively 
sequence-selective manner, with a preference being shown for binding to a guanine base 
flanked on either side by a purine base revealed by footprinting-type studies (Hertzberg 
et al., 1986; Hurley et al., 1988; Thurston, 1993).  It has been shown that PBD 
compounds form covalent adducts with the exocyclic N2 of guanine, in the minor 
groove of DNA (Remers, 1988; Thurston, 1993).  The site within the PBD molecule 
that is involved in binding to DNA (the N10-C11 region), can exist in three different 
forms, all possessing the ability to alkylate N2-guanine residues: a) imine (Figure 6.2, 
2), b) carbinolamine (Figure 6.2, 3), and c) carbinolamine methyl ether (Figure 6.2, 4,). 
 
 
Figure 6.2 Possible forms of PBDs that can interact with duplex DNA (from 
(Baraldi et al., 1999)). 
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There are three potential mechanisms by which this bond may form (Figure 6.3): 
1. There may be a direct SN2Ca-type attack of the protonated carbinolamine 
(Figure 6.3, 6) or its 11-methyl ether (7), by the guanine, resulting in the adduct 
(9) (Hurley, 1977). 
2. The mechanism may involve Schiffs base formation between N2-guanine 
functionality and the acyclic amino aldehyde of the DNA-drug adduct (Figure 
6.3, 8) (Ostrander et al., 1981), followed by intramolecular cyclisation via attack 
of the aromatic amino acid function. 
3. Or there could be a direct attack of the biological nucleophile on the imine 
function (Figure 6.3, 2) (Kopka et al., 1994). 
 
 
Figure 6.3 Possible mechanism of DNA alkylation by PBDs (from (Baraldi et al., 
1999)). 
 
There has been some interest in separately studying the non-covalent and covalent 
components involved in the binding of a PBD molecule to DNA.  To investigate the 
non-covalent portion of the reaction, a series of compounds was studied that lacks the 
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N10-C11 function by which the covalent bond is formed.  Molecules studied in this 
experiment were shown to retain the ability to form non-covalent bonds, provided 
hydroxyl or acetoxy groups were maintained at the C2 and C8 positions, and a further 
requirement of an (R)-configuration at C2 was met (Jones et al., 1990). 
 
Covalent bond formation was studied using a model nucleophile (thiophenol), in order 
to deduce the reactive species of PBD molecule involved, and attempt to measure the 
rate of reaction (Morris et al., 1990). 
 
The sequence selectivity of the PBDs could be partly due to the ability of the PBD 
molecule to bind to DNA, and then migrate to another site where it binds more strongly, 
prompting the suggestion that the compound could bind to DNA and then “creep” along 
the minor groove to a more favourable site without actually dissociating from the DNA 
(Hertzberg et al., 1986; Remers, 1988). 
 
It has been shown, by use of thermal denaturation, ethidium bromide displacement, and 
endonuclease digestion studies, that there is a distinct order of DNA reactivity of the 
naturally-occurring PBDs (sibiromycin > anthramycin > tomaymycin > DC-81 > 
neothramycin) (Puvvada et al., 1993).  However, there has been less success in 
elucidating a link between DNA-binding affinity, sequence selectivity, in vitro 
cytotoxicity or in vivo antitumour activity. 
 
6.3 Biological activity of PBD compounds 
Biological assessment of the PBD series of compounds has mostly centred around the 
naturally-occurring PBDs, anthramycin, tomaymycin, sibiromycin, neothramycin and 
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DC-81.  Furthermore, not all PBDs have been tested in all systems, so direct 
comparison required to identify a structure-activity relationship is not particularly easy.  
This has been further hampered by the limited number of available compounds, and the 
difficulty in synthesising further analogues. 
 
Work in the late 1970’s has indicated the cytotoxic effects of the naturally-occurring 
PBDs covers a wide range of biological systems, ranging from the inactivation of 
viruses and bacteriophages to their antibacterial and antitumour effects. 
 
Anthramycin has been shown to inhibit a broad spectrum of bacteria and fungi in 
culture.  However this has not been noted to translate into a useful in vivo property, as 
no activity in animals has been observed other than some effects on parasites such as 
Trichomas vaginalis, Entamoeba histolitica and Syphcia obvelata (Horwitz, 1975).  
Some derivatives of anthramycin have shown activity in one or more biological 
systems, although a substantial deviation from the original PBD structure tends to result 
in a loss of activity (Hurley, 1977).  Antibacterial activity was also observed with 
tomaymycin and derivatives (Arima et al., 1972; Shimizu et al., 1982; Tozuka et al., 
1983).  The most active of the naturally-occurring PBDs is sibiromycin.  This has been 
found to be active against many bacteria, as well as showing activity against a number 
of tumours (Gauze et al., 1969; Dudnik et al., 1971).  Neothramycins show weak 
antibacterial activity, but have good antitumour potency (Takeuchi et al., 1976).  The 
simple PBD molecule, DC-81, has also proved to be less cytotoxic than tomaymycin in 
selected cell lines (Bose et al., 1992c). 
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Current research into the use of PBDs as antitumour agents has resulted in two distinct 
classes of agent.  There is interest in both using original PBD-style compound 
analogues, referred to as monomers, and in exploring the creation of PBD dimers where 
two PBD sub-unit molecules are linked. 
 
6.4 PBD monomers 
This class of PBD originates from the original series of naturally-occurring compounds, 
such as anthramycin, tomaymycin, sibiromycin, neothramycin and DC-81.  The original 
work on the pyrrolobenzodiazepine group of compounds was able to identify the 
primary mechanism of action of PBDs as a function of DNA binding.  This produces a 
consequential inhibition of DNA/RNA synthesis, resulting in toxicity as a product of the 
inhibition of vital cellular processes, although direct evidence for this as the only cause 
of toxicity has not yet been forthcoming.  Thus far, sibiromycin has remained the 
favourite PBD monomer in terms of ability to bind DNA as measured by thermal 
denaturation studies, ethidium bromide displacement, and restriction endonuclease 
digestion studies (Puvvada et al., 1993).  It has been suggested that there is a structure-
activity relationship (SAR) between strong DNA binding, as indicated in these 
experiments, and cytotoxicity when translated into a biological system (Thurston, 1993; 
Thurston et al., 1999).  However, this is difficult to observe, as there is a limited number 
of studies that have been performed that allow comparison of these characteristics.  
Sibiromycin especially, has been neglected as far as biological characterisation is 
concerned, having only had a rough characterisation of efficacy against a tumour model.  
While the results obtained against the tumour model with sibiromycin were impressive 
(lyo-1 > 90% tumour inhibition, OG-5 = 100% tumour inhibition), the actual dosage 
was recorded only as “maximum tolerated” (Brazhnikova et al., 1972), and therefore 
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could not be compared with other results.  Sibiromycin has been examined in 
preliminary clinical trials, and effectiveness against squamous cell carcinoma was 
suggested (Gauze et al., 1972).  However, this does not appear to have been pursued, 
probably as a result of earlier research that indicated cardiotoxicity of sibiromycin in 
dogs (Bazhanov & Shepelevtseva, 1974).  A similar fate appears to have befallen 
anthramycin and neothramycin, the other two naturally-occurring PBD monomers to 
have reached clinical trials.  Almost half the number of terminal patients responded to 
crude anthramycin; however, a quarter of those given pure anthramycin went into 
irreversible shock, and some showed abnormal electrocardiograms (Korman & Tendler, 
1965).  Neothramycin indicated responses to some types of cancer, without the 
cardiotoxic aspect, but this PBD agent has not progressed further (Hisamatsu et al., 
1980; Fujita et al., 1982; Tsugaya et al., 1986). 
 
The monomers anthramycin, neothramycin, tomaymycin, sibiromycin, and DC-81 have 
all been shown to inhibit transcription in vitro in a bacteriophage T7 RNA polymerase 
model.  A quantitative in vitro transcription (QIVT) assay was used to assess the level 
of inhibition of the compounds to ascertain whether the binding of PBD monomer to 
DNA was able to inhibit transcription.  This allowed quantitation of the level of 
transcription inhibition by each compound, and resulted in an experimental rank order 
of inhibiting ability as: sibiromycin > tomaymycin > anthramycin > DC-81 > 
neothramycin.  This was accompanied by in vitro transcription footprinting assay, 
which led to the conclusion that agents involved primarily favoured binding to a 5'-
AGA sequence, although binding was influenced by bases flanking this sequence 
(Puvvada et al., 1997). 
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Other work has attempted to assess the influence of the A ring of the PBD nucleus, by 
synthesising a range of compounds with different modifications to the A-ring.  
However, it was found that no changes to the A-ring conformation resulted in either an 
increase in in vitro cytotoxicity or  DNA-binding ability of the compounds (Thurston et 
al., 1999). 
 
An alternative strategy to increasing the cytotoxicity of PBD-based compounds has 
been to examine C2-exo-unsaturated PBDs.  A selection of these compounds was 
synthesised and assessed in a selection of ovarian carcinoma cell lines.  Of the new 
compounds, two managed to produce a higher denaturation temperature for double-
stranded DNA, indicating stronger DNA binding.  These agents also effected an 
increase in cytotoxicity in two of the cell lines used, relative to DC-81.  However, this is 
not necessarily useful, as tomaymycin itself is noted to have over 270-fold higher 
toxicity in the CH1 cell line, although it assists in the elucidation of a SAR as the only  
difference involves one hydroxyl group (Gregson et al., 2000).  However, sibiromycin, 
previously noted to be most strongly bound to DNA of the naturally-occurring PBDs 
(Puvvada et al., 1993), was not considered in this study. 
 
6.5 PBD dimers 
Interest in the PBD series has diversified over recent years, with the linking of two 
PBD-based molecules together to form a dimer.  This was initially started with the 
synthesis of a dimer of DC-81 (Figure 6.4), termed DSB-120 (Figure 6.5) (Bose et al., 
1992a).  It was reported that this molecule allows recognition of an increased number of 
bases, and binds with an increased affinity compared to the PBD monomer DC-81, 
resulting in an increased level of in vitro cytotoxicity (measured as decreased IC50) in 
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the cell lines used (Bose et al., 1992b).  The effect of the length of the linker used 
between PBD units was studied, and the conclusion drawn from the data found that an 
odd number of linker units gave the best cytotoxic activity (Bose et al., 1992b).  DSB-
120 was found to be the most cytotoxic of the compounds examined. 
 
This led to further work to study the cellular pharmacology of a series of C8-linked 
PBD dimers, with varying linker length.  Results showed DSB-120 to be the most 
potent in terms of cytotoxicity, with an odd number of linker units resulting in better 
activity than that observed for an even number of linker units (Smellie et al., 1994).  It 
was further noted that the agents used produced a cell-cycle block in the G2/M phase of 
the cell cycle, noted to be a characteristic of agents that interfere with DNA (Konopa, 
1988), more specifically a characteristic of cross-linking drugs such as mephalan and 
cisplatin (Brox et al., 1980; Sorenson & Eastman, 1988).  It was noted that in the 
A2780cisR cell line (cisplatin-resistant), a similar pattern of resistance to DSB-120 was 
observed as that shown with cisplatin.  It was noted that GSH levels in this cell line are 
elevated compared to other cell lines, and hence it was suggested that GSH may 
responsible for inactivation of the drug.  This was tested by depleting cellular GSH 
using BSO (D,L-buthionine-S,R-sulfoximine), and partial reversal of resistance was 
observed (Smellie et al., 1994).  Evidence that the A2780cisR cell line shows increased 
expression of ECRCC-1 mRNA (the translated protein being involved in NER) suggests 
that DSB-120 induced DNA interaction may be modulated via the NER pathway as well 
(Li et al., 1998; Aquilina et al., 2000; Massey et al., 2003).  Other evidence has shown 
an increased IC50 for cell line HX62 compared to 41M, which may be attributable to 
HX62 having up to 4-fold higher GSH levels than 41M (Mistry et al., 1991; Smellie et 
al., 1994), and thus suggests GSH binding may be a metabolic route for this compound. 
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Interestingly, a cell line with acquired doxorubicin resistance (41MdoxR), showed a 
resistance to DSB-120.  This appears to be correlated with the high level of resistance to 
other compounds noted in this cell line (vinblastine, taxol, colchicine) conferred by 
elevated levels of P-glycoprotein (P-gp), the multidrug resistance protein responsible for 
efflux of several therapeutic compounds (Smellie et al., 1994).  P-gp was blocked by 
use of verapamil (Smellie et al., 1994), a well-known inhibitor of P-gp function (Wils et 
al., 1994; Wilkinson, 2000), and partial reversal of resistance was observed.  This 
indicated that DSB-120 may be a substrate for this efflux mechanism, a potential 
pharmacokinetic problem, as P-gp has been observed to be implicated in several cancers 
and the resulting occurrence of multidrug resistance. 
 
 
Figure 6.4  Structure of DC-81. 
 
 
Figure 6.5  Structure of DSB-120. 
 
Work by Walton and colleagues (Walton et al., 1996) has produced some of the only 
pharmacokinetic data currently available in the literature on the behaviour of a PBD 
molecule in vivo.  The PBD dimer, DSB-120, was studied both in vitro for cytotoxicity 
in cultured cell lines, and stability in blood and plasma, and were investigated in vivo 
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for clearance and tumour distribution data.  The cell panel cytotoxicity data was 
consistent with earlier data from other studies, in that DSB-120 showed marked 
cytotoxicity in all cell lines.  Furthermore, DSB-120 appeared to be stable in plasma, 
although a rapid degradation in whole blood was observed.  In contrast to the in vitro 
data, DSB-120 showed very poor activity in vivo, with a significantly lower therapeutic 
index compared to other DNA-crosslinking drugs used in the study (cisplatin, 
carboplatin), and thus a markedly higher toxicity to the mice used in the experiment.  
Plasma pharmacokinetics showed biexponetial characteristics, with an initial short 
distribution phase (t½ = 4 min), and a longer elimination phase (t½ = 38 min).  However, 
the steady-state tumour/plasma ratio was about 5%, and thus the drug showed poor 
specificity for the tumour relative to normal tissue.  LD50 data also showed DSB-120 to 
be much more toxic than either cisplatin or carboplatin.  Hence, despite strong DNA 
binding and good in vitro data, DSB -120 looks to be of no use as an in vivo compound. 
 
Refinement work to improve the DNA binding of PBD dimers has resulted in the 
synthesis of SJG-136 (Gregson et al., 1999; Gregson et al., 2001).  This analogue of 
DSB-120 has been reported to have an increased ability to thermally stabilise double-
stranded calf thymus DNA significantly more than any previously studied compound, 
indicating a much higher affinity for DNA than previous agents.  SJG-136 has been 
shown to have increased toxicity (pM rather than µM) compared to DSB-120 and 
cisplatin in an A2780cisR cell line, and does not appear to suffer from the proposed 
reactivity with glutathione as reported previously (Smellie et al., 1994).  In fact a 320-
fold increase in cytotoxicity to the cell line was reported compared to DSB-120.  
However, as yet no in vivo data has been reported, therefore it is unknown as to whether 
this increase in toxicity of SJG-136 will translate in a similar manner to that of DSB-
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120, and result in unfavourable pharmacokinetics and inauspicious toxicity, as observed 
with this other dimer (Walton et al., 1996). 
 
6.6 Sequence selectivity of the PBDs 
The antitumour activity of many of the early PBDs was thought to be attributed to the 
ability of the compounds to covalently bind to the N2 of guanine in double-stranded or 
duplex DNA (Hurley & Petrusek, 1979; Graves et al., 1984).  The adducts formed by 
this binding were observed to neatly fit into the minor groove of the double helix, with 
the right-handed twist of the PBD molecule following the curve of the DNA (Petrusek 
et al., 1981; Hertzberg et al., 1986; Hurley et al., 1988; Thurston, 1993).  This 
observation that the twist of the drug and the twist of the DNA were closely matched 
led to interest as to whether the drug-DNA interaction may be sequence-dependent, and 
therefore if alteration in the 3-dimensional structure of the drug would influence its 
DNA binding selectivity (Hertzberg et al., 1986). 
 
Early evidence to indicate a level of sequence selectivity of the PBD compounds was 
found.  Competitive binding experiments showed incomplete competition for binding 
sites between anthramycin and tomaymycin (Hurley, 1977) and between anthramycin 
and CC-1065 (Swenson et al., 1982), suggesting that different PBD molecules have a 
preference for binding to different areas within DNA.  Work by Petrusek and co-
workers (Petrusek et al., 1981), indicated that anthramycin expressed a preference for 
binding to G (guanine) when flanked by G, rather than C (cytosine).  This was further 
confirmed by other studies that showed that anthramycin produces greater inhibition of 
the action of restriction enzymes whose recognition sequences include a 5'-GG over 
those including a 5'-GC (Sumner & Bennett, 1981; Kaplan, 1982). 
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A more direct method of establishing a degree of PBD sequence selectivity was shown 
by the use of methidiumpropyl-EDTA-iron(II) footprinting (Hertzberg et al., 1986).  
This study showed that anthramycin, tomaymycin and sibiromycin exhibited 2 - 3 base 
pair sequence selectivity, centred around the covalently-bound G residue.  It was shown 
that a 5'-PuGPu sequence was the most preferred sequence, while 5'-PyGPy was the 
least preferred.  However, it is important to be aware that while there is a degree of 
selectivity, binding was still observed to the less preferred sequences.  Other work has 
confirmed this 5'-PuGPu selectivity, and has further allowed a rank order of preference 
of these sequences to be established, this being 5'-PuGPu > 5'-PuGPy ~ 5'-PyGPu >5'-
PyGPy (Hurley et al., 1988; Thurston, 1993). 
 
Further work using IVTF (in vitro transcription footprinting) techniques has allowed the 
characterisation of sequences to which PBD compounds bind preferentially, by looking 
at the sequences which result in a blockage of transcription by bacteriophage T7 RNA 
polymerase in vitro.  Anthramycin and sibiromycin showed an exclusive preference for 
5'-AGA sequences.  Tomaymycin and neothramycin showed a similar affinity for 5'-
AGA (i.e. blocked transcription at the same sites), but in addition blockages of 
transcription were observed at sites corresponding to 5'-AGG, 5'-GGA, and 5'-TGA 
(Puvvada et al., 1997).  It was also proposed that the base sequences flanking the 5'-
AGA sequence, preferred by anthramycin and sibiromycin, influence the degree of 
transcription block observed, with 7 bases purportedly involved in this selectivity 
(Puvvada et al., 1997). 
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The use of PBD dimers is currently thought to be a route by which the number of base 
pairs recognised by the molecule can be expanded.  The use of dimers has led to an 
increase in cytotoxicity of the PBD compound; however, thus far there is no practical 
demonstration of the increased sequence selectivity and recognition of a larger number 
of base pairs.  Molecular modelling (Jenkins et al., 1994) and NMR (Mountzouris et al., 
1994) studies have indicated that a larger 6 base pair sequence may be recognised, with 
the DSB-120 molecule actively recognising a 5'-Pu-GATC-Py or 5'-Py-GATC-Pu 
sequences, although this has yet to be demonstrated in an in vitro situation.  Similar 
molecular modelling studies have indicated a similar increased number of base pair 
recognition by the SJG-136 dimer (Gregson et al., 2001). 
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7 Aims of the research 
The pyrrolobenzodiazepine (PBD) class of DNA-interactive compounds has been 
demonstrated to show a sequence-selective binding affinity for DNA, and as such are of 
particular interest as DNA-interactive agents with a selective mechanism of action. 
 
This study aims to investigate the pharmacological characteristics of the novel PBD 
dimer SJG-136, and the PBD monomers, D709119, SJG-303 and MMY-SJG.  To this 
end, analytical methods will be developed to allow extraction and analysis of the 
compounds in biological fluids and tissues.  Furthermore, in vitro systems will be used 
to characterise the pharmacodynamic and pharmacokinetic behaviours of these agents.  
Where possible, in vivo models will be used to investigate the pharmacokinetics of these 
agents and assess pharmacodynamic endpoints.  The proposed reactivity of PBD agents 
with reduced glutathione (GSH) will also be investigated. 
 
This main focus of these studies will centre on the PBD dimer, SJG-136, as this agent is 
of particular interest due to selection for progression into man in forthcoming phase I 
clinical trials.  This selection was the result of demonstrably potent in vivo antitumour 
activity and a novel pattern of action as assessed by the NCI COMPARE analysis 
algorithm (personal communication, Prof. D. E. Thurston). 
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8 Materials and methods 
 
8.1 Test compounds 
SJG-136, D709119, MMY-SJG, SJG-303 and DC-81 were supplied as pale yellow 
powders and were obtained from Professor D. E. Thurston (University of London, UK).  
Purity and identity data was unavailable, however molecular weights were confirmed 
using mass spectrometry. 
 
SJG-136 (Figure 8.1) is a novel PBD dimer shown to bind to DNA with high affinity, 
and is believed to bind to DNA in a sequence-selective manner (Gregson et al., 1999; 
Gregson et al., 2001).  SJG-136 has previously been shown to have potent cytotoxicity 
in in vitro tumour cell line models, and has shown a novel pattern of action in the NCI 
60-cell-line screen COMPARE analysis. 
 
Figure 8.1  Structure of SJG-136.  Molecular weight 556.61 (monoisotopic MW 
556.23). 
 
D709119 (Figure 8.2) is a PBD monomer that has shown a novel mechanism of action 
in the NCI 60-cell-line COMPARE analysis (unpublished data). 
 
Figure 8.2  Structure of D709119.  Molecular weight 364.39 (monoisotopic MW 
364.14). 
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MMY-SJG (Figure 8.3) is the monomeric form of SJG-136.  MMY-SJG has been 
shown to have potent cytotoxic activity in the NCI 60-cell-line screen (unpublished 
data). 
 
Figure 8.3  Structure of MMY-SJG.  Molecular weight 272.30 (monoisotopic MW 
272.12). 
 
SJG-303 (Figure 8.4) is a PBD monomer shown to have potent cytotoxicity in the NCI 
60-cell-line screen (unpublished data). 
 
Figure 8.4  Structure of SJG-303.  Molecular weight 378.42 (monoisotopic MW 
378.16). 
 
DC-81 (Figure 8.5) is a PBD monomer used for preparation of the first synthesised PBD 
dimer, DSB-120 (Jenkins et al., 1994; Mountzouris et al., 1994) and has been shown to 
bind to DNA and have potent cytotoxicity (Bose et al., 1992c; Puvvada et al., 1993). 
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Figure 8.5  Structure of DC-81.  Molecular weight 246.26 (monoisotopic MW 
246.10). 
 
8.2 In vivo studies 
 
8.2.1 Animals 
Female NMRI (B and K Universal, Hull, UK) and NCR-Nu (NCI, USA) mice aged 6-8 
weeks were used in in vivo studies.  Mice were housed in an air-conditioned room with 
regular 12 h cycles of light and dark, and received CRM diet (SDS, Witham, UK) and 
water ad libitum.  All animal procedures were carried out under a project licence issued 
by the UK Home Office, and UKCCCR guidelines (UKCCCR, 1997) were followed 
throughout. 
 
8.2.2 Compound formulation 
D709119 was dissolved in DMSO and then diluted to the required concentration in 10% 
DMSO / arachis oil.  D709119 was administered via the intra-peritoneal (i.p.) route as a 
single bolus injection at the maximum tolerated dose (MTD) of 0.5 mg kg-1. 
 
SJG-136 was dissolved in DMSO (for i.p. studies) or DMA (for intravenous studies) 
and then diluted in physiological saline to a final solution containing < 1% DMSO.  
SJG-136 was administered via the i.p. route at the MTD of 0.2 mg kg-1.  SJG-136 was 
administered via the intravenous (i.v.) route at the MTD of 0.3 mg kg-1. 
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8.2.3 Determination of MTD 
Test compound in solvent was administered to 2 mice once daily and mice were 
weighed daily and assessed for signs of toxicity.  Toxicity is defined as weight loss of 
greater than 15% of the initial body weight.  Dose was incremented daily until toxicity 
was observed.  A solvent control group (administered dose vehicle only) was set up and 
observed in parallel.  MTD was defined as the maximum dose at which test compound 
could be administered without evidence of toxicity. 
 
8.2.4 Tumour models 
Tumour pieces were removed form storage in liquid nitrogen, defrosted and implanted 
subcutaneously into the flanks of 2 mice under aseptic conditions.  Once grown, 
tumours were removed, placed in sterile saline containing antibiotics and cut into 
approximately 1 – 2 mm fragments.  Fragments were implanted subcutaneously into the 
flanks of experimental animals.  Animals were used when tumours had grown to 
approximately 8 – 12 mm in diameter. 
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8.3 Analytical method development 
 
8.3.1 Chemicals and reagents 
All chemicals and reagents were of analytical grade and were obtained from Sigma 
(Poole, UK).  Al solvents were of analytical grade and were obtained from Fisher 
(Loughborough, UK).  All PBD compounds were obtained from Professor D. E. 
Thurston (University of London, UK). 
 
8.3.2 Characterisation of fluorescence of compounds 
Test compound was diluted in methanol or acetonitrile to a final concentration of 1 mM.  
The compound solution was manually infused into the flow cell of a Waters 454 
scanning fluorescence detector (Waters, Hertsford, UK) using a syringe, and was 
allowed to remain in the flow cell for determination of fluorescent parameters.  The 
scan function of the detector was used to obtain excitation and emission spectra of the 
compound over a wavelength range of 200 to 900 nm.  Wavelengths derived from initial 
scans were used to fine tune parameters for each compound.  Detailed instructions on 
the operation of excitation and emission scans are published in the operator’s manual 
for the scanning fluorescence detector. 
 
8.3.3 Characterisation of UV absorbance of compounds 
UV absorbance characterisation was determined following development of initial HPLC 
separation of compound.  Compound was injected onto the HPLC system at a 
concentration of 1 mM.  A Waters 996 photodiode array detector (Waters, Hertsford, 
UK) was set to record wavelengths from 210 to 700 nm during sample acquisition.  
Waters Millennium software (Waters, Hertsford, UK) was used to obtain the UV 
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absorbance spectrum as determined by the photodiode array detector at the time of 
compound elution. 
 
8.3.4 Mass spectral characterisation of compounds 
Mass spectrometry was performed unless otherwise stated using a Micromass ZMD 
single quadrupole mass spectrometer (Manchester, UK).  A Micromass Quattro Ultima 
tandem mass spectrometer was used where stated.  An electrospray ionisation probe was 
used in positive mode throughout all mass spectrometry work.  Mass spectral 
compounds were characterised by infusion into the mass spectrometer (MS) at a flow 
rate of 100 µl min-1 and concentration of 100 µM in selected solvent.  Gas flows, 
voltages and MS conditions were adjusted until optimal detection of the compound 
parent ion could be seen ([M + H]•+). 
 
8.3.5 HPLC method development 
Method development for the PBD compounds investigated in this study centred initially 
around the compound MMY-SJG due to lack of availability of the other PBD 
compounds.  Upon receipt of further PBD monomer compounds DC-81, SJG-303 and 
D709119, method development on these new compounds progressed rapidly as initial 
method development was found to be largely transferable, likely to be a result of 
structural similarities.  The compound SJG-136, a dimer of MMY-SJG, was found to be 
compatible with the methods developed for the monomers with minor alterations. 
 
Method development for the test compounds aimed to create a MS-compatible method 
to allow transference to an MS-based platform as required. 
 
8 Materials and methods 
71 
8.3.5.1 Chromatographic system 
The HPLC system consisted of a Waters 2690 separations module (Waters, Hertsford, 
UK) for solvent delivery and autosampling.  Detection was performed using a Merck L-
7480 fluorescence detector (Merck KGaA, Darmstadt Germany), a Waters 996 
photodiode array detector (Waters), a Micromass ZMD MS or a Micromass Quattro 
Ultima MS/MS (Micromass).  The detectors were used alone where appropriate, or 
connected in series to investigate several parameters per run.  When flow was directed 
into a mass spectrometer, a flow splitter was employed to ensure flow into the MS was 
within instrument specifications (<200 µl min-1).  A 0.5 µm pre-column filter 
(HiChrom, Theale, UK) was used to protect the HPLC column from any residual 
particulate matter in samples, and was found to affect chromatography less than a pre-
column cartridge. 
 
8.3.5.2 MMY-SJG, SJG-303 and DC-81 
During the course of method development, several combinations of conditions were 
tested to obtain optimal chromatography. 
 
8.3.5.2.1 Methanol-based method 
Initial method development was performed with the compound MMY-SJG.  Conditions 
used were methanol (MeOH) and water running isocratically in a 35:65% ratio, with a 
flow rate of 1 ml min-1, using a reverse-phase LiChrosorb RP8 C8 endcapped (5 µm x 
250 mm x 4 mm) column, and detection using a Waters 996 Photodiode Array detector 
(set to perform a full-scan 200 to 700 nm) and a Waters 474 fluorescence detector 
(excitation at 260 nm and emission at 420 nm, as determined from fluorescence 
8 Materials and methods 
72 
characterisation of MMY-SJG).  30 µl of a 0.1 µg ml-1 solution of MMY-SJG in MeOH 
was injected onto the column to assess chromatography. 
 
To improve peak shape, column selection was changed to a reverse-phase HiRPB C18 
endcapped (5 µm x 150 mm x 4.6 mm) column.  Buffering capacity was introduced into 
the mobile phase to enhance peak reproducibility.   Loss of peak was observed when 
using a 0.1 M phosphate buffer at pH 7.  Choice of buffer was altered to 0.01 M 
ammonium formate, adjusted to pH 4.0 using formic acid.  This replaced the previous 
aqueous component of the mobile phase.  A flow rate of 1 ml min-1 and a mobile phase 
composition of 47.5% MeOH and 52.5% 0.01 M ammonium formate (pH 4.0) running 
isocratically was used. 
 
Both SJG-303 and DC-81 were found to produce satisfactory peak shapes and 
reproducible retention times on this system, although mobile phase composition of 
aqueous and organic solvents was altered.  DC-81 was analysed using a flow rate of 1 
ml min-1 with mobile phase composition of 35% MeOH with 65% 0.01 M (pH 4.0) 
ammonium formate.  SJG-303 was analysed using a flow rate of 1 ml min-1 and mobile 
phase composition 55% MeOH with 45% 0.01 M (pH 4.0) ammonium formate. 
 
8.3.5.2.2 Acetonitrile-based method 
In order to inhibit the formation of the carbinolamine methyl ether form of the PBD 
imine compounds (as was observed by MS with MeOH in the analytical solution; see 
results sections 9.1.4, 10.1.3 and 11.3), it became apparent that it would be 
advantageous to develop a non-MeOH HPLC method.  This was achieved by 
substituting acetonitrile (MeCN) for the MeOH in the existing method.  This altered the 
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retention times and peak shapes of the compounds such that it became necessary to alter 
the choice of HPLC column to a reverse-phase Hypersil phenyl (5 µm x 150 mm x 4.6 
mm) endcapped column.  Reproducible peak shapes and retention times were achieved 
with this column/mobile phase combination with the conditions described in Table 8.1 
and a flow rate of 1 ml min-1. 
 
Compound % MeCN % 0.01M (pH 4.0) 
ammonium formate 
MMY-SJG 14 86 
DC-81 9.5 90.5 
SJG-303 20.75 79.25 
Table 8.1 HPLC mobile phase conditions for selected PBD monomer compounds. 
 
8.3.5.2.3 Mass spectrometry 
Both methods described above were assessed for use with MS detection.  The mobile 
phase conditions, flow rate, and column described above were used to analyse samples 
using a Micromass ZMD mass spectrometer (Micromass).  Flow into the mass 
spectrometer was reduced to 100 µl min-1 by use of a flow splitter.  Mass spectrometer 
conditions were optimised to: 
• Desolvation gas, 340 l h-1. 
• Cone gas, 160 l h-1. 
• Capillary, 3.13 kV. 
• Sample cone, 34 V. 
• Extraction cone, 9 V. 
• Rf lens, 0.1 V. 
• Source block temperature, 100 ºC. 
• Desolvation temperature, 150 ºC. 
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8.3.5.3 D709119 
Chromatographic separation of D709119 used a reverse-phase Hypersil phenyl (5 µm x 
150 mm x 4.6 mm) endcapped column (Sigma).  Initial chromatographic conditions 
used a methanol (MeOH)/ammonium formate based method, however it was found that 
D709119 could exist as an alternate form with methanol present so choice of organic 
solvent was switched to acetonitrile.  Isocratic conditions were developed for elution of 
D709119 using 30% MeCN and 70% 0.01 M ammonium formate (pH 4.0).  Flow rate 
was 1.8 ml min-1. 
 
Detection of D709119 was via use of a Micromass ZMD single quadrupole mass 
spectrometer detecting the parent ion ([M + H]•+) at a mass to charge ratio (m/z) of 
365.2.  High concentrations of D709119 were detectable using a Waters 996 photodiode 
array detector with optimal detection at λ 260 nm.  D709119 was not detectible by 
fluorescence detection.  MS conditions were optimised to: 
• Desolvation gas, 340 l h-1. 
• Cone gas, 160 l h-1. 
• Capillary, 3.00 kV. 
• Sample cone, 35 V. 
• Extraction cone, 17 V. 
• Rf lens, 0.5 V. 
• Source block temperature, 125 ºC. 
• Desolvation temperature, 350 ºC. 
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8.3.5.4 SJG-136 
Chromatographic separation of SJG-136 was achieved using a reverse-phase Hypersil 
phenyl (5 µm x 150 mm x 4.6 mm) endcapped column (Sigma). 
 
Isocratic conditions were developed for elution of SJG-136 using 20% MeCN and 80% 
0.01 M ammonium formate (pH 4.0).  Flow rate was 1.8 ml min-1.  It was observed that 
retention time and peak shape degraded with time using the isocratic method, therefore 
a gradient method was developed to attempt to address this problem.  Gradient 
separation gave better performance in terms of peak separation and resolution. 
 
Gradient elution of SJG-136 was performed using MeCN and 0.01 M ammonium 
formate (pH 4.0).  Changes in gradient conditions over time were linear.  Gradient 
conditions were as follows;  MeCN 14% at time 0 increased to 19% over 5 min, then 
further increased to 26% between 5 and 26 minutes, increased from 26% to 48% MeCN 
between 26 and 30 min and held at 48% MeCN for 15 min and finally allowed to re-
equilibrate at 14% MeCN for 15 min.  Flow rate was 1.8 ml min-1. 
 
Detection of SJG-136 was primarily by use of a Merck 4780 fluorescence detector 
[excitation λ 260 nm and emission λ 420 nm].  SJG-136 could be detected at high 
concentrations using a Waters 996 photodiode array detector, with optimal detection at 
λ 260 nm.  SJG-136 could be detected using a Micromass ZMD single quadrupole mass 
spectrometer, with the parent ion appearing at a m/z of 557.4 ([M + H]+) using single-
ion recording mode. 
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8.3.6 Calibration and limit of detection 
Calibration curves were performed by spiking test compound into 100 µl of drug-free 
mouse plasma to achieve set final concentrations in plasma.  Samples were then 
extracted as described (section 8.3.8) and checked for linear response over the range 
examined.  Replicate samples at a midpoint along the calibration curve were examined 
to ensure reproducibility.  The limit of detection was considered to be the lowest 
concentration that could be reliably detected following a 70 µl injection onto the HPLC 
system.  These data were used to obtain the relationship between peak area and amount 
of drug in the spiked mouse plasma. 
 
8.3.7 Stability in biological fluids 
Blood or plasma was placed on ice and spiked with test compound to desired 
concentration.  At time t = 0, a 100 µl aliquot was removed and extracted as described 
(section 8.3.8).  Spiked blood or plasma was then incubated at 37 °C with 100 µl 
aliquots removed for extraction at required time points.  The half-life for the test 
compound in plasma or blood was calculated by log-linear regression. 
 
8.3.8 Extraction from biological samples 
It was necessary to develop methods of extraction of analyte from pre-clinical samples 
for all compounds and a separate method for extraction from clinical samples for 
SJG-136 due to its imminent progression towards clinical trials. 
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8.3.8.1 Pre-clinical samples 
Extraction methodology for pre-clinical samples was designed to extract test compound 
from murine samples for use in in vivo pharmacokinetic studies as well as to be used for 
extraction from in vitro samples studying drug characteristics. 
 
8.3.8.1.1 Plasma; MeCN protein precipitation 
To 100 µl mouse plasma in a 1.5 ml microcentrifuge tube, 200 µl MeCN was added and 
the sample was vortex mixed.  Sample was centrifuged at room temperature for 20 min 
at 20,000 g.  Supernatant was removed to a fresh 1.5 ml microcentrifuge tube and spun 
in a Jouan RC 10.10 centrifugal evaporator (Jouan Ltd, Ilkeston, UK) under vacuum at 
room temperature until dry.  Sample was reconstituted in 100 µl of mobile phase, and 
centrifuged for 20 min at 20,000 g to remove any residual particulate matter.  70 µl of 
supernatant was injected onto the HPLC system for analysis. 
 
Extraction efficiencies were calculated by spiking 10 µl of test compound diluted in 
PBS to a total 100 µl of mouse plasma to give a set concentration, and extracting using 
the MeCN protein precipitation protocol.  Standards were prepared by spiking the same 
solution of test compound into 90 µl of water to give and total volume of 100 µl and 
thus identical amount of drug in plasma and standard.  Extraction efficiency was 
considered to be the percentage of drug recovered from plasma versus drug seen in the 
standard.  Controls used consisted of plasma spiked with 10 µl of PBS containing no 
test compound. 
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8.3.8.1.2 Tissue; MeCN protein precipitation 
Tissue was weighed, and 3 volumes per unit weight of PBS were added to the tumour in 
a universal tube.  Tissue was homogenised using an Ultra Turrax homogeniser (IKA 
Labortechnik, Staufen, Germany) until homogenous. 
 
200µl of tissue homogenate was aliquoted into a 1.5 ml microcentrifuge tube, and 400 
µl of MeCN was added and the sample was vortex mixed.  Sample was centrifuged at 
room temperature for 20 min at 20,000 g.  Supernatant was removed to a fresh 1.5 ml 
microcentrifuge tube and spun in a Jouan RC 10.10 centrifugal evaporator (Jouan Ltd, 
Ilkeston, UK) under vacuum at room temperature until dry.  Sample was reconstituted 
in 100 µl of mobile phase, and centrifuged for 20 min at 20,000 g to remove any 
residual particulate matter.  70 µl of supernatant was injected onto the HPLC system for 
analysis. 
 
Efficiency of extraction from tissue was calculated by spiking tissue homogenate with 
10 µl of test compound solution diluted in PBS to desired final concentration in 200 µl 
homogenate and extracting.  An identical 10 µl of test compound solution was pipetted 
into 90 µl of water as a standard.  To 200 µl of homogenate 10 µl of PBS was added as 
control, and was extracted.  Extraction efficiency was considered the percentage of drug 
recovered from homogenate versus the standard. 
 
8.3.8.2 SJG-136 phase I clinical trial 
The PBD dimer SJG-136 is expected to go into clinical trials in the near future, 
therefore an extraction method was developed here to enable extraction of SJG-136 
from clinical samples.  The criteria desired for a clinical extraction method differ as 
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sample volume will be much higher (1 – 2 ml plasma / sera from human samples versus 
100 – 200 µl from mice) and starting dose will be much lower than that used in pre-
clinical in vivo studies.  This necessitates a more sensitive method and the use of 
concentrating steps. 
 
8.3.8.2.1 MeCN Protein precipitation 
The method described in section 8.8.1.1 was used.  There was also development of an 
augmented method in which 0.5 ml of human sera was extracted by addition of 1 ml 
MeCN.  All other steps were identical to section 8.8.1.1. 
 
8.3.8.2.2 Solid phase extraction 
In all instances 100 mg, 1 ml solid phase extraction (SPE) cartridges were used.  CN-
endcapped Bond Elut (Varian) SPE cartridges were routinely used after method 
development which additionally investigated C18-endcapped, C8-endcapped, C2-
endcapped and phenyl-endcapped (Varian) cartridges. 
 
Liquid was pulled through the SPE cartridge by use of a SPS24 vacuum manifold 
(Varian).  SPE cartridges were primed with 2 ml of MeCN, conditioned with 2 ml of 
water, sample was loaded onto the cartridge, and cartridge was washed with 2 ml of 
water.  Cartridge was air dried by passing 10 ml of air through the cartridge.  Analyte 
was eluted in 500 µl of MeCN, and evaporated to dryness using a centrifugal evaporator 
(Jouan).  Sample was reconstituted in mobile phase (14% MeCN) and injected onto the 
HPLC system for analysis. 
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8.3.8.2.3 Ethyl acetate 
To 200 µl of plasma sample 1 ml of ethyl acetate was added, and the sample was vortex 
mixed.  The sample was then centrifuged at 10,000 g for 5 min.  Supernatant was 
removed to a fresh tube and transferred to a centrifugal evaporator and evaporated to 
dryness.  Sample was reconstituted in 100 µl mobile phase. 
 
Extraction efficiency was calculated by spiking plasma with 20 µl SJG-136 at 1 µM in 
PBS to give a final concentration of 0.1 µM and extracting.  20 µl SJG-136 at 1 µM in 
PBS was spiked into 80 µl of PBS as a standard, and extraction efficiency considered 
the percentage of SJG-136 recovered from plasma versus the standard.  PBS and sera 
were extracted as blanks. 
 
8.3.8.2.4 Influence of temperature 
1 ml MeCN was spiked with SJG-136 to a final concentration of 0.1 µM.  Samples were 
placed in a centrifugal evaporator and evaporated under vacuum at either at room 
temperature or 35 °C until dry.  Samples were reconstituted in 100 µl of mobile phase 
(14% MeCN) and injected onto the HPLC system.  Recovery of SJG-136 after 
evaporation was compared to unevaporated standards. 
 
8.3.8.2.5 Influence of pH 
SJG-136 was spiked into human sera to a final concentration of 0.1 µM.  Samples were 
then extracted by solid phase extraction as described, with a modification (section 
8.8.2.2).  After elution from the SPE cartridge, 10 µl of concentrated ammonia solution 
(Sigma) was added to the eluant to increase the alkalinity of the sample.  Sample was 
then evaporated to dryness using a centrifugal evaporator (Jouan) and reconstituted in 
8 Materials and methods 
81 
100 µl mobile phase (14% MeCN).  Samples alkalinised with ammonia were compared 
to samples extracted without the added ammonia, and both were compared to SJG-136 
standards to assess extraction efficiency. 
 
8.3.8.2.6 Influence of silicon coating and tube material 
Polypropylene and glass sample tubes, both uncoated and silicon coated were used, as 
well as uncoated polystyrene tubes (Sigma).  MeCN was spiked with SJG-136 to a final 
concentration of 0.1 µM, and 1 ml aliquots were distributed into each type of tube, 
placed in a centrifugal evaporator (Jouan) and evaporated until dry.  Samples were 
reconstituted in 1 ml of mobile phase (14% MeCN) and injected onto the HPLC system.  
Samples were compared to each other and to SJG-136 standards to determine effect of 
material on SJG-136 recovery. 
 
8.3.8.2.7 Zinc sulphate protein precipitation 
Sample processing to be conducted at room temperature.  To 1000 µl of sample add 100 
µl of 1 M ZnSO4 in a 1.5 ml microcentrifuge tube.  Vortex mix briefly and centrifuge at 
20,000g for 20 min.  Remove supernatant and dispose of.  Reconstitute pellet in 500 µl 
MeOH.  Mix thoroughly and centrifuge at 20,000g for 20 min.  Transfer supernatant to 
fresh 1.5 ml microcentrifuge tube.  Add 50 µl ammonia solution (30% w/w), vortex mix 
briefly and evaporate to dryness in at room temperature in Jouan RC 10.10 centrifugal 
evaporator (Jouan Ltd, Ilkeston, UK). 
 
Reconstitute sample in 100 µl mobile phase.  Centrifuge at 20,000g for 20 min to 
remove any residual particulate matter and inject 70 µl of supernatant onto HPLC 
system for analysis. 
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8.4 Glutathione reactivity studies 
Reactivity of the compounds with reduced glutathione (GSH) was assessed. 
 
8.4.1 Reaction with GSH versus time 
The reactivity of test compound with GSH over time was investigated as a function of 
disappearance of compound (as determined by HPLC) over time. 
 
Test compound was spiked into phosphate buffer (19.7% KH2PO4 0.2 M : 80.3% 
Na2HPO4 0.2 M ; pH 7.4) containing GSH at concentrations of 50 mM, 5 mM, 500 µM 
or 50 µM on ice, to a final concentration of 50 µM.  Samples were briefly vortex mixed 
and 100 µl immediately transferred to the HPLC autosampler at room temperature, 
whereon 10 µl of sample was injected onto the HPLC system for analysis.  A repeat 
injection from the same sample vial was injected every 4 h up to 24 h.  Controls assayed 
on the HPLC system were: GSH without test compound, buffer solution with test 
compound at 50 µM, and buffer solution containing neither GSH or test compound.  
Samples were compared to the control 50 µM test compound in buffer (no GSH) to 
determine relative loss of compound. 
 
8.4.2 Reaction with increasing concentrations of GSH 
The reactivity of test compound with increasing concentrations of GSH was 
investigated as a function of disappearance of compound with altered GSH 
concentration as determined by HPLC. 
 
Solutions of GSH were made up in phosphate buffer (19.7% KH2PO4 0.2 M : 80.3% 
Na2HPO4 0.2 M ; pH 7.4) at concentrations of 50, 30, 16, 8, 4, 2 and 1 mM, and 500 
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and 50 µM.  Test compound was spiked into 100 µl of each of the GSH solutions to a 
final concentration of 50 µM.  Samples were vortex mixed briefly, and 30 µl was 
injected onto the HPLC system.  Controls assayed on the HPLC system were: GSH 
without test compound, buffer solution with test compound at 50 µM, and buffer 
solution containing neither GSH or test compound.  Samples were compared to the 
control 50 µM test compound in buffer (no GSH) to determine the relative loss of 
compound. 
 
8.4.3 Effect of GSH on pH 
The effect of GSH on the pH of buffered solutions was investigated, as mimicking of 
biological pH was considered highly important. 
 
GSH was made up fresh in PBS at concentrations of 50 mM, 5 mM, 500 µM and 50 µM 
by addition of GSH as a powder and vortex mixing until GSH dissolved.  pH was 
measured in the resulting solutions using Hanna 209 pH meter (Hanna Instruments Ltd, 
Beds., UK). 
 
GSH was also made up fresh (as above) in 0.067 M phosphate buffer (19.7% KH2PO4 
0.067 M: 80.3% Na2HPO4 0.067 M; pH 7.4) and in 0.2 M phosphate buffer (19.7% 
KH2PO4 0.2 M: 80.3% Na2HPO4 0.2 M; pH 7.4).  pH was measured in the resulting 
solutions using an Hanna 209 pH meter (Hanna Instruments Ltd, Beds., UK). 
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8.5 Protein binding 
Assessment of binding of test compound to human sera proteins was performed in order 
to predict potential effects this may have on pharmacokinetics and tissue distribution of 
the compounds. 
 
8.5.1 Ultrafiltration 
100 µl of human sera (Sigma) or PBS was spiked with test compound to a final 
concentration of 500 nM.  Samples were vortex mixed briefly, and then placed in low 
binding regenerated cellulose Ultrafree-MC centrifugal filter units (Millipore, Watford, 
UK) with a molecular weight cut-off of 30,000.  Samples were centrifuged for 40 min at 
12,000 g.  Filtrate was collected and assayed by HPLC, and percentage of binding to 
protein or non-specific binding to the filter membrane was calculated by comparing 
filtered serum to filtered PBS controls and unfiltered PBS controls. 
 
8.5.2 Ultracentrifugation 
500 µl of human sera (Sigma) or PBS was spiked with test compound to a final 
concentration of 10, 100 or 1000 nM.  Samples were vortex mixed briefly, and 
transferred into polycarbonate thick-walled ultracentrifuge tubes.  Samples were then 
centrifuged at 250,000 g for 16 h at 4 °C.  Supernatants were collected and analysed on 
the HPLC system.  Both sera and PBS samples were compared to PBS samples that had 
not been centrifuged, and percentage of compound protein bound was calculated 
compound recovered from sera samples versus compound recovered from PBS samples. 
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8.6 Metabolism studies 
In order to attempt to predict the formation of metabolites in vivo, the formation of 
metabolites of SJG-136 in vitro in metabolically intact systems was investigated.  This 
is especially relevant to SJG-136 as extensive metabolism can complicate 
pharmacological characteristics of a compound and the progression of this agent into 
clinical trials, making this an especially important issue. 
 
8.6.1 S9 fraction incubations 
NMRI mice were sacrificed by cervical dislocation and liver was removed and placed 
immediately on ice.  Liver was weighed, placed in a conical based centrifuge tube and 3 
volumes per unit weight of PBS were added.  Liver was homogenised, and homogenate 
was centrifuged at 9000 g for 20 min.  The S9 fraction (supernatant) was removed to a 
fresh tube and placed on ice. 
 
Test compound was spiked into 700 µl of S9 fraction to a final concentration of 1 µM.  
Co-factors NADPH and NADH were added to the S9 fraction to a final concentration of 
1 mM, vortex mixed briefly and S9/compound/co-factor solution was incubated at 37 
°C.  100 µl samples were removed at times 0, 0.5, 1, 1.5 and 2 h, were extracted as 
described in section 8.8.1 and injected onto the HPLC system. 
 
8.6.2 Microsomal incubations 
NMRI mice were sacrificed by cervical dislocation and liver was removed and placed 
immediately on ice.  Liver was weighed, placed in a conical based centrifuge tube and 3 
volumes per unit weight of PBS were added.  Liver was homogenised and homogenate 
was centrifuged 12,000 g for 20 min.  Supernatant was removed to a fresh tube and 
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centrifuged at 100,000 g for 60 min at 4 °C.  Supernatant was removed and pellet was 
resuspended in PBS (1 ml per 1 g of liver) to produce a suspension of microsomes. 
 
Test compound was spiked into 1 ml of microsome suspension containing co-factors 
NADPH at 1 mM and MgCl2 at 2.5 mM to a final concentration of 1 µM, and incubated 
at 37 °C.  100 µl samples were taken at time 0, 5, 15, 30, 45, 60 and 90 min.  Samples 
were extracted as described in section 8.8.1, and injected onto the HPLC system for 
analysis. 
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8.7 Pharmacokinetic studies 
The pharmacokinetic profile of SJG-136 was assessed in NCR-Nu mice.  Plasma profile 
was assessed after dosing via the i.p. and i.v. route at the appropriate MTDs (0.2 mg 
kg-1 i.p.; 0.3 mg kg-1 i.v.) and also at ⅓ MTD via the i.v. route.  The i.p. study 
investigated the plasma concentration profile only in non-tumour-bearing mice.  The i.v. 
studies used HL-60 tumour-bearing mice and investigated plasma, tumour and brain 
levels of test compound.  Plasma, tumour and brain levels of test compound were 
investigated in the i.v. studies.  Mice were treated (n = 3 per time point) and samples 
were collected up to 24 h post dose. 
 
The pharmacokinetic profile of D709119 was assessed in MAC15A or MAC29 tumour 
bearing NMRI mice.  Mice were dosed via the i.p. route at the MTD (0.5 mg kg-1).  The 
study investigated the plasma time course in the MAC15A tumour-bearing mice, and 
tumour levels of test compound in both MAC15A and MAC29 tumour-bearing mice.  
Mice were treated (n = 3 per time point) and samples were collected up to 24 h post 
dose. 
 
8.7.1 Sample treatment 
Blood samples were obtained using cardiac puncture under terminal anaesthesia.  
Samples were immediately transferred onto ice for transportation and centrifuged at 
7000 g to separate plasma within 10 min of sampling.  Samples were stored at -20 °C 
prior to extraction and analysis.  Brains and tumours were removed, snap frozen in 
liquid nitrogen and stored at -80 °C prior to extraction and analysis.  Extraction 
procedures are described in detail elsewhere (see section 8.3.8). 
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8.7.2 Pharmacokinetic parameters 
Pharmacokinetic parameters were calculated using previously described methods 
(Gibaldi, 1984; Rowland & Tozer, 1989).  Sigmaplot (SPSS, Surrey, UK) was used to 
perform curve fitting according to the equations described below, with 1/y2 weighting 
applied to data points. 
 
The area under the plasma/tissue concentration time curve (AUC) was calculated using 
the trapezoidal rule.  AUC is defined as the sum of all trapezoids (to last time point at 
which concentration is determined; Equation 1) plus the extrapolated area to infinity 
(Equation 2). 
 
Area of trapezoid = (C1 + C2)/2 x (t2 – t1) 
Equation 1  Formula to calculate area of trapezoid where C1 is concentration at t1 
and C2 is concentration at t2. 
 
Extrapolated area to infinity = Clast / kel 
Equation 2  Formula to extrapolate area to infinity where Clast is concentration at 
last determined time point and kel is the elimination rate constant. 
 
The elimination rate constant, kel, was calculated by non-linear regression of the 
concentration time curve using Equation 3 to account for the distribution and 
elimination phases of drug disposition.  Equation 4 was used to account for an 
absorption component to enable curve fitting to i.p. derived data. 
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C (t) = C1e-kel1t + C2e-kel2t 
Equation 3  Equation to describe bi-exponential kinetics of compound 
elimination.  C denotes concentration, keln denotes the elimination rate constant 
and t denotes time. 
C (t) = C1e-kel1t + C2e-kel2t - (C1 + C2)ekat 
Equation 4  Equation to describe bi-exponential kinetics of compound elimination 
and absorption.  C denotes concentration, keln denotes the elimination rate 
constant ka denotes absorption rate constant and t denotes time. 
 
Cmax was determined from observations of the plasma concentration time data as the 
maximum observed concentration of drug in plasma. 
 
Half life (t½) was calculated using Equation 5. 
 
t½ = ln2 / kel 
Equation 5  Equation to calculate half life (t½). 
 
Initial volume of distribution (Vi) was calculated using Equation 6. 
 
Vi = Dose / C0 
Equation 6  Equation to calculate initial volume of distribution (Vi).  Where dose 
is the amount of compound administered and C0 is concentration at time t = 0. 
 
Volume of distribution at steady state (Vss) was calculated using Equation 7. 
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Vss = (AUMC / AUC) x (Dose / AUC) 
Equation 7  Equation to calculate volume of distribution at steady state (Vss).  
Where dose is the amount of compound administered and AUMC is the area 
under the first moment curve and AUC is the area under the curve. 
 
Clearance (CL) was calculated using Equation 8. 
 
CL = Dose / AUC 
Equation 8  Equation to calculate clearance (CL).  Dose is the amount of 
compound administered and AUC is the area under the concentration vs. time 
curve. 
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8.8 In vitro studies 
 
8.8.1 Cell culture 
Selected cell lines were cultured in RPMI-1640 medium containing 10% foetal bovine 
serum and 2 mM L-glutamine.  Cells were cultured in either 25 cm2 or 75 cm2 bottomed 
tissue culture treated non-vented flasks (depending upon numbers of cells required) in a 
5% CO2 atmosphere at 37 °C. 
 
All cell lines used were adherent.  Cells were subcultured by removing all medium, 
washing cells with 5 ml of Hanks Balanced Salt Solution (HBSS), and addition of 1 ml 
(25 cm2 flasks) or 2 ml (75 cm2 flasks) of trypsin/EDTA and incubation at 37 °C until 
cells became detached.  Cells were vigorously drawn up into and expelled from a 10 ml 
pipette to break up cell clumps.  Cells were split 1 flask into 3 flasks for further growth.  
Subculturing was performed when cells were approximately 80% confluent. 
 
8.8.2 Cytotoxicity studies 
Cytotoxicity of test compounds was assessed using the MTT assay, in which the 
tetrazolium salt, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT), 
is reduced to insoluble formazan crystals by metabolically active cells.  In this manner 
the MTT assay was used as a measure of cell viability, as described originally by 
Mosmann and co-workers (Mosmann, 1983). 
 
Cells were passaged as described (section 2.1) and the number of cells per unit volume 
was determined using a haemocytometer.  Cells were diluted if necessary to a final 
concentration of 10,000 cells per ml in culture medium.  200 µl of cell suspension was 
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aliquoted into wells on a 96-well microtitre plate, so as to give 2000 cells per well, 
excepting in columns 1 and 12 of the plates, in which culture medium only was 
dispensed.  Cells were allowed to attach overnight.  Test compound was diluted out in 
cell culture media to final concentrations in 10-fold dilution steps of 1 mM to 10 pM.  
Medium was removed from the microtitre plate wells and was replaced with culture 
medium in 8 replicates (1 column of the plate) of either test compound containing 
medium at each concentration, or of culture medium alone (1 column).  Plates were 
incubated at 37 °C in a 5% CO2 atmosphere for 96 h. 
 
MTT was dissolved in PBS at a final concentration of 5 mg ml-1 and filtered by passing 
the solution through a 0.2 µm syringe filter (Corning, Schiphol-Rijk, The Netherlands).  
Media was removed from wells and replaced with 180 µl of fresh culture medium to 
which 10 µl of MTT solution was added.  The plates were incubated for 4 h at 37 °C.  
200 µl of MTT/media solution was removed from wells taking care not to disturb 
formed formazan crystals.  150 µl of DMSO was dispensed into each well and gently 
pipetted up and down to dissolve formazan crystals.  Plates were then read using a 
Labsystems Multiskan PLUS plate reader (Vantaa, Finland) at an absorbance 
wavelength of 550 nm. 
 
8.8.3 Cellular localisation studies 
The favourable fluorescent characteristics of SJG-136 implied possibilities of using 
fluorescence microscopy or ultraviolet confocal microscopy to locate SJG-136 within 
the cell.  As there is a distinct proposed site of action of the PBD compounds in their 
activity within the nucleus of the cell the possibility of localisation of SJG-136 within 
the nucleus would support delivery of the compound to its target site. 
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Glass coverslips (BDH, Poole, UK) were disinfected by immersion in 70% ethanol: 
30% distilled water.  Cells were passaged as described (section 8.8.1), counted using a 
haemocytometer and diluted if necessary in culture medium to a final concentration of 
105 cells per ml.  Coverslips were placed in 6-well plates and 2 ml of cell suspension 
was pipetted into each well.  Cells were allowed to attach to the coverslips and grow 
until approximately 50% confluent. 
 
SJG-136 was spiked into the culture medium to a final concentration of either 100 nM 
or 1 µM.  Cells were incubated with or without compound present for 1, 6 or 18 h.  
Coverslips with attached cells (live) were mounted by inverting and placing on a 
microscope slide.  Slides were viewed immediately by fluorescence microscopy using a 
Leica DMRB fluorescence (Leica, Milton Keynes, UK) microscope with UV 
illumination and a filter allowing excitation wavelengths of 340–380 nm. 
 
8.8.4 Chromosomal staining 
 
8.8.4.1 Preparation of chromosomal DNA 
Cells were prepared so that chromosomal DNA could be observed.  Cells were grown in 
a 75 cm2 tissue culture flask, and were used when 80% confluent.  To the culture 
medium, demecolcine solution (10 µg ml-1, Sigma) was added to give a final 
concentration of 0.04 µg ml-1, and cells were incubated for 4 h.  Medium was removed 
and cells were harvested as described (section 8.8.1).  The cell suspension was 
transferred to a conical-based centrifuge tube and centrifuged at 1000 g for 10 min.  
Supernatant was discarded and cells were resuspended in 10 ml of 0.075 M KCl and 
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allowed to sit for 15 min.  Cells were centrifuged at 1000 g for 10 min and all 
supernatant, other than 0.5 ml, was removed and 10 ml of ice-cold fixative 
(Methanol:Glacial acetic acid, 3:1 ratio) was added and mixed well.  This step was 
repeated. 
 
Cell suspension was centrifuged at 1000 g for 10 min, and supernatant was removed.  
Cells were gently resuspended in 1 ml of ice-cold fixative.  Slides were cleaned to 
remove traces of grease and placed on a flat surface.  3 drops of cell suspension were 
dropped from a height of approximately 15 cm onto the centre of a slide, allowed to dry, 
and then a further 3 drops were dropped onto slide.  This was repeated until 9 drops had 
been dropped onto the slide, the slide was then allowed to dry completely.  Slides were 
examined using phase contrast microscopy to view chromosomal DNA. 
 
8.8.4.2 Staining of DNA 
Slides were incubated with 100 nM SJG-136 for 18 h at 4 °C.  Slides were viewed 
either using a Leica DMRB fluorescence microscope (Leica, Milton Keynes, UK) with 
UV illumination and filters set to excite the slide at 340 – 380 nm, or a Leica TCS-SP 
confocal microscope (Leica, Milton Keynes, UK) with pseudo-UV illumination 
(wavelength = 360 nm). 
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8.9 Flow cytometry 
Effects of the PBD dimer SJG-136 on the cell cycle were assessed using flow 
cytometry. 
 
8.9.1 Treatment of cells 
Cells were seeded into 75 cm2 tissue culture treated flasks (as described in section 
8.8.1), and allowed to grow until approximately 80% confluent.  Cells were then 
exposed to SJG-136 at 10 nM in cell culture medium, a concentration close to the 1 h 
IC50 for each cell line (as determined in section 8.8.2).  Exposure was either for 1 h, 
after which cells were washed in culture media and allowed to recover, or continuous 
exposure over the entire time.  Cells were exposed continuously or allowed to recover 
for 24, 48 or 72 h, alongside untreated controls.  At the end of treatment/recovery 
period, cells were harvested as described earlier (section 8.8.1) and additional pipetting 
was used to ensure a single cell suspension. 
 
8.9.2 DNA measurement using ethanol fixation 
Measurement of DNA content of cells was performed as previously described 
(Ormerod, 2000).  The prepared single cell suspension was centrifuged at 1000 g for 5 
min, the supernatant was discarded, and cells were resuspended in 200 µl PBS.  2 ml of 
ice-cold ethanol:distilled water (70:30 v/v ratio) was added, the suspension was briefly 
vortex mixed and the left of ice for 30 min.  Cells were harvested by centrifugation at 
300 g for 5 min, supernatant was discarded, and cells were resuspended in 400 µl PBS.  
Cells were checked microscopically to ensure minimal clumping.  50 µl of RNase 
solution (1 mg ml-1 in PBS) and 50 µl propidium iodide solution (400 µg ml-1 in water) 
were added, and the suspension was incubated at 37 °C for 30 min.  Cells were vortex 
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mixed briefly and passed through a 50 µm syringe filter (Corning, Schiphol-Rijk, The 
Netherlands) immediately before injection onto the FACS (fluorescence activated cell 
sorter) to prevent potential cell clumps. 
 
Cells were analysed using a FACSCalibur flow cytometer (BD Biosciences, Oxford, 
UK), with an argon ion laser tuned to 488 nm, and measuring forward and orthagonal 
light scatter and red fluorescence (measuring area and width). 
 
Cell counts were plotted as width versus area using Cellquest software (BD 
Biosciences, Oxford, UK), and were gated to ensure inclusion only of single cells.  
Histograms produced were processed using WinMDI (Joe Trotter, Scripps Institute, La 
Jolla, CA) software and analysed using Cylchred software (Terry Hoy, Cardiff, UK) to 
determine the proportion of cells in each of the G1, S and G2/M phases. 
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8.10 Pharmacodynamic studies 
The single-cell gel electrophoresis (Comet) assay was used to assess interstrand 
crosslinking as a pharmacodynamic endpoint in vivo in the lymphocytes and tumour 
cells of mice exposed to the PBD dimer SJG-136.  All chemicals and reagents were 
obtained from Sigma unless otherwise indicated. 
 
8.10.1 Sample preparation 
 
8.10.1.1 Isolation of lymphocytes 
Whole blood was obtained from mice under terminal anaesthesia by cardiac puncture 
following drug administration, and transferred directly to a heparinised tube on ice.  
Blood (up to 0.5 ml) was layered onto 0.75 ml Ficoll-Paque (Pharmacia Biotech, St. 
Albans, UK) in a 1.5 ml polypropylene microcentrifuge tube.  Sample was centrifuged 
at room temperature for 20 min at 450 g.  The fluffy mononuclear layer at the interface 
of the Ficoll-Paque and plasma water was removed to a fresh tube, resuspended in cold 
RPMI 1640 (Sigma) and centrifuged at 4 °C for 5 min at 200 g.  Supernatant was 
discarded, and the pellet was resuspended in 1 ml of ice cold freezing mixture (70% 
RPMI 1640, 20% foetal calf serum and 10% DMSO) and transferred to cryovials.  
Samples were immidiately placed in a -80 °C freezer for storage until analysis. 
 
8.10.1.2 Preparation of tumours 
Tumour was removed from killed mice as quickly as possible and placed in cold RMPI 
1640 medium on ice.  Tumour was placed in a petri dish in a small volume of RPMI 
1640 and chopped finely to form a cell suspension.  Cell suspension was transferred to a 
fresh universal tube and cold medium was added to a total volume of 5 ml.  The 
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suspension was centrifuged at 200 g for 5 min at 4 °C.  Supernatant was discarded and 
cells were resuspended in 1 ml of freezing mixture (70% RPMI 1640, 20% Foetal calf 
serum and 10% DMSO) and transferred into cryovials.  The suspension was 
immediately transferred to a -80 °C freezer for storage until analysis. 
 
8.10.2 Comet assay for detection of interstrand crosslinks 
The procedure for the use of the Comet assay to measure ICLs has been described in 
detail previously (Spanswick et al., 1999).  All procedures were carried out on ice and 
in subdued lighting.  Cells were irradiated with 10 Gy of X-ray radiation immediately 
prior to analysis to deliver a fixed number of random DNA strand breaks.  Cells were 
embedded in 1% agarose on a precoated microscope slide and lysed for 1 h in lysis 
buffer (100 mM disodium EDTA, 2.5 M NaCl, 10 mM Tris-HCl, pH 10.5; to which 1% 
Triton X-100 was added immediately prior to analysis), after which the slides were 
washed with distilled water every 15 min for 1 h.  Slides were incubated in alkali buffer 
(50 mM NaOH, 1 mM disodium EDTA, pH 12.5) for 45 min, and the electrophoresed 
in the same buffer for 25 min at 18 V (0.6 V cm-1), 250 mM.  The slides were then 
rinsed with neutralising buffer (0.5 M Tris-HCl, pH 7.5) and then with saline. 
 
Slides were allowed to dry, and were then stained with propidium iodide (2.5 µg ml-1) 
for 30 min, after which they were rinsed with distilled water.  Slides were examined 
using a NIKON inverted microscope using a high pressure mercury light source 
(NIKON UK Ltd, Kingston Upon Thames, UK) with a 510 – 560 nm filter and a 590 
barrier filter at x20 magnification.  Pictures were captured using a charge-coupled 
device (CCD) camera and analysed by use of Komet Analysis software (Kinetic 
Imaging, Liverpool, UK).  25 cells were analysed for each duplicate slide.  Tail moment 
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was calculated using Komet Analysis software, based on the definition of Olive and co-
workers (Olive et al., 1990).  Crosslinking was expressed as: percentage of decrease in 
tail moment = [1 – (TMdi –TMcu/TMci – TMcu)] x 100.  TMdi is tail moment of drug 
treated irradiated sample, TMcu is tail moment of untreated irradiated control, and TMci 
is tail moment of untreated irradiated control. 
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9 The PBD dimer, SJG-136 
SJG-136 (NSC D694501; Figure 9.1) is s PBD dimer compound investigated in this 
study as a result of evidence of potent cytotoxicity (and novel mechanism of action as 
indicated by NCI COMPARE analysis), proposed sequence-selective DNA binding and 
current progress towards phase I clinical trials.  As such there is much interest in this 
compound.  Further understanding of the pharmacology of SJG-136 is vital in 
predicting and understanding the properties of the agent as it progresses towards use in 
man. 
 
 
Figure 9.1  Structure of the PBD dimer, SJG-136. 
The study is the first to characterise SJG-136 for analytical detection and the 
pharmacological description for behaviour of the compound in in vivo and in vitro 
models. 
 
9.1 Compound characterisation 
To facilitate analysis of SJG-136, the compound was assessed for detection using 
several available methods.  This allowed selection of optimal detection parameters for 
analytical method development. 
 
9.1.1 UV absorbance spectra 
UV spectral characteristics of SJG-136 were identified using photodiode array 
detection.  This allowed a UV absorbance spectrum to be generated and optimal 
wavelengths for detection to be determined from these data (Figure 9.2).  UV 
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absorbance spectra were determined by development of a basic MeCN/water HPLC 
method, injection of the compound onto the system using this method (at 1 mM), and 
subsequent analysis of the spectral properties of the eluted peak (as described in section 
8.3.3). 
 
 
Figure 9.2  UV absorbance spectrum of SJG-136.  Useful maxima for optical 
detection are seen at 225, 236, 262 and 317 nm. 
 
The spectrum demonstrated peaks for detection at 225, 236, 262 and 317 nm, although 
spectral peaks were observed to be broad. 
 
9.1.2 Fluorescence characterisation 
The fluorescent spectral characteristics of SJG-136 were investigated over the 
wavelength range 210 – 900 nm.  SJG-136 was trapped in the flow cell of the scanning 
fluorescence detector as described (section 8.3.2) and the solution was scanned to obtain 
excitation and emission spectra.  Excitation scans were performed by detecting emission 
at a wavelength of 400 nm (Figure 9.3); emission scans were performed by excitation at 
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a wavelength of 235 nm (Figure 9.4).  These wavelengths were determined from 
preliminary work suggesting optimal excitation and emission at approximately these 
wavelengths in PBD compounds. 
 
 
Figure 9.3  Excitation fluorescence spectrum of SJG-136 (using emission 
wavelength 400 nm).  Optimal wavelength for detection seen at 235 nm; 
optimal selectivity at 260 nm due to reduction in background noise. 
 
Results showed the optimal excitation wavelength for SJG-136 as 235 nm, although 
spectral peaks were observed to be broad with excitation peaks of lower fluorescence 
intensity at 260 and 320 nm.  A wavelength of 260 nm was chosen for detection due to 
the decreased background noise and interference generally observed at this wavelength 
versus 235 nm.  Optimal emission wavelength was seen at 420 nm. 
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Figure 9.4  Emission fluorescence spectrum of SJG-136 (using excitation 
wavelength of 235 nm).  Optimal wavelength for emission seen at 420 nm. 
 
9.1.3 Effect of solvent on fluorescence intensity 
The effect of solvent upon the intensity of fluorescence of SJG-136 was investigated in 
solvents typically involved in the detection or handling of the compound (Figure 9.5).  
It was found that SJG-136 fluoresced most intensely in MeOH or 50% MeCN:50% 
water (no significant difference between the two groups; P  > 0.05, two tailed unpaired 
Students t-test).  The intensity of fluorescence in either of these solvents was 
significantly higher than that in any of the other investigated solvents (P < 0.005, two 
tailed unpaired Students t-test). 
 
Analytically, there are implications in the effect of solvent on the intensity of SJG-136 
fluorescence, as the limit of detection may be affected by the choice of solvent.  
However, due to other unique properties for SJG-136, solvent choice for analysis of the 
agent was constrained and choice of MeOH was not viable (see section 9.1.4). 
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Figure 9.5  The effect of solvent on fluorescence intensity of SJG-136 (mean ± 
SD; n = 3).  Note: 0.01 M AF = 0.01 M ammonium formate, pH 4. 
 
9.1.4 Mass spectral characteristics 
The mass spectral characteristics of SJG-136 were obtained by infusing SJG-136 
directly into the mass spectrometer with no chromatography, and tuning of the mass 
spectrometer (MS) to maximise the intensity of the SJG-136 ion (see section 8.3.4). 
 
9.1.4.1 Single quadrupole mass spectrometry 
Single quadrupole mass spectrometry was used to identify the dominant ion for SJG-
136 as it was envisioned that MS may be used for detection of compound and 
identification of metabolites.  SJG-136 was infused directly into the MS, and tune page 
conditions were adjusted to give optimal detection of the ionised parent compound at 
mass + 1 ([M + H]•+); detected as a mass to charge (m/z) ratio of 557.1 (Figure 9.6a).  
The exact or monoisotopic molecular weight of SJG-136 is calculated as 556.2.  It was 
proposed that the imine functional groups of SJG-136 possess the potential to react with 
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water and/or methanol to form carbinolamine or carbinolamine methyl ether versions of 
the compound respectively (illustrated in Figure 9.7); this was investigated to examine 
the impact on method development.  This phenomenon has been speculated for many 
PBD compounds, but no successful attempts to prove the existence of these forms have 
been published to date. 
 
In order to detect these additional forms of SJG-136, the compound was infused into the 
MS in either 100% MeCN, 50% water: 50% MeCN or 100% MeOH.  The 
carbinolamine form of SJG-136 was detected at m/z 615.1 and 631.1, corresponding to 
an addition of a water molecule at both imine groups (+36) plus a sodium (+23; 
[M + 2H2O + Na]•+) or potassium (+39; [M + 2H2O + K]•+) adduct formed within the 
MS (Figure 9.6b).  In this instance the most intense ion is still the parent compound ion 
at 557.1.  The carbinolamine methyl ether form of the compound was detected at 589.4, 
643.1 and 659.1, corresponding to the addition of one MeOH molecule (+32; 
[M + MeOH]•+) or two MeOH molecules (+64) plus either sodium (+23; [M + 2MeOH 
+ Na]•+) or potassium (+39; [M + 2MeOH + K]•+) adducts (Figure 9.6c).  These data 
demonstrate that SJG-136 in the presence of MeOH will react with MeOH to form the 
carbinolamine methyl ether.  This formation produced a molecular ion of equivalent 
intensity to the SJG-136 imine form.  As a consequence of this discovery, it was 
decided to avoid using MeOH in HPLC method development as detection using MS 
may show decreased sensitivity if the SJG-136 ion is present in two forms.  The 
reactivity of SJG-136 with water appeared to be relatively insignificant, as SJG-136 
parent ion remained the obviously most intense ion.  This, coupled with the 
impracticality of removing water from the analytical systems and the impossibility of 
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removing water from biological systems, precluded removal of water from method 
development. 
 
 
Figure 9.6  Mass spectra of SJG-136 showing potential of SJG-136 to react with 
water and methanol.  SJG-136 with: a) MeCN showing SJG-136 in imine form 
at m/z 557.1; b) water present showing imine (557.1), and carbinolamine (+Na 
adduct at 615.1 or +K adduct at 631.1); c) MeOH present showing imine 
(557.1), mono-carbinolamine methyl ether (589.4) and bis-carbinolamine 
methyl ether (+Na adduct at 643.1 or +K adduct at 659.1). 
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These data indicate that SJG-136 can exist in 3 forms depending upon the solvent in 
which it is dissolved.  The imine form (as illustrated in both Figure 9.1 and Figure 
9.7-1), the bis-carbinolamine form (Figure 9.7-2) and the bis-carbinolamine methyl 
ether form (Figure 9.7-3).  This behaviour was seen in all the PBD compounds 
investigated (see sections 10.1.3 and 11.3).  However, due to the dimeric form of SJG-
136, this is further complicated as it is possible that each arm of the dimer may be in a 
different form, for which there is evidence (Figure 9.6c indicates the formation of a 
mono-carbinolamine methyl ether form of SJG-136). 
 
 
Figure 9.7  The three forms of PBD compounds illustrated by showing the 
reactive imine element of PBD compounds.  a) The bis-imine form.  b) The 
bis-carbinolamine form (resulting from the addition of water).  c) The bis-
carbinolamine methyl ether form (resulting from the addition of MeOH).  d) 
The mono-carbinolamine methyl ether form.  Red colouring denotes the 
reactive groups. 
 
9.1.4.2 Tandem quadrupole mass spectrometry 
SJG-136 was characterised using MS/MS to enable the use of this technique as a 
sensitive and selective form of detection.  SJG-136 was infused into the mass 
spectrometer, and the tune conditions of the first quadrupole were optimised to give 
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maximal intensity of the SJG-136 parent ion.  The second quadrupole was then used to 
perform a daughter ion scan, and collision cell conditions and gases were tuned to 
identify the most intense daughter ion for SJG-136 (Figure 9.8).  Finally, these data 
were used to fine-tune a sensitive and selective MRM (multiple reaction monitoring) 
detection method which afforded approximately 10-fold lower limit of quantification 
versus single quadrupole detection. 
 
 
Figure 9.8  Daughter ion scan of SJG-136 showing major fragment at m/z 475.7.  
SJG-136 parent ion can be seen at m/z 557.1. 
 
 
Figure 9.9  Diagram of SJG-136 showing probable fragmentation of the molecule 
for MS/MS analysis.  * deontes possible site/s of protonation. 
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The major fragment of SJG-136 was determined to be at an m/z of 475.7, corresponding 
to the loss of one of the c-ring pyrrolidine structures from the molecule (Figure 9.9). 
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9.2 Analytical method development 
It was evident that a highly sensitive method for detection of SJG-136 was needed due 
to the low MTD of SJG-136 (0.2 mg kg-1).  A MeCN-based mobile phase was chosen 
for method development of SJG-136 based on data indicating reactivity of the 
compound with MeOH (section 9.1.4.1).  Fluorescence detection was chosen as the 
primary mode of detection, as it provided greater than 10-fold lower limit of 
quantification in early method development versus UV absorbance detection using a 
photodiode array detector (Figure 9.10). 
 
 
Figure 9.10  Early method development chromatograms illustrating relative 
sensitivity of detection for SJG-136 via (1) fluorescence detection (Ex λ 260 
nm, Em λ 420 nm) or (2) UV absorbance detection with photodiode array 
detector (260 nm).  Peaks labelled (a) show injection of SJG-136 at 1 µM (39 
ng on column) on both (1) and (2); peak labelled (b) shows 0.1 µM (3.9 ng on 
column) injection (no peak found with UV absorbance detection). 
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Furthermore, fluorescence detection was found to be more sensitive than single 
quadrupole MS detection using the selected ion recording (SIR) function.  Fluorescence 
resulted in a 10% better signal-to-noise ratio than MS detection, as calculated using 
MassLynx software. 
 
 
Figure 9.11  Comparison of SJG-136 detection with: (a) fluorescence detection 
(Ex λ 260 nm, Em λ 420 nm) or (b) mass spectrometer detection using the SIR 
function  (39 ng SJG-136 injected on column).  Intensity / fluorescence are not 
directly comparable; however fluorescence detection (a) shows a 10% better 
signal-to-noise ratio versus MS detection (b). 
 
Though twin quadrupole (MS/MS) detection was found to be as sensitive as 
fluorescence detection, MS/MS detection was not available for routine analytical work 
and was therefore not considered for mainstream method development. 
 
9.2.1 Isocratic separation 
Initial development focused on developing an isocratic method with a short run time (< 
20 min) to facilitate rapid sample processing.  Method development for SJG-136 was 
based on earlier work in this study on PBD monomer compounds (section 11).  The 
9 The PBD dimer, SJG-136 
112 
structural similarity of SJG-136 to the PBD monomer compounds meant that it was 
probable that the analytical conditions would be largely transferable (in terms of mobile 
phase and column selection), although the organic/aqueous balance of solvents would 
likely need to be optimised.  Fluorescence detection of SJG-136 was preferred, as this 
was found to be the most sensitive form of detection compared to UV absorbance and 
single quadrupole mass spectrometry.  Excitation λ of SJG-136 was 260 nm and 
emission was 420 nm. 
 
SJG-136 was injected onto the HPLC system as a 70 µl injection of a 100 nM SJG-136 
solution.  Mobile phase conditions were found to be optimal at 20% MeCN: 80% 0.01 
M ammonium formate (pH 4.0), giving a symmetrical peak shape and highly 
reproducible retention time (standard deviation of 0.027 min during a sample run; n = 
10) during individual sample runs (Figure 9.12). 
 
Figure 9.12  Example chromatographic trace for SJG-136, using the isocratic 
method.  Trace shows a 70 µl injection of a 100 nM solution of SJG-136 (3.9 
ng on column injection). 
 
Following the development of an extraction method for SJG-136 from plasma (section 
9.3.1) there was observation of a gradual build up of plasma interference on the column 
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(Figure 9.13), as well as intermittent interference close to the retention time of SJG-136 
which became progressively worse following subsequent injections.  As detection limits 
were intended to be in the low nM range, this problem was considered severe enough to 
switch to a gradient method of separation. 
 
9.2.2 Gradient separation 
The use of a gradient method for SJG-136 elution resulted in better peak separation 
from plasma interferences following extraction (Figure 9.14), while maintaining 
symmetrical peak shape (Figure 9.15).  Including a strong organic component (50% 
MeCN) at the end of the gradient method resulted in the removal of build-up of material 
on the column.  Retention times for SJG-136 with the gradient method were highly 
reproducible within sample sets (standard deviation of 0.032 min during a sample run; n 
= 20).  The gradient method resulted in much improved separation, although the 
analytical run time was much increased.  The improvement in peak separation was 
sufficient to warrant the extended run time, and thus the gradient method was used in 
further studies. 
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Figure 9.13  Example chromatogram showing a gradient separation of SJG-136 
from plasma interference in murine plasma.  Trace shows a 70 µl injection of 
an extraction from 100 nM SJG-136 in murine plasma (3.9 ng on column 
injection). 
 
Figure 9.14  Example chromatographic trace for SJG-136, using the gradient 
method.  Peaks shown are SJG-136 at 18.3 min (39 ng on column injection) 
and the PBD monomer DSB-120 at 11.3 min (3.9 ng on column injection). 
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9.3 Pre-clinical method development 
 
9.3.1 Extraction from biological samples 
Extraction efficiencies of SJG-136 from plasma and tissue homogenate were calculated 
by spiking SJG-136 into plasma or tissue homogenate to a final concentration of 100 
nM (described in section 8.3.8), a concentration likely to be pharmacokinetically 
relevant (i.e. achievable in vivo).  Extraction from preclinical murine plasma and tissue 
samples resulted in the extraction efficiencies detailed in Table 9.1.  High recovery of 
SJG-136 from plasma and simplicity of the MeCN protein precipitation method made 
this technique the method of choice.  The lower extraction efficiencies of SJG-136 from 
tissues, while not ideal were considered to be adequate.  Investigations into the use of 
solid phase extraction for use with tissue homogenate proved impractical (the 
particulate nature of the homogenate caused blockage of the cartridges).  It is important 
to consider these data alongside plasma protein binding data (section 9.5.1), as this 
indicates that the process of MeCN protein precipitation is liberating protein-bound 
drug during the extraction process.  It would not be possible to achieve such high 
extraction efficiency if SJG-136 remained protein-bound, as approximately 80% of drug 
would remain in the protein pellet. 
 
Biological sample Extraction efficiency 
(% ± 1 SD) 
Plasma 98.1 ± 0.07 
Brain 53.6 ± 0.06 
Tumour 52.6 ± 0.03 
Table 9.1  Plasma and tissue extraction efficiencies of SJG-136 using MeCN 
protein precipitation (n = 3; mean ± SD). 
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9.3.2 Calibration 
9.3.2.1 Calibration curve 
Calibration curves for SJG-136 were produced in murine plasma and were found to be 
linear over the range 5 to 1000 nM, with low intra-day variation (coefficient of variation 
= 0.06) as tested by repeat injections at the midpoint of the calibration curve, 100 nM 
(Figure 9.15).  Calibration curves were performed as recommended (Shah et al., 1992) 
before analysis of any pharmacokinetic samples to ensure inter-day reliability of the 
assay. 
 
Figure 9.15  Calibration curve for SJG-136 in murine plasma (5 – 1000 nM; 2.8 – 
556 ng ml-1; n = 1); inset shows calibration curve over 5 – 100 nM (r2 = 0.99; 
linear curve fit is defined as y = 274.8x - 1053 using 1/y2 weighting). 
 
Calibration of SJG-136 showed a linear relationship between integrated peak area and 
concentration over the range studied (5 – 1000 nM), with good correlation as assessed 
by the coefficient of determination (r2; calculated by the method of least-squares) and 
by back calculating values for points on the calibration curve from the fitted curve 
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(Table 9.2).  The deviation from nominal values was found to be within acceptable 
parameters as previously defined (Shah et al., 1992).  The use of the structurally similar 
PBD dimer DSB-120 was investigated as an internal standard for the method, although 
due to the reactivity of the compound this increased the variation of the assay. 
 
Standard 
Concentration (nM) 
Calculated 
Concentration (nM) 
% Dev 
5 5.4 7.9 
10 8.7 13.2 
30 28.1 6.4 
70 59.8 14.6 
100 85.1 14.9 
300 336.3 12.1 
700 708.1 1.2 
1000 987.2 1.3 
Table 9.2  Back calculation of points on the calibration curve for SJG-136 in 
murine plasma (from Figure 9.15) showing back calculated concentrations and 
% deviation from the standard concentration. 
 
9.3.2.2 Reproducibility of analysis 
Day-to-day variation of calculated concentrations of SJG-136 were assessed by 
repeating calibration curves on different days.  Inter-day variation was calculated as the 
coefficient of variation (Table 9.3).  CV was found to be within acceptable limits (Shah 
et al., 1992).  
 
Intra-day variation was found to be low; repeated injections of SJG-136 at 100 nM 
during one day gave a coefficient of variation of 6% (n = 6). 
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Day Calculated concentration (nM) 
 10 100 1000 
1 8.6 89.6 985.1 
2 8.7 80.8 986.6 
3 12.8 87.5 1001.2 
CV (%) 24.1 5.3 0.9 
Table 9.3  Inter-day variation of calculated concentrations of SJG-136 extracted 
from mouse plasma samples; CV = coefficient of variation. 
 
9.3.2.3 Limit of detection 
Limit of quantification (LOQ) was found to be 5 nM in mouse plasma, with a signal to 
noise ratio of >5:1 (Figure 9.16) as calculated using MassLynx software.  Figure 9.16 
shows a 70 µl injection of extract at 5 nM (2.78 ng ml-1), which equates to an injection 
of 0.2 ng onto the column. 
      
Figure 9.16  a) 5 nM SJG-136 extracted from mouse plasma. b) Blank extracted 
mouse plasma without added compound. 
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9.4 Clinical method development 
The progression of SJG-136 to phase I clinical trials necessitated the development of an 
appropriate method for extraction of SJG-136 from human samples.  All work was 
performed using pooled human sera (Sigma) due to ethical problems in obtaining fresh 
human blood and plasma.  While there was no technical reason why the extraction 
method developed for murine samples could not be used for human samples, the 
starting dose for SJG-136 in man will be many times lower than the MTD in mice.  This 
reduced starting dose will probably require a lower limit of detection, therefore a 
method that will make use of the increased sample volume obtained from patients 
(typically 1 ml or above) to extract drug and concentrate it to enable increased detection 
of drug was required.  Extracting drug from 1 ml of sera and concentrating the sample 
into 100 µl to give a 10-fold increase in drug concentration (and thus a lower limit of 
detection) was desirable.  To this end, alternative methods of extraction were 
investigated. 
 
9.4.1 MeCN protein precipitation 
Extraction of SJG-136 from 100 µl of sera using an identical method to that described 
(section 8.3.8.1) for extraction from murine samples, yielded an extraction efficiency of 
60.9 ± 10% (mean ± %RSD).  While this extraction efficiency was adequate, it did not 
include a concentration step and thus there is no increase in sensitivity of the assay 
overall.  Using 100 µl rather than all of the available 1 ml ignores the possibility of 
increased limit of detection via use of a concentrating step. 
 
Optimisation of this method in view of the evaporation issues discussed in section 
9.4.3.2, and increasing the volume of sera extracted from 100 µl to 500 µl (to which 1 
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ml of MeCN was added for protein precipitation) indicated potential extraction 
efficiencies of approximately 95% while still including a concentration step.  However, 
it was not possible to further investigate the reproducibility and validation of this 
method due to time constraints. 
 
9.4.2 Ethyl acetate extraction 
Ethyl acetate protein precipitation was investigated as a potential extraction procedure, 
however preliminary investigations indicated an unacceptably low extraction efficiency 
using this method (20%; n = 2).  Consequentially this was not investigated further. 
 
9.4.3 Solid phase extraction 
Solid phase extraction (SPE) was investigated for extraction of SJG-136 from human 
sera.  There were several steps in the development and optimisation of this method as it 
is a chromatography-based extraction method and as such requires selection of optimal 
SPE cartridge packing material (the solid phase), elution solvents and factors such as 
modulation of pH. 
 
9.4.3.1 SPE cartridge selection 
SJG-136 was extracted from 1 ml of human sera using a simple water/MeCN-based 
extraction method for selection of cartridge packing material.  It was found that 
cyanopropyl endcapped (CN-E) cartridge packing material produced the highest 
extraction efficiency (Table 9.4).  This extraction method development did not initially 
include a concentrating evaporation step, but was used purely to assess the efficiency of 
the cartridges investigated. 
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Extraction 
cartridge 
Extraction 
efficiency ± CV
CN-E 82 ± 7.4% 
C18-E 66.8 ± 3% 
C8-E 68.6 ± 2.2% 
C2-E 56.4 ± 29.8% 
Phenyl 56.1 ± 26.8% 
Table 9.4  Comparative extraction efficiencies for SJG-136 from human sera 
using a variety of available solid phase extraction cartridges (mean ± SD; 
n = 3). 
 
Due to the selection of a phenyl column for HPLC analysis, it was expected that the 
phenyl SPE cartridge would give the highest extraction efficiency.  However, the data 
showed that CN-E based cartridges offered an approximate 15% advantage over the 
next best cartridge.  Consequently, CN-E cartridges were selected for further 
development of the SPE extraction method. 
 
9.4.3.2 Effect of evaporation on extraction efficiency 
In order to achieve a 10-fold increase in concentration of drug from a 1 ml sample as 
desired, it was necessary to include an evaporation step in the extraction process.  The 
MeCN eluate from the SPE was evaporated to dryness and reconstituted to one tenth of 
the original volume in mobile phase and analysed.  This was designed to produce a 
10-fold increase in peak area relative to the un-evaporation concentrated eluate, and 
therefore a tenfold increase in the limit of detection.  However it was found that the 
inclusion of an evaporation step into the extraction process resulted in a drastic drop in 
relative extraction efficiency from 82% when not evaporated to 30-45% when 
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concentrated by evaporation.  Inter-day reproducibility of the extraction technique 
became highly variable alongside this development. 
 
To isolate the step within the extraction process causing loss of compound, each step of 
the process was investigated.  The evaporation step proved to be the cause, as it was 
observed that spiking drug into MeCN alone and evaporating to dryness did not result in 
100% recovery of compound as expected.  Factors investigated to identify the cause of 
this loss of compound during evaporation were microcentrifuge tube selection and 
temperature. 
 
9.4.3.2.1 Tube selection 
The possibility of sample tube material contributing to the loss of compound during the 
evaporation step was considered.  Several different sample tube types were used; 
siliconized tubes were investigated as siliconization may alter binding of compound to 
sample tube surfaces.  Several sample tube types were used, and the full extraction 
procedure was performed to assess impact of tube material. 
 
It was observed that the polypropylene sample tubes previously used in method 
development resulted in the highest extraction efficiency (Figure 9.1).  However, only a 
small difference in extraction efficiency was observed by changing sample tube material 
(difference between most inefficient and efficient tubes was observed to be 15%).  
Interestingly, siliconisation, which was used to reduce loss of compound by preventing 
binding to sample tube material, actually resulted in a lower recovery of compound. 
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Figure 9.17  Effect of sample tube selection on extraction efficiency of SJG-136 
using SPE method (mean ± SD; n = 4). 
 
9.4.3.2.2 Temperature 
To assess the effect of temperature on recovery from evaporation, MeCN spiked with 
SJG-136 was aliquoted into polypropylene sample tubes and samples were evaporated 
to dryness then reconstituted in mobile phase and analysed on the HPLC system.  No 
extraction step was included.  Samples were either evaporated at 37 °C or at room 
temperature. 
 
Analysis showed that after evaporation at 37 °C only 41% of SJG-136 was recovered, 
whereas evaporation at room temperature resulted in recovery of 86% of compound.  
This indicated that temperature at which the evaporation step is performed (routinely 
37 °C) leads to a loss of compound and a reduced extraction efficiency.  This may be 
due to temperature-induced degeneration of compound, or could be a result of 
temperature-induced binding of SJG-136 to the sample tubes.  Ideally, radiolabelling of 
the compound would allow the loss of compound to be traced, but this facility was 
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unavailable for the present study.  As a result of these data, all further evaporation was 
carried out at room temperature to minimise loss of compound. 
 
9.5 Pre-clinical pharmacokinetics 
 
9.5.1 Protein binding 
 
9.5.1.1 Ultrafiltration 
Preliminary studies of protein binding of SJG-136 using ultrafiltration indicted that this 
method would be unsuitable for use with SJG-136.  SJG-136 was observed to show a 
high level of binding to the filter membrane.  This was assessed by comparing SJG-136 
diluted in PBS passed through the filter to SJG-136 in PBS not passed through the filter 
membrane.  While it may be possible to estimate protein binding by comparison of 
filtered SJG-136 in PBS to an unfiltered standard to calculate percentage of compound 
bound to the filter membrane, the binding of drug to filter would be liable to introduce a 
significant margin of error. 
 
At an SJG-136 concentration of 500 nM, only 11.3 ± 2.2% (n = 3) of compound was 
recovered from a filtered standard (SJG-136 diluted in PBS), indicating extensive 
binding of SJG-136 to the filter membrane.  From murine plasma, 4.8 ± 2% (n = 3) of 
SJG-136 was recovered by ultrafiltration.  This method of assessment of protein binding 
indicates moderate binding of SJG-136 to plasma proteins (approximately 57% drug 
bound).  However, due to the high degree of non-specific binding to the filter, alternate 
methods of assessing protein binding were investigated. 
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9.5.1.2 Ultracentrifugation 
Using ultracentrifugation to precipitate sera proteins enabled circumvention of the filter 
membrane binding seen with ultrafiltration.  Recovery from ultracentrifuged samples 
was checked by comparison of standards of SJG-136 in PBS after centrifugation with 
samples that had not been centrifuged, and was found to be 91.4 ± 10.8% (mean ± SD) 
in human sera.  Human serum was used in these studies as ethical issues prevented the 
sacrifice of animals to obtain the increased volume of plasma needed for 
ultracentrifugation studies; human plasma was unavailable.  However, the use of human 
biological fluids should give a more accurate prediction of pharmacokinetic parameters 
in man. 
 
Protein binding was calculated by comparison of spiked SJG-136 samples with identical 
spiked PBS standards after ultracentrifugation.  Protein binding was calculated to be 
78.2% and 82.3% at 1000 nM and 100 nM respectively (Table 9.5), SJG-136 could not 
be detected in 10 nM samples due to chromatographic interference. 
 
SJG-136 concentration (nM) 
in human sera 
% protein bound 
(mean ± SD) 
1000 78.2 ± 10.6% 
100 82.3 ± 13.1% 
10 n / d 
Table 9.5  Assessment of % of SJG-136 bound to human sera protein using 
ultracentrifugation (n = 4). 
 
The major difference between plasma and serum is the lack of fibrinogen and clotting 
factors in serum.  Studies have suggested that in the majority of cases there is little drug 
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binding to fibrin, fibrinogen or other components of the blood clot, making use of 
plasma or serum essentially identical.  The major pharmacokinetically important 
components such as albumin and α1-acid glycoprotein are present in both serum and 
plasma at equivalent levels (Lum & Gambino, 1974; Sadee et al., 1980).  Other sources 
suggest that use of serum is preferable to plasma as this avoids the possibility of 
interference with anticoagulants necessary to prevent clotting when using plasma 
(Kwon, 2001).  These data indicate that SJG-136 shows a moderate level of protein 
binding, as it could be estimated that at any given time in systemic circulation 
approximately 20% of drug present will be unbound to plasma/serum proteins. 
 
It is of note that total plasma protein in man is comparable to total plasma protein found 
in mouse (per unit weight).  However, of the two major plasma proteins, albumin and 
α1-acid-glycoprotein, albumin levels in man are similar to those found in the mouse 
whereas there is a 10-fold difference in the amount of α1-acid-glycoprotein found 
(Davies & Morris, 1993).  It may be of use to characterise the level of binding of SJG-
136 to α1-acid-glycoprotein in order to better predict pharmacokinetic differences that 
may be seen moving from mouse to man (i.e. more or less free drug in plasma); it would 
also be helpful to characterise the level of plasma or sera protein binding seen in the 
mouse for the same reason. 
 
9.5.2 Stability in blood and plasma 
Stability of SJG-136 in murine blood and plasma was assessed to determine the 
possibility of degradation of drug ex vivo during sample handling.  Characterisation of 
SJG-136 stability was performed over a 6 h period, with SJG-136 spiked into blood and 
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plasma to a final concentration of 100 nM and incubated at 37 °C for the duration of the 
experiment. 
 
Figure 9.18  Stability of SJG-136 in murine plasma over time at 37 °C.  Values 
are expressed as a % of drug recovered at t = 0 h (mean ± SD; n = 3). 
 
SJG-136 was stable in plasma, with no appreciable loss of compound up to 6 h.  In 
blood, SJG-136 showed a gradual loss of recovery of compound over the 6 h of the 
experiment.  The half-life of SJG-136 in plasma and blood was calculated by fitting a 
log-linear curve to the plasma and blood data points, and extrapolating to 50% recovery.  
Due to the apparent lack of degradation of SJG-136 over the 6 h time period of the 
experiment, extrapolation of the curve indicated a half-life in plasma of SJG-136 in 
excess of 24 h.  Half-life in blood was calculated as 11.5 h.  These data imply that 
sample processing should be rapid in that plasma should be separated from blood as 
soon as possible ex vivo.  As demonstrated, the plasma stability indicates that there is 
unlikely to be any significant loss of compound from plasma during sample handling. 
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9.5.3 In vivo intra-peritoneal pharmacokinetics 
The pharmacokinetic plasma time-course of SJG-136 in the NCR-Nu mouse was 
evaluated following i.p. administration of SJG-136 at the i.p. MTD of 0.2 mg kg-1 
(Figure 9.19). 
 
 
Figure 9.19  SJG-136 concentration (mean ± SD) versus time profile in NCR-Nu 
mouse plasma following i.p. administration at 0.2 mg kg-1 (n = 3, LOQ = 
5 nM).  Curve shows fit using 3 compartment model (Equation 4: C1 = 2776, 
C2 = 70, ka = 3.8, kel1 = 3.1, kel2 = 0.6). 
 
The area under the concentration time curve (AUC) was calculated to be 337.9 nM h 
(188.1 ng h ml-1).  Terminal elimination half life from plasma was moderate, with a 
calculated t½ of 1.2 h (kel calculated as 0.58 h-1 by curve fitting, t½ calculated as ln2 / 
kel).  A moderate plasma clearance of 17.7 ml min-1 kg-1 (approximately 20% of murine 
hepatic blood flow; calculated assuming complete absorption from the peritoneal cavity) 
was calculated for SJG-136.  SJG-136 was not detectable after 4 h post dose.  Cmax of 
SJG-136 was detected at 30 min post-dose as 315.7 nM (175.7 ng ml-1). 
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9.5.4 In vivo intravenous pharmacokinetics 
 
Further to the i.p.-dosed pharmacokinetic study, SJG-136 was administered i.v. at the 
MTD (0.3 mg kg-1 via the i.v. route) and ⅓MTD (0.1 mg kg-1) to HL-60 (a human-
derived promyelocytic leukaemia cell line) tumour-bearing NCR-Nu mice.  Plasma, 
tumour and brain were analysed at each time point for concentration of SJG-136 in 
order to determine pharmacokinetic parameters.  Tumour and brain were assessed in 
this case principally to establish whether SJG-136 reaches the tumour following i.v. 
dosing, and brain was analysed to determine SJG-136 penetration into the central 
nervous system. 
 
9.5.4.1 Intravenous MTD pharmacokinetics 
SJG-136 was easily detectable in plasma, tumour and brain following i.v. administration 
of drug at the MTD (Figure 9.20).  SJG-136 appeared to have a low terminal 
elimination half-life in plasma of 0.66 h (kel calculated as 1.05 h-1 using a two 
compartment model curve fit).  A moderate plasma clearance of 11.8 ml min-1 kg-1 
(approximately 14% of murine hepatic blood flow), similar to the value obtained for 
plasma clearance following i.p. dosing, was calculated.  The AUC was shown to be 
759.8 nM h (422.9 ng h ml-1) with Cmax of 4.8 µM (2.7 µg ml-1) at 2 min post-dose.  
Volume of distribution was calculated as Vss 239 ml kg-1 or Vz 743 ml kg-1.  The i.v. 
AUC data was used to calculate the bioavailability of SJG-136 via the i.p. route; SJG-
136 was found to be 67% bioavailable via the i.p. route. 
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Levels of SJG-136 in the tumour reached an easily detectable Cmax of 72.4 nM at 2 min, 
with an AUC of 22.2 nM h (12.4 ng h ml-1).  The elimination half life of SJG-136 from 
the tumour was 0.18 h (with an elimination rate constant of 3.6 h-1).  Levels of drug in 
the brain were found to reach a Cmax of 30.2 nM at 2 min post-dose, with an AUC of 5.1 
nM h (2.8 ng h ml-1).  The elimination rate constant was calculated to be 3.78 h-1, 
resulting in an elimination half life of 0.18 h.   
 
SJG-136 was below the limit of detection in plasma after 4 h post-dose, after either 30 
min in tumour or 15 min in brain.  Curve fits on all 3 concentration time profiles 
showed good correlation for data fitted using a 2 compartment pharmacokinetic model. 
 
Figure 9.20  SJG-136 concentration versus time profile (mean ± SD; n = 3) in HL-
60 tumour-bearing NCR-Nu mice, in plasma, tumour and brain following i.v. 
administration at the MTD (0.3 mg kg-1). 
 
LOQ for detection of SJG-136 in tumour was 20 nM, calculated from a 5 nM LOQ in 
spiked tumour homogenate, and corrected from the initial 4-fold dilution (w/v) of 
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tumour in buffer to calculate concentration in tissue.  LOQ for detection of SJG-136 in 
brain was 8 nM, calculated from a 2 nM LOQ in spiked brain homogenate, and 
corrected from the initial 4-fold dilution (w/v) of brain in buffer to calculate 
concentration in tissue.  This equates to an LOQ of 11.1 ng g-1 tumour tissue, and 2.8 ng 
g-1 in brain tissue.  When considering the detection of SJG-136 in tumour or brain 
samples, it is important to be aware that it was not possible to remove blood that was 
perfused into the tissues after removal.  Consequentially it is unknown whether there is 
enough blood within the tissue to result in the levels of drug detected, and thus detected 
compound may not accurately reflect the amount of agent within the tissue itself.  In 
brain, it is suggested that there is 30 µl of blood per gram of tissue (Altman & Dittmer, 
1971), as 200 µl of tissue homogenate was used for analysis (1:4 dilution w/v in PBS); 
this equates to 50 µg of brain per sample, a minute amount of tissue relative to the 
concentration detected.  This indicates that it is unlikely that the concentration detected 
within the brain tissue is solely a result of blood present.  It is difficult to estimate the 
volume of blood within the tumour, hence it cannot be assessed if the levels of SJG-136 
detected can be accounted for by remaining blood. 
 
9.5.4.2 Intravenous ⅓MTD pharmacokinetics 
SJG-136 was also studied in vivo at ⅓MTD to determine linearity of the plasma 
pharmacokinetics at different dose levels (i.e. ⅓MTD should result in ⅓ of the AUC 
compared to the AUC for dosing at the MTD).  Administration of SJG-136 via the i.v. 
route at ⅓MTD resulted in easily detectable levels of drug in plasma (Figure 9.21).  The 
terminal elimination half-life of SJG-136 in plasma was calculated to be 1.44 h 
(calculated from an elimination rate constant of kel = 0.48 h-1; determined from a two-
compartment model curve fit).  A moderate plasma clearance of 12.88 ml min-1 kg-1 
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(approximately 15% of murine hepatic blood flow) was calculated, and was observed to 
correlate closely to both the previous i.v. MTD study and the earlier i.p. MTD study.  
The AUC was calculated as 232.6 nM h (129.5 ng h ml-1), approximately 31% of the 
i.v. MTD study, showing linearity of pharmacokinetics over a threefold concentration 
range with high linear correlation.  Cmax was observed at 2 min post dose as 1.6 µM 
(0.89 µg ml-1).  Volume of distribution was calculated as Vss of 245 ml kg-1 or Vz of 368 
ml kg-1. 
 
 
Figure 9.21  SJG-136 concentration versus time profile (mean ± SD) in HL-60 
tumour bearing NCR-Nu mice, in plasma, tumour and brain following i.v. 
administration at ⅓MTD (0.1 mg kg-1). 
 
SJG-136 was detectable in both brain and tumour samples; however, detected levels 
were erratic and could not be fitted with a pharmacokinetically relevant curve fit.  This 
produced difficulties in extrapolating back to the axis to predict C(0) values and values 
for kel.  Consequentially tissue t½ values could not be calculated and AUC values were 
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calculated as areas under detectable time points rather than by extrapolation to t = 0 and 
t = ∞.  Cmax was found to be 117.1 nM (65.1 ng ml-1) at 5 min in the tumour, and 53.5 
nM (29.8 ng ml-1) at 15 min in the brain samples. 
 
SJG-136 was below the limit of detection in plasma after 4 h or after 15 min in tumour 
and brain samples.  The curve fit of the plasma time course showed good correlation (r2 
> 0.9). 
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9.6 Metabolic stability 
The metabolic stability of SJG-136 was investigated using the analytical method 
developed for the pharmacokinetic studies (section 8.3).  The aim of the metabolism 
study was to assess the stability of SJG-136 in liver-derived tissues and to identify the 
formation of any metabolites.  In vitro models for murine metabolism were used in a 
predictive manner to identify potential in vivo metabolites. 
 
9.6.1 Liver S9 fraction 
The liver S9 subcellular fraction contains both microsomal and cytosolic enzymes and 
is capable of both phase I and phase II metabolism.  While the S9 fraction is often 
considered a crude preparation for metabolism studies, the presence of both phases of 
metabolism suggested it was a good predictive in vitro model for hepatic metabolism of 
SJG-136 in vivo. 
 
Experiments with the liver S9 fraction indicated rapid metabolism of SJG-136, resulting 
in a mean recovery of 9.9 ± 0.75% at time t = 0 h, with no significant metabolism after 
this point (Figure 9.22).  SJG-136 was found to be stable in PBS and plasma over the 
time period investigated in this study.  It was observed that the chromatographic profile 
of samples injected after extraction from S9 incubations showed remarkable similarity 
to other work investigating the reactivity of SJG-136 with GSH (section 12.3).  
Therefore it was possible the metabolism seen in the S9 fraction is skewed by reactivity 
of SJG-136 with GSH. 
 
Preparation of the S9 fraction involves mechanical processing of liver tissue, and 
subsequent lysis of cells will therefore release the GSH contained therein, reported to be 
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(dependent on cell type) typically in the 5 – 20 mM range.  Studies have shown that 
levels of GSH in murine liver homogenate are in the region of 5 mM (Kim et al., 2003).  
Concentrations of GSH in this range were shown to drastically affect recovery of SJG-
136, resulting in a poor recovery of drug (section 12.1).  It was therefore concluded that 
results obtained from an S9 fraction may be an inaccurate reflection of metabolism of 
the drug as a result of this phenomenon. 
 
Figure 9.22  Percentage recovery of SJG-136 from liver S9 fraction relative to 
time after incubation at 37 °C (mean ± SD; n = 3). 
 
9.6.2 Microsomal incubation 
Hepatic microsomes are a subcellular fraction obtained from differential centrifugation 
of liver homogenate.  Mainly consisting of membrane-bound endoplasmic reticulum 
fragments (vesicles), this preparation predominantly contains enzymatic capacity for 
phase I reactions due to a lack of the cofactors required for phase II conjugative 
reactions.  A key factor in the use of hepatic microsomes for this study was the removal 
of GSH from the preparation via an ultracentrifugation step, in order to assess the 
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metabolic potential of SJG-136 without the effect of the non-enzyme-mediated 
reactivity of the compound with GSH. 
 
Figure 9.23  Metabolism of SJG-136 incubated with hepatic microsomes.  
Percentage recovery of SJG-136 from liver microsomal fraction relative to time 
after incubation at 37 °C (mean ± SD; n = 3).  Line denotes a bi-exponential 
curve fit to illustrate biphasic nature of SJG-136 metabolism. 
 
Incubation of SJG-136 with microsomes indicates a rapid metabolism of the compound 
over the first 15 min, with a half-life of SJG-136 in the microsomal incubation 
calculated from a biphasic curve fit equation as 0.96 min (Figure 9.23).  Levels of 
SJG-136 in the microsomal incubation fell below the limit of detection after 30 min.  
There was no apparent metabolism / disappearance of SJG-136 in either heat inactivated 
microsomes or buffer (PBS) containing NADPH alone. 
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9.6.3 Metabolite identification 
For metabolite identification studies, a high concentration of SJG-136 (50 µM) was 
incubated with hepatic microsomes, as a measure to produce high concentrations of 
metabolite.  Metabolite identification was carried out by LC-MS analysis of the 
microsomal incubation of SJG-136, scanning from m/z 150 – 600, alongside 
fluorescence detection.  It was necessary to use a high concentration of SJG-136 to 
compensate for the relatively insensitive (compared to fluorescence detection) scanning 
method of the mass spectrometer.  After the HPLC run, these data were scrutinized for 
the presence of compound masses corresponding to potential SJG-136 metabolites, as 
defined from predictions of potential sites of metabolism based on compound structure. 
 
 
Figure 9.24  Mass spectra of SJG-136 and potential metabolites at a) 26.5 min, b) 
25.3 min (SJG-136), c) 23.7 min, d) 18.1 min, and e) 15.5 min. 
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Several peaks at masses corresponding to potential metabolites were identified by 
examining the mass spectra extracted from scans performed during the sample run 
(Figure 9.24).  The MW derived from the mass spectra were correlated to structures 
based on predictive metabolism from examination of the SJG-136 molecular structure 
(Table 9.6).  These data were used to extract chromatograms of potential metabolites 
(see Figure 9.25). 
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Molecular weight 
(Exact MW) 
Retention time 
(min) 
Probable structure 
572.61 (572.23) 26.5 
556.61 (556.23) 
SJG-136 
25.3 
 
542.59 (542.22) 23.7 
348.39 (348.17) 18.1 
 
334.37 (334.15) 18.1 
 
316.35 (316.14) 18.1 
 
276.29 (276.11) 15.5 
 
258.27 (258.10) 15.1 
 
Table 9.6  Potential SJG-136 metabolites detected following incubation with 
hepatic microsomes, listed as MW with possible structures (* denotes hydroxyl 
group which may be attached to any similar ring position).  Metabolites were 
detected using LC-MS (scan m/z 150 – 600). 
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Figure 9.25  Chromatograms for SJG-136 and potential metabolites extracted 
from MS scan after incubation of SJG-136 with liver microsomes.  
Chromatograms are shown offset, and on the same scale to enable comparison 
of intensities for detected ions. 
 
Of the several metabolites identified, the metabolite corresponding to O-dealkylation on 
one of either (but not both – interestingly this was not detected) benzene rings of 
SJG-136 produced the largest peak in the chromatogram.  It is possible that metabolic 
dealkylation on one of the rings results in a 3-dimensional structural shift rendering the 
opposing group inaccessible to metabolic enzymes; further work with molecular 
modelling studies would be required to investigate this.  Assuming equivalent response 
of the MS to this highly structurally similar metabolite compared to SJG-136 and other 
metabolites, this appears to be the major metabolite produced by microsomal 
metabolism.  As expected due to the nature of the microsomal model, no phase II 
conjugative metabolic products were detected. 
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9.6.4 Metabolite detection in vivo 
Following detection of a major metabolite at m/z 542.59, a highly sensitive LC-MS/MS 
method was developed to attempt to detect the metabolite in in vivo PK samples.  A 
daughter ion for SJG-136 was identified at m/z 475.6 (seen in the mass spectra for SJG-
136 after incubation with microsomes; Figure 9.24) and an apparent corresponding 
daughter ion is seen for the metabolite at m/z 461.6.  These were used to tune the 
MS/MS to SJG-136, and to set up a multiple reaction monitoring (MRM) detection 
method.  Due to lack of isolated metabolite, SJG-136 was used to tune the instrument 
for both compounds, therefore the method was optimised using SJG-136.  To 
investigate the appearance of the metabolite in vivo, a 30 min PK sample (time point 
selected as maximum concentration of SJG-136 was detected at this time) from the i.p. 
pharmacokinetic study (section 9.5.3) was analysed using the optimised method for 
MS/MS detection of SJG-136 and metabolite. 
 
The metabolite was detected in vivo (Figure 9.26).  As metabolite was not available in 
an isolated form to produce calibration curves, for the sake of comparison of relative 
abundance of metabolite versus SJG-136 in the in vivo sample, it was assumed that the 
mass spectrometer gave an equivalent response per unit metabolite to SJG-136.  This 
assumption is reasonable given the predicted high structural similarity of the 
compounds.  Integration of the peaks gave peak areas for SJG-136 of 370555 versus a 
peak area in the sample of 4409 for the metabolite.  This equates to approximately 1.2% 
of total detected SJG-136 converted to the metabolite at the 30 min time point in vivo.  
Comparison with the in vitro microsomal metabolism data (section 9.6.2), which 
indicate rapid metabolism of SJG-136, suggests a low metabolic potential for the 
SJG-136 dimer in vivo. 
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Figure 9.26  Detection of SJG-136 and major metabolite in vivo (30 min post-
dose; i.p. dose @ 0.2 mg kg-1) using LC-MS/MS.  SJG-136 (a) was detected at 
26.9 min, and metabolite (b) was detected at 25.0 min post injection. 
 
Time constraints prevented a re-analysis of the full pharmacokinetic profiles (i.p. and 
both i.v. profiles) for characterisation of the total extent of metabolite production.  It is 
entirely possible that further time points would show an increase detected metabolite as 
levels of SJG-136 decrease (possible conversion to metabolite).  Furthermore, in an in 
vivo situation there is potential for further metabolism and formation of conjugates 
derived from phase II metabolic processes.  However, this study demonstrates the 
usefulness of the in vitro microsomal model, as the predicted metabolite was detected. 
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9.7 Cellular effects of SJG-136 
In order to better characterise the effects of SJG-136 at the cellular level, several models 
were used to assess toxicity, localisation and cell cycle effects of SJG-136.  Cytotoxicity 
of the parent PBD dimer compound was assessed in selected cell lines to investigate 
reproducibility of previous data and to determine cell-type selective cytotoxicity. 
 
The ability of SJG-136 to bind to chromosomal DNA was investigated to verify its 
DNA interactivity and to examine proposed sequence selectivity of the compound.  In 
addition to this, as the pharmacodynamic endpoint of SJG-136 is interstrand DNA 
crosslinking in vivo, the level of crosslinking achieved in an in vivo murine system was 
assayed to assess pharmacodynamic efficacy of SJG-136 as a function of DNA 
crosslinking achieved. 
 
The effect of SJG-136 on cell cycle was studied in an in vitro system to help elucidate 
the mechanism of action of this agent, and to correlate its behaviour with previous DNA 
interstrand crosslinking agents. 
 
Five cell lines were chosen for study based on data from the NCI 60-cell line screen 
data for SJG-136.  Cell lines were chosen from the “fingerprint” of data (Figure 9.27) 
based on relative sensitivity or resistance to SJG-136 in order to identify any cell-type 
selectivity of the compound.  Chosen cell lines were: M14 (melanoma), SK-MEL-2 
(melanoma), UACC-62 (melanoma), SK-OV-3 (ovarian) and DU-145 (prostate). 
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Figure 9.27  NCI 60-cell-line screen data for SJG-136.  Data shows relative 
resistance or sensitivity of cell lines to SJG-136.  * Denotes cell lines chosen 
for investigation in this study.  From top to bottom, cell lines: M14, SK-MEL-
2, UACC-62, SK-OV-3 and DU-145. 
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9.7.1 MTT cytotoxicity assay 
The cytotoxicity of SJG-136 in the selected cell lines was assessed using the MTT assay 
method to determine the potential cell-type selectivity, and thus potential tumour 
selectivity of the compound.  Growth curves were initially constructed to ensure that the 
seeding density of the cell lines allowed the cells to grow in the exponential growth 
phase for all five cell lines.  It was found that at a seeding density of 2000 cells per well 
(i.e. 2000 cells per 200 µl; equivalent to 10000 cell per ml) for all cell lines showed 
exponential growth for each cell line studied over the eight day period (Figure 9.28). 
 
Cytotoxicity of SJG-136 was investigated as either a continuous exposure of cells to the 
drug throughout the 96 h period of the experiment, or as a 1 h exposure to the drug after 
which drug was removed from culture medium; cells were washed and allowed to 
recover for the remaining 95 h of the experiment.  The 1 h exposure allowed 
investigation of a more closely relevant in vivo exposure time of cells to SJG-136. 
 
Exposure 
time (h) 
IC50 value (nM) by cell line & cell type 
 DU-145 UACC-62 SK-MEL-2 SK-OV-3 M14 
 prostate melanoma melanoma ovarian melanoma 
1 22.2 ± 2.6 16.6 ± 11 29.8 ± 5.5 18.38 ± 2.6 4.2 ± 0.7 
96 0.5 ± 1.1 0.12 ± 0.33 1.3 ± 1.0 2.5 ± 1.4 0.4 ± 0.1 
Table 9.7  IC50 values calculated for selected cell lines (mean ± SD; n = 3). 
 
Cytotoxicity was assessed as IC50 (inhibitory concentration at which 50% growth 
reduction is observed versus untreated controls) values.  IC50 values were calculated by 
plotting absorbance versus concentration of SJG-136 and the IC50 value was defined as 
the value at which 50% growth inhibition (defined as a 50% reduction in MTT 
absorbance) was seen (Figure 9.29, Figure 9.30).  This was repeated in triplicate and 
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mean IC50 and standard deviation were calculated from these values.  SJG-136 was 
observed to have a significant cytotoxic effect in each of the 5 cell lines studied, with 
both 96 h and 1 h exposure to the drug (Table 9.7).  There is a range of cell sensitivities 
to SJG-136, up to 20-fold difference after 96 h exposure, and up to 7-fold difference 
after 1 h exposure.  The IC50 values expressed for the SK-OV-3 cell line correlate 
closely with previously reported values of 9.1 nM for SJG-136 (Gregson et al., 2001). 
 
These data illustrate the potent cytotoxicity of SJG-136.  Furthermore, the 1 h exposure 
data shown here indicates that a short exposure time of cells to SJG-136, as would be 
characteristic of an in vivo situation, can result in significant cytotoxic effect at low 
concentrations.  Relating these data to the in vivo pharmacokinetic profiles of SJG-136 
(section 9.5), it is shown that SJG-136 achieves concentrations well above the IC50 
values in these cell lines, and maintains these levels for over the 1 h exposure used here, 
even when dosed at ⅓MTD. 
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Figure 9.28  Growth curves for selected cell lines.  Dashed line indicates 
exponential curve fit.  Assayed as increase in absorbance using the MTT dye 
conversion assay over time (y axis plotted on log scale; mean ± SD).  Cell lines 
(+ doubling times) a) UACC62 (2.8 days), b) SK-MEL-2 (3.2 days), c) SKOV-
3 (1.7 days), d) M14 (2.1 days) and e) DU145 (1.5 days). 
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Figure 9.29  Dose response curves showing MTT absorbance (at 550 nm) versus 
concentration of SJG-136.  Cells lines used noted on graph.  Cells incubated 
with SJG-136 for 96 h continuously.  3 independent replicates. 
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Figure 9.30  Dose response curves showing MTT absorbance (at 550 nm) versus 
concentration of SJG-136.Cell lines used noted on graph.  Cells incubated with 
SJG-136 for 1 h, washed, and allowed to recover for remainder of 96 h period.  
3 independent replicates. 
 
9 The PBD dimer, SJG-136 
150 
9.7.2 Cellular localisation studies 
SJG-136 is a fluorescent PBD dimer compound.  In order to investigate the cellular 
distribution of the drug within cells, cells were treated with SJG-136 and viewed using 
UV fluorescence microscopy to determine the intracellular distribution of the agent. 
 
Initial experiments examined cells at short time points of 1 h exposure to SJG-136, and 
concentrations of SJG-136 close to the IC50 values (as previously determined; Table 
9.7).  It was found that SJG-136 fluorescence was not sufficiently intense to be seen 
above background fluorescence level at these time points, presumably due to low 
concentrations of the agent.  By increasing the concentration of SJG-136 to 1 mM, and 
incubating for 18 h, localisation of the drug became apparent.  Intracellular SJG-136 
could not be seen up to 8 h after incubation, and intermediate time points could not be 
investigated due to laboratory access restrictions.  It was observed that SJG-136 
localised within the nucleus of the cell in both the UACC62 (Figure 9.31) and DU145 
(Figure 9.32) cell lines studied.  Cells treated with SJG-136 at high concentration 
relative to the IC50 values appear distressed versus control cells; however, cell viability 
was tested using trypan blue exclusion and approximately 80% of cells were 
impermeable to trypan blue at the endpoint of the experiment. 
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Figure 9.31  Localisation of SJG-136 within UACC62 cells after incubation with 
1 mM SJG-136 for 18 h (left) versus control (right). 
 
 
Figure 9.32  Localisation of SJG-136 within DU145 cells after incubation with 1 
mM SJG-136 for 18h. 
 
Cellular localisation of SJG-136 within the nucleus is especially relevant for SJG-136, 
as nuclear DNA is its proposed site of drug action.  These data clearly show evidence of 
SJG-136 fixation within the cell nucleus.  Further work planned, but unfortunately not 
completed, was to repeat these experiments with a counter-stain for elements known to 
be found exclusively within the nucleus.  This would have enabled a less subjective 
assessment of localisation within the nucleus than observation of cellular morphology. 
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9.7.3 Chromosomal staining 
SJG-136 is proposed to bind to cellular DNA in a sequence-selective manner.  To 
investigate this visually chromosomal spreads were prepared from cultured cells and 
stained with SJG-136 at 100 µM overnight.  Cells were then examined using confocal 
microscopy with a pseudo-UV laser (360 nm) to enhance sensitivity over UV 
microscopy and increase resolution.  It was envisioned that sequence-selective binding 
may result in a “spotting” effect on chromosomal DNA. 
 
SJG-136 was observed to stain chromosomal DNA (unstained chromosomal DNA 
showed no visible fluorescence), but no evidence of any spotting effect was seen 
(Figure 9.33).  The concentration at which chromosomal DNA was treated with SJG-
136 is much in excess of that used in vivo, hence it is possible that sequence-selective 
binding was masked as a result of increasingly unselective binding resulting from 
saturation of the DNA with SJG-136.  Unfortunately, the sensitivity of this assay was 
such that binding of SJG-136 to DNA could not be detected at concentrations less than 
100 µM with a 24 h incubation period.  It is possible that assay sensitivity could be 
improved with use of UV laser confocal microscopy for further work. 
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Figure 9.33  Staining of chromosomal DNA by SJG-136.  Photograph shows 
chromosomal spread of cellular DNA after incubation with SJG-136 overnight.  
Image captured using confocal microscopy; fluorescence induced with 360 nm 
laser. 
 
9.7.4 Cell cycle analysis 
Flow cytometry was used to identify the effects of SJG-136 on cell cycle progression, 
and to establish how the effects of SJG-136 compare to that of other DNA interstrand 
crosslinking agents.  Data from cytotoxicity assays (section 9.7.1) of SJG-136 was used 
to decide on concentration of exposure of cells to SJG-136.  A drug concentration of 10 
nM was selected, as this was close to the IC50 values for SJG-136 with all cell lines, 
thereby eliciting a substantial effect without 100% toxicity to all exposed cells. 
 
Cells were treated with SJG-136 either chronically (continuous exposure for the course 
of the experiment) for up to 72 h, or to more accurately mimic an in vivo pattern of 
exposure cells, were exposed for 1 h after which drug was removed and cells were 
allowed to recover for up to 72 h.  It was found that cells exposed to SJG-136 
9 The PBD dimer, SJG-136 
154 
chronically for 24 h, exhibited a lower G1 peak area and increases in both S and G2 
peak area along with a loss of histogram definition in all cell lines (Figure 9.34).  At 48 
h, loss of histogram definition was apparent in the treated cells; at 72 h histogram 
definition was completely lost in four of the five cell lines to the point of being un-
analysable.  All cell lines used grew adherent to tissue culture vessels under normal 
(untreated) conditions.  Cells at 48 h and 72 h after initiation of exposure to SJG-136 
were noted to be considerably less adherent than controls; a large proportion of cells 
were observed to be in suspension (however this was not quantifiable).  This was 
indicative of levels of toxicity that would be predicted from earlier cytotoxicity studies 
(section 9.7.1) to produce maximal cell kill.  This effect was noted in all cell lines.  As a 
10 nM concentration is in excess of the 96 h exposure IC50 values for all cell lines, it is 
inevitable that there will be a high degree of cytotoxicity. 
 
Cells exposed to SJG-136 for 1 h with a wash step and recovery time showed a 
markedly different reaction to SJG-136.  At 24 h post exposure, all cell lines showed a 
noticeable decrease in G1 peak area, with a similar S phase area and a clear increase in 
G2 peak area (Figure 9.35).  This effect persisted to varying degrees in 3 of the 5 cell 
lines examined for 72 h, with the most apparent and enduring effects observed in the 
SK-MEL-2 cell line.  After 72 h the DU-145 cell line appears to have recovered from 
the effects of SJG-136 exposure, showing a similar histogram to control cells.  This is 
indicative of a cell cycle-blocking effect of SJG-136 during the G2/M phase of the cell 
cycle. 
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SK-MEL-2 cell line 
 
DU145 cell line 
 
SK-OV-3 cell line 
 
M14 cell line 
Figure 9.34  Disruption of the cell cycle by continuous exposure of cells to 10 nM 
SJG-136 after 24, 48 and 72 h versus control.  Cells were harvested, fixed, and 
stained with propidium iodide.  10,000 stained cells were then subjected to 
FACScalibur analysis to determine distribution of cells throughout the cell 
cycle. 
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Figure 9.35  G2/M phase arrest induced by exposure of cells to SJG-136 and 
subsequent recovery.  Cells were exposed to SJG-136 at 10 nM for 1 h, 
washed, and allowed to recover for 24, 48 or 72 h.  Cells were fixed and 
stained with propidium iodide and analysed using FACS.  SJG-136 appeared to 
cause a G2/M phase arrest in all cell lines, with cell populations recovering to 
differing degrees. 
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A block in G2/M of the cell cycle is a common feature of DNA minor groove-binding 
agents (Erba et al., 1995; Turner & Denny, 1996; Yamori et al., 1999).  These data 
indicate that chronic exposure of cells to SJG-136 at 10 nM (approximately an IC90 
concentration for the cell lines studied with continuous exposure) results in rapid 
degradation of the cell cycle histogram (sub-24 h effects) such that it is not possible to 
identify the phase of the cell cycle in which SJG-136 is acting.  Further studies 
investigating time points prior to 24 h may allow some elucidation. 
 
Following 1 h exposure of cells to SJG-136 in an exposure pattern closer to that which 
may be expected to be seen in vivo, there is an obvious increase in the G2/M peak 
indicating a block at this phase of the cell cycle.  While earlier time-points need to be 
studied in order to establish how quickly following exposure this block will set in, these 
data indicate that the effects persist for at least 24 h following exposure, with obvious 
persistence of effects up to 72 h post-exposure in the UACC-62, SK-MEL-2 and M14 
cell lines.  Cycle perturbation was still apparent in both DU145 and SK-OV-3 up to 48 h 
post exposure.  SJG-136 is proposed to evade DNA repair mechanisms by binding 
within the minor groove of DNA without causing distortion of the host double helix 
(Jenkins et al., 1994; Gregson et al., 2001), these data may be indicative of a reduced 
cellular repair capacity as a result of lack of lesion recognition due to minimal or no 
distortion (Sancar & Sancar, 1988).  Distortion of DNA is believed to play a role in 
recognition of DNA damage and subsequent initiation of repair. 
 
9.7.5 Comet assay for assessment of in vivo crosslinking 
The Comet assay was used to detect and quantify the formation of DNA interstrand 
crosslinks (ICL) in vivo in murine lymphocytes extracted from blood samples at 1 h and 
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24 h after dosing via either the i.p. or i.v. route at the MTD and ⅓MTD.  As the 
formation of DNA interstrand cross-links (ICL) is the proposed mechanism of toxicity 
of SJG-136, this was considered an appropriate pharmacodynamic endpoint for 
detection of SJG-136 activity in vivo.  Experiments were also undertaken to attempt to 
identify the formation of ICL in tumour xenografts of the HL-60 cell line.  However, it 
was found that untreated (control) cells prepared from this tumour showed DNA 
damage and strand breakage to the point where control cells were indistinguishable 
from irradiated cells.  Hence, the presence of ICLs could not be quantified effectively.  
Project time constraints prevented further investigation into formation of ICLs within 
tumour tissues. 
 
Typical examples of Comet images examined in this experiment are shown in Figure 
9.36, taken from the i.v. studies.  In control cells not irradiated or exposed to SJG-136, 
lymphocyte cells show no DNA damage (Figure 9.36a); characterised by the lack of a 
Comet tail due to unfragmented DNA and high-molecular-weight supercoiled DNA 
remaining intact.  Following irradiation of untreated cells with 10 Gy to induce a fixed 
number of random DNA strand breaks, the shorted fragments of DNA can be observed 
to have migrated from the bulk of the DNA during electrophoresis giving the 
characteristic Comet tail (Figure 9.36b).  SJG-136 was shown not to induce strand 
breaks in unirradiated, treated controls (Figure 9.36g).  The extent of DNA damage was 
quantified by image analysis and defined as the percentage of DNA in the Comet tail 
combined with the distance between the means of the head and tail distributions as 
defined by Olive (Olive et al., 1990). 
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It was found that SJG-136-induced ICLs could be easily detected in all samples, with 
detection of up to a 57% decrease in tail moment (Figure 9.37).  There was no 
significant difference in formation of ICL between the i.p. and i.v. dosed routes.  SJG-
136 appeared to cause the formation of ICL in a non-dose-dependent manner, as there 
was no significant difference between levels of DNA crosslinking detected after dosing 
at the MTD or ⅓MTD (two-tailed, Students t-test; p > 0.05).  This finding has 
significant implications, as it suggests that SJG-136 can be dosed at levels lower than 
the MTD without a significant decrease in the efficiency of DNA ICL formation. 
 
It was observed anecdotally that extraction of lymphocytes from blood samples taken 
from mice dosed with SJG-136 yielded a drastically lower number of lymphocytes than 
from control mice in samples taken both 1 and 24 h post-dose.  An average 20-fold 
decrease in lymphocytes extracted was observed.  While the robustness of the extraction 
method was not extensively tested, the samples at 1 h were extracted alongside the 
control samples; this is indicative of drug induced lymphopenia rather than an 
extraction artefact.  This apparent rapid elimination of lymphocytes indicates in vivo 
cytotoxicity of SJG-136, but is certainly in need of further study.  Implications for 
lymphocyte cytotoxicity will be important in predicting overall toxicity of SJG-136; 
however, these will not be speculated on in the present work. 
 
Repair of SJG-136 induced ICLs was studied at both doses via both routes 24 h after 
dosing.  There was no evidence of repair of SJG-136 induced ICLs 24 h after dosing in 
any of the samples, suggesting a prolonged persistence of effect of SJG-136.  These 
data corroborate suggestions from previous work performed with SJG-136 suggesting 
that the lack of distortion of DNA from the binding of SJG-136 may lead to impairment 
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of ICL detection and reduced DNA repair competency for SJG-136-mediated 
crosslinks. 
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Figure 9.36  Comet images from i.v. in vivo lymphocyte study.  Comparison of 
non-drug-treated unirradiated lymphocytes (a) with irradiated (10 Gy) non-
drug-treated lymphocytes (b) showed distinct comets.  After dosing at either 
the MTD (c & d) or ⅓MTD (e & f) in vivo and lymphocyte extraction, comet 
tails were visible but showed decreased tail length due to the presence of SJG-
136 induce ICLs.  There appeared to be no repair of DNA ICLs as comparison 
of 1 h (c & e; MTD and ⅓MTD respectively) with 24 h (d & f; MTD and 
⅓MTD respectively) post-dose samples showed no significant difference in tail 
length.  SJG-136 did not induce single strand breaks in treated unirradiated 
cells (g). 
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Figure 9.37  SJG-136 induced interstrand crosslinking.  ICL formation, measured 
as percentage decrease in tail moment, showed no significant dose-dependent 
relationship between the MTD and ⅓MTD doses in i.v. or i.p. dosing in vivo.  
There was no significant indication of repair of ICLs 24 h after dosing at any 
dose level (mean ± SD; n = 3). 
 
These data clearly demonstrate the efficacy of ICL formation by the PBD dimer SJG-
136 in vivo.  Furthermore, the apparent repair evasion of SJG-136-induced ICLs 
supports the proposed DNA repair evading binding mechanisms of SJG-136.  SJG-136-
induced ICLs in lymphocytes are formed at <1 h post-dose, and persist for >24 h post-
dose with no significant repair of DNA ICLs.  Additionally, there is no significant 
difference in the % decrease in tail moment induced by SJG-136 after treatment at the 
MTD versus ⅓MTD, after dosing via either the i.p. or i.v. route. 
 
SJG-136 has been shown in this study to achieve its pharmacodynamic endpoint, 
formation of DNA crosslinks, in vivo.  Activity of SJG-136 in lymphocytes does not, 
however, demonstrate the ultimate pharmacodynamic endpoint of formation of ICLs in 
tumour in situ.  Experiments designed for this purpose did not work as planned, as 
tumour samples showed extensive DNA fragmentation that precluded the use of the 
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Comet assay for assessment of ICL formation.  This may be a characteristic of the 
tumour type chosen (HL-60 tumour cell line), or may instead have been a result of the 
method used to prepare a single cell suspension for Comet analysis from the tumour.  
This would require further study to establish the cause. 
 
9.8 Summary 
This study has aimed to characterise SJG-136 pharmacokinetically and 
pharmacodynamically as fully as possible within the PhD research timeframe.  The 
importance of this investigation has been further emphasised as SJG-136 is due to 
progress to clinical trials within the year.  Consequentially, a better characterisation of 
the agent will allow more informed decisions to be made using data derived from man. 
 
This investigation has provided the first example of characterisation of the analytical 
properties of SJG-136, identifying optimal detection parameters and using these to 
develop a sensitive and selective analytical method for the detection of SJG-136 in 
biological samples.  This has included development of a robust extraction procedure for 
SJG-136 from pre-clinical murine samples, and initial method development for 
extraction from clinical samples.  This work has formed the basis of other work which 
is currently ongoing to generate a validated analytical method for use in the phase I 
clinical trials. 
 
For the first time, pharmacokinetic parameters have been defined for SJG-136 within 
this study.  This has enabled the determination that SJG-136 shows linear 
pharmacokinetics over a 3-fold dose range (⅓MTD – MTD).  Establishment of these 
parameters will allow scaling from murine pharmacokinetics in order to predict the 
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behaviour of SJG-136 in man.  SJG-136 was detected in murine brain and tumour 
samples in these studies, indicating distribution of the SJG-136 agent across the 
blood/brain barrier and also into its target site.  Levels of SJG-136 detected in brain 
samples exceed those that may be predicted from blood volume per weight tissue as 
cited in the literature (Kwon, 2001).  Both factors are pharmacokinetically desirable 
characteristics for this agent.  SJG-136 shows a moderate plasma clearance in the mouse 
of 11.8 and 12.8 ml min-1 kg-1 (MTD and ⅓MTD respectively) reproducible at two dose 
levels.  Volume of distribution at steady state (Vss) was shown to be low, and similar at 
both MTD (239 ml kg-1) and ⅓MTD (245 ml kg-1); typical total body water of a mouse 
is approximately 600 ml kg-1 (Davies & Morris, 1993), indicating poor distribution into 
tissues.  Vz (volume of distribution of the terminal elimination phase) was slightly 
higher, at 849 ml kg-1 (MTD) and 488 mg kg-1 (⅓MTD). 
 
The metabolism of SJG-136 in vitro has also been studied.  The drug is shown to be 
metabolised rapidly in the liver microsomal model, with little or no metabolism in the 
liver S9 fraction model; behaviour derived from predicted glutathione reactivity of the 
compound (discussed in detail in section 12).  Further work has characterised the 
metabolites of SJG-136, and predicted structures of these metabolites have been 
elucidated based on the molecular weight of detected metabolites and the probable 
metabolic processes for this compound.  The major metabolite of SJG-136, a mono-
demethylated form of the compound, was identified in vivo.  Further studies are 
necessary to discover the extent of metabolite production in vivo, although these 
preliminary studies indicate that this in vivo metabolite does not contribute significantly 
to overall elimination of SJG-136. 
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The cytotoxicity of SJG-136 was investigated, based upon earlier data from the NCI, 
and IC50 values for chronic (96 h) and acute (1 h) exposure of cells to SJG-136 were 
defined.  These results showed a similar level of cytotoxicity of the compound 
compared to previously reported data and NCI (unpublished) data.  However, cell-
specific cytotoxicity was apparent but less pronounced than previously described.  Cell 
localisation studies indicated the localisation of SJG-136 within the cell nucleus, its 
proposed site of action, revealing cellular distribution desirable for a DNA-interactive 
agent.  However, chromosomal staining studies did not indicate a determinable 
sequence-selective binding pattern of SJG-136. 
 
Cell cycle effects were investigated using FACS analysis.  This study demonstrated a 
G2/M block of the cell cycle in all 5 cell lines investigated, persisting for up to 72 h 
post-exposure in acutely exposed cells.  These data are consistent with the action of 
DNA minor groove-binding agents, indicating a similar mode of action of SJG-136 to 
this class of compound.  Furthermore, this demonstrates a poor repair of SJG-136-
induced cell cycle effects, likely a result of the formation of interstrand DNA crosslinks.  
This supports the proposed DNA-repair mechanism evading properties of SJG-136. 
 
Comet analysis to determine the formation of SJG-136 induced ICLs in vivo clearly 
demonstrated the efficacy of ICL formation in lymphocytes, and thus the reaching of a 
pharmacodynamic endpoint of the compound.  Further studies to identify the 
pharmacodynamic effects of SJG-136 in vivo in tumour models were unsuccessful due 
to problems with DNA strand breakage in control tumour-derived cells; this DNA 
damage is believed to be an inherent characteristic of the tumour.  These data indicate 
rapid formation of DNA ICLs, and persistence of the formed crosslinks for up to 24 h.  
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This finding further supports the hypothesis that the minimal distortion of DNA 
structure by SJG-136 allows a degree of circumvention of DNA damage recognition 
and tracing  repair mechanisms. 
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10 PBD monomer D709119 
D709119 (Figure 10.1) is a PBD monomer compound selected for study based on 
indication of potent cytotoxicity and a novel mechanism of action, as defined by 
screening through the NCI 60-cell-line screen and COMPARE analysis.  This 
compound is currently of interest and is being pursued here for further characterisation, 
although currently there has been no formal decision to move this compound toward the 
clinical trials stage.  This study aims to characterise the preliminary pharmacokinetics of 
D709119 and to establish whether the compound exhibits favourable attributes; 
consequentially this will feed back and influence decisions on how investigation of 
D709119 proceeds. 
 
 
Figure 10.1  Structure of the PBD monomer, D709119. 
 
This study is the first to develop an analytical detection method for D709119, and to 
characterise the pharmacokinetic properties of the compound. 
 
10.1 Compound characterisation 
In order to establish a reliable and optimal mode of analytical detection for the PBD 
monomer D709119, the compound was characterised using several methods.  Each 
method will be described briefly, as follows.  Fluorescence, UV absorbance and mass 
spectrometry typically facilitate sensitive and specific detection of compounds for 
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HPLC analysis.  To determine optimal detection parameters, spectra for the compound 
were elucidated for each mode of detection. 
 
10.1.1 Fluorescence characterisation 
Scanning fluorescence detection was used to attempt to determine optimal excitation 
and emission wavelengths for D709119.  Unfortunately, D709119 did not fluoresce 
sufficiently to be able to obtain fluorescence spectra for the compound. 
 
10.1.2 UV absorbance spectra 
UV absorbance spectra were obtained using a photodiode array detector (Figure 10.2).  
A simple MeCN/water HPLC method was developed and D709119 was injected onto 
the system.  Spectral analysis of the eluted peak allowed determination of D709119 
spectral properties. 
 
Figure 10.2  UV absorbance spectrum for D709119.  Useful maxima for detection 
were observed at 233, 271 and 325 nm. 
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The UV absorbance spectrum for D709119 demonstrated useful wavelengths for 
detection at 233, 271 and 325 nm, however spectral peaks were broad. 
 
10.1.3 Mass spectral characteristics 
Mass spectral detection of D709119 was optimised by infusing a D709119 solution 
directly into the mass spectrometer without the use of a chromatographic component. 
 
D709119 conditions were optimised using single quadrupole mass spectrometry.  The 
exact monoisotopic molecular weight of D709119 was calculated as 364.1.  D709119 
was infused directly into the mass spectrometer in MeCN, and MS tune conditions were 
adjusted to give optimal detection of the parent ion at [M + H]•+; the compound was 
detected at an m/z of 365.2 (Figure 10.3a).  The same phenomenon seen in Section 9.1.4 
with SJG-136 was seen with D709119, in that the compound was observed to exist in 
both the imine (Figure 10.3a) and carbinolamine (Figure 10.3b) states dependent on the 
presence of water.  The D709119 carbinolamine methyl ether form of the compound 
could not be detected in the presence of methanol. 
 
The existence of alternate forms of D709119 dependent on the presence of water poses 
a similar potential difficulty to that discussed for the PBD dimer, SJG-136.  Due to the 
presence of two forms of the compound during analysis, it is possible that method 
sensitivity may be affected.  Optimisation of mass spectrometer tuning to D709119 in 
the presence of both water and MeCN resulted in the determination that the imine form 
of D709119 is the most intense ion when both solvents are present.  However, the 
carbinolamine form could not be completely eliminated.  Avoidance or elimination of 
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water from the HPLC method was considered impractical, due to the presence of water 
in the biological systems to be studied. 
 
 
Figure 10.3  Mass spectra of D709119, showing the compound in: a) imine form 
([M + H]•+), and b) carbinolamine form ([M + H2O + H]•+). 
 
These data suggest the presence of D709119 in both the imine and carbinolamine forms 
(Figure 10.4). 
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Figure 10.4  The imine (top) and carbinolamine (bottom) forms of D709119. 
 
10.2 Analytical method development 
Analysis of D709119 was performed using a MeCN-based HPLC method.  Photodiode 
array or single quadrupole mass spectrometry was used for detection of the compound 
initially.  However, although both  modes of detection gave similar limits of detection, 
mass spectrometry was selected as this allowed selective detection of D709119 and 
prevented peak interference in samples extracted from biological matrices.  Both 
isocratic and gradient HPLC methods were developed for D709119.  However, due to 
the selectivity of mass spectrographic detection, the additional separation provided by 
the gradient method was not necessary. 
 
10.2.1 Isocratic separation 
Initial method development for D709119 analysis used an isocratic method (with 
photodiode array detection) to allow a short run-time for rapid sample throughput.  
However, it was observed that there was interference with plasma constituents in the 
chromatogram when this method was used following compound extraction from 
plasma.  This led to a change of detection using mass spectrometry. 
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Injection of 70 µl of a 50 nM sample of D709119 using a mobile phase consisting of 
25% MeCN: 75% 0.01 M ammonium formate (pH 4) gave a symmetrical peak with a 
reproducible retention time of 5.1 min (standard deviation of 0.06 min during a sample 
run; n = 8) (Figure 10.5). 
 
 
Figure 10.5  Example chromatographic trace showing D709119 eluted at 5 min 
using an isocratic HPLC method. 
 
It was found that due to the ability of the mass spectrometer to select for specific 
analytes, it was unnecessary for complete separation from plasma constituents.  This 
allowed the use of the isocratic method for analysis.  In order to obtain maximal 
sensitivity for the compounds of interest, the MS protocol was set to use a “windowed” 
method so that during the sample run a single ion is monitored for a window of time 
during which the compound is eluted, as defined during HPLC method development.  
D709119 is eluted at ~5 min and its internal standard (SJG-303; see structure shown in 
Figure 11.1) was found to elute at ~3.2 min.  Thus the MS instrument was set to monitor 
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only for SJG-303 from time 2.5 – 4.0 min, and for D709119 from time 4.0 – 6.0 min 
(Figure 10.6).  This was found to give sensitive and selective detection of D709119; no 
interference from plasma components was detected using this method. 
 
 
Figure 10.6  Example chromatogram showing D709119 (4.7 min) and internal 
standard (SJG-303; 3.2 min) detected using MS after extraction from 30 min 
(post-i.p. dosing) plasma PK sample. 
 
 
10.2.2 Gradient separation 
A gradient method was investigated to provide enhanced separation of D709119 from 
plasma constituents that were found to interfere with analysis of D709119 after 
extraction from plasma samples.  This method was developed and found reliable, but 
was ultimately supplanted by the optimised isocratic method as the superior selectivity 
of mass spectral detection enabled detection of drug among potential interference 
components and a favourably shorter run-time. 
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10.3 Pre-clinical method development 
 
10.3.1 Extraction from biological samples 
Extraction efficiency of D709119 from murine plasma, tumour and brain tissues was 
performed using MeCN protein precipitation (Table 10.1).  Preliminary studies using 
solid phase extraction indicated a much lower recovery from plasma and tissue (29% 
and 11%, respectively) than using MeCN protein precipitation; hence protein 
precipitation was selected as the optimal extraction method.  Recovery of D709119 
from tissue was appreciably lower than from plasma, but this was noted to be similar to 
that observed with SJG-136, and sufficient compound could be recovered to allow 
detection to approximately 50 nM in in vivo samples.  Extraction efficiencies were 
calculated using a 100 nM final drug concentration in the biological sample, as this 
concentration was estimated to be pharmacokinetically achievable.  Efficiency of 
extraction of D709119 from plasma should be considered alongside protein binding data 
for this agent (section 10.4.1), as protein binding studies indicate that approximately 
80% of D709119 is protein-bound; thus there is only 20% unbound D709119 available 
in plasma.  However, as approximately 80% of drug is recovered from plasma using the 
MeCN protein precipitation extraction procedure this indicates that the procedure acts to 
disrupt binding of the agent to plasma proteins. 
 
Biological sample Extraction efficiency 
(% ± 1 SD) 
Plasma 79.2 ± 5.2 
Brain 49.9 ± 6.5 
Tumour 46.7 ± 4.3 
Table 10.1  Plasma and tissue extraction efficiencies of D709119 using MeCN 
protein precipitation (n = 3; mean ± SD). 
10 PBD monomer D709119 
175 
 
10.3.2 Calibration 
 
10.3.2.1 Calibration curve 
D709119 calibration curves were produced in murine plasma and found to be linear 
over the range 10 – 1000 nM (Figure 10.7).  Intra-day variation was found to be low; 
the coefficient of variation was calculated as 6.5%.  Limited calibration curves (points 
at 10, 100 and 1000 nM) were performed immediately before pharmacokinetic samples 
to (i) ensure accurate results, and (ii) to compensate for any inter-day variation. 
 
 
Figure 10.7  Calibration curve for D709119 in murine plasma (10 – 1000 nM; 
n = 3, mean ± SD); inset shows calibration curve over 10 – 1000 nM (n = 6 at 
100 nM illustrating intra-day variability). (r2 = 0.99; linear curve fit is defined 
as y = 18909x - 246). 
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Calibration of D709119 was observed to be linear over the range investigated with good 
correlation as assessed by the coefficient of determination (r2, calculated by the method 
of least-squares regression). 
 
10.3.2.2 Limit of detection 
The limit of detection of D709119 in mouse plasma was found to be a 70 µl injection of 
extract from 10 nM of compound in mouse plasma, with a signal-to-noise ratio 
calculated as 12:1 (Figure 10.8).  Figure 10.8 shows a 70 µl injection extracted from 
100 µl of mouse plasma with D709119 spiked at 10 nM (extracted using protein 
precipitation). 
 
 
Figure 10.8  Chromatogram showing 10 nM D709119 extracted from mouse 
plasma.  Signal-to-noise ratio calculated using MassLynx software as 12:1.  
D709119 eluted at 5.27 min.  Evidence of baseline fluctuation as a result of 
injection artefact is seen at ~1 min post-injection. 
 
10.3.3 Stability in blood and plasma 
The stability of D709119 in murine plasma and blood was assessed at 37 °C over a 6 h 
period to assess potential degradation of D709119 ex vivo during sample handling.  
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D709119 was found to be stable in murine plasma and blood for up to 2 h (92 and 90% 
of T0 sample recovered respectively), with a gradual decrease in recovery of drug at 
later time-points (Figure 10.9).  The plasma and blood t½ were calculated by 
extrapolation of a log-linear curve fit (mono-exponential decay) obtained from the time-
points.  Plasma t½ was calculated as 6.5 h, blood t½ was calculated as 10.3 h.  The 
stability of the monitored compound indicates that rapid sample processing will be 
necessary to prevent degradation of D709119 in samples ex vivo. 
 
 
Figure 10.9  Stability of D709119 in murine blood and plasma relative to time at 
37 °C.  Values are expressed as a percentage of drug recovered at t = 0 h (mean 
± SD; n = 3). 
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10.4 Pre-clinical pharmacokinetics 
 
10.4.1 Protein binding 
Ultracentrifugation was used to evaluate sera protein binding of D709119 as 
preliminary experiments with the PBD dimer SJG-136 indicated problems with binding 
to filter membranes for the structurally-similar PBD compound. 
 
Ultracentrifugation was used to pellet out proteins in order to assess the proportion of 
unbound drug present in plasma water and thereby enable an estimation of the 
percentage of D709119 monomer bound to proteins.  This was compared directly to 
ultracentrifuged standards (PBS containing D709119) in order to ensure recovery of 
drug after the procedure.  Human serum was used for the study as it was not ethically 
justifiable to sacrifice the number of animals that would be required to obtain the 
volume of plasma necessary to perform this study using murine plasma. 
 
D709119 concentration (nM) 
in human serum 
% protein bound 
(mean ± SD) 
1000 88.5 ± 4.1% 
100 80.3 ± 10.5 
10 n / d 
Table 10.2  Assessment of % of D709119 bound to human sera protein using 
ultracentrifugation (n = 3). 
 
Protein binding of D709119 was observed to be moderate, with 88% of drug bound at 
1000 nM and 80% of drug bound at 100 nM (Table 10.2).  D709119 could not be 
detected at 10 nM. 
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10.4.2 In vivo intra-peritoneal pharmacokinetics 
Pharmacokinetic plasma time course of D709119 was investigated in the MAC15A 
tumour-bearing NMRI mouse following i.p. administration of the compound at the 
previously determined MTD of 0.5 mg kg-1 (Figure 10.10).  At each time-point, tumour 
and brain tissue were also analysed to assess tumour and CNS penetration of the agent.  
A second study was performed in parallel administering D709119 at the MTD to 
MAC29 tumour-bearing NMRI mice, where plasma levels were not monitored but 
tumour and brain samples were again analysed for comparative penetration of drug in 
the different tumour types. 
 
 
Figure 10.10  D709119 concentration (mean ± SD) versus time profile in 
MAC15A tumour-bearing NMRI mouse plasma following i.p. administration 
at 0.5 mg kg-1 (n = 3; LOQ 10 nM).  Curve shows fit using 3 compartment 
model (Equation 4: C1 = 165, C2 = 120, ka = 20, kel1 = 2.05, kel2 = 0.29). 
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The area under the concentration-time curve was calculated to be 540 nM h (197.1 ng h 
ml-1).  D709119 showed a terminal elimination half-life of 2.7 h (kel calculated as 0.29 
h-1 by curve fitting to the exponential decay portion of the plasma profile), although this 
data must be taken as tentative due to the high deviation seen at the 1 and 2 h time 
points.  D709119 showed a moderate plasma clearance of 42.28 ml min-1 kg-1 
(approximately half murine hepatic blood flow) estimated from the i.p. data.  D709119 
was detectable up to 4 h post-dose, but could not be detected after 4 h.  The Cmax 
detected for D709119 in this study was 171 nM (62.4 ng ml-1), achieved at 30 min post-
dose. 
 
Volume of distribution of D709119 can be estimated as 3202 ml kg-1 (Vss) or 742 ml 
kg-1 (Vz).  Total body water of the mouse is estimated as 600 ml kg-1 (Davies & Morris, 
1993).  An volume of distribution greater than total body water but less than 5 l kg-1 is 
moderate.  The larger volume of distribution of D709119 may account for the longer t½ 
of this agent compared to that seen for SJG-136.  While calculation of volume of 
distribution from i.p. data is not accurate compared to i.v. data, it is able to give an 
approximate value. 
 
D709119 could not be detected at any time-points in tumour or brain tissue from either 
the MAC15A or MAC29 tumour-bearing mice. 
 
10.5 Cellular effects of D709119 
D709119 was assessed for cytotoxicity using the MTT cytotoxicity assay in cell lines 
selected based on data describing the agent obtained from the NCI 60-cell-line screen 
(Figure 10.11).  Previous work by the NCI calculated a 96 h continuous exposure IC50 
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for D709119 in SK-OV-3 cells at 9.8 nM (unpublished NCI data).  The present work 
sought to confirm this and also to investigate the cytotoxicity of the compound for 
shorter exposure times. 
 
10.5.1 MTT cytotoxicity assay 
Cytotoxicity of D709119 was assessed over a range of concentrations in selected cell 
lines in order to investigate claims of cell-type selectivity of the compound.  Exposure 
of cells to D709119 was either continuous for 96 h or as a short 1 h exposure to better 
reflect exposure of tumour cells to the agent in an in vivo situation.  Growth curves for 
all cell lines were obtained as described previously (Section 9.7.1). 
 
IC50 value (nM) by cell line and cell type Exposure 
time (h) DU-145 
prostate 
UACC-62 
melanoma 
SK-MEL-2 
melanoma 
SK-OV-3 
ovarian 
M14 
melanoma 
1 7.9 ± 0.8 41.0 ± 4.7 40.3 ± 3.1 47.9 ± 8.9 7.7 ± 2.1 
96 0.14 ± 0.03 0.15 ± 0.01 0.7 ± 0.7 1.7 ± 0.2 0.02 ± 0.01 
Table 10.3  IC50 values calculated for selected cell lines after either 96 h 
continuous or 1 h exposure to D709119 (mean ± SD; n = 3). 
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Figure 10.11  NCI 60-cell-line screen data for D709119.  Data show relative 
resistance or sensitivity of cell lines to D709119.  * Denotes cell lines chosen 
for investigation in this study.  From top to bottom, cell lines: M14, SK-MEL-
2, UACC-62, SK-OV-3 and DU-145. 
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These data support the NCI 60-cell-line screen data showing nM potency of D709119.  
Each cell line shows an approximate 100-fold increase in growth inhibition after 96 h 
exposure compared to the 1 h exposure (which would be expected with an approximate 
100-fold longer exposure time), except for the SK-OV-3 cell line which appears less 
sensitive after prolonged exposure.  This may be a result of compound degradation, 
metabolism or upregulation of drug resistance mechanisms (for example MRP1, P-gp) 
within the cell population.  However, compound degradation is an unlikely cause as this 
effect would manifest across all cell lines studied.  The UACC-62, SK-MEL-2 and SK-
OV-3 cell lines appear approximately 4-fold less sensitive than the M14 and DU-145 
cell lines after 1 h exposure, though this pattern is not reflected in the 96 h continuous 
exposure results.  DU-145 and M14 remain the most sensitive cell lines to D709119 
after either 96 h or 1 h exposure although there is a less marked difference in sensitivity 
compared to the other three cell lines after 96 h exposure.  These data suggest a tumour 
cell-type selectivity for D709119, in this case as a more potent agent against the DU-
145 (prostate-derived) and M14 (melanoma-derived) cell lines. 
 
10.6 Summary 
This study has aimed to characterise and develop a pre-clinical method, including 
extraction procedures, for analysis of D709119 in murine samples.  This has included a 
preliminary pharmacokinetic study to establish basic pharmacokinetic parameters and to 
attempt to detect penetration of D709119 into the brain and tumour, two sites of specific 
interest with this compound.  These studies are the first report for this compound 
(specifically on a C2-aryl-substituted PBD agent), and are intended to feed back to drug 
designer chemists in order to illustrate the pharmacokinetic properties of D709119 and 
relate the structural differences of this compound to its pharmacokinetics and cytotoxic 
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activity compared to other PBD agents.  It is also intended that these data will provide a 
basis for decisions regarding further development of D709119. 
 
This investigation is the first study to elucidate analytical properties for D709119, and 
to define optimal detection parameters for the compound.  This has allowed the 
development of a sensitive and selective method for the detection of D709119 in 
biological fluids. 
 
The pharmacokinetic profile of D709119 following i.p. dosing has demonstrated that 
D709119 is readily available in the systemic circulation, shows moderate clearance and 
plasma protein binding, and has a high initial volume of distribution (greater than total 
body water).  It has also been established that D709119 is present in vivo in the systemic 
circulation at concentrations well in excess of those needed to achieve IC50 values in 
vitro for up to 4 h post-dose.  This indicates potential for D709119 to be present in the 
body at efficacious concentrations.  However, attempts to detect D709119 in murine 
tumour models or in the brain showed the levels of D709119 to be below the limit of 
detection.  Further work needs to be performed to examine this finding, preferably in a 
human tumour xenograft model with optimisation of extraction procedures to enhance 
detection in tumour samples. 
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11 PBD monomer compounds 
These agents were investigated in order to develop basic analytical methods to allow 
examination of levels of compounds in biological fluids.  This was done with a view to 
providing a basis for future work allowing study of the pharmacokinetics of these 
compounds in vivo.  DC-81 is a previously-studied compound that is the monomer unit 
of the first synthetic PBD dimer, DSB-120.  The monomer also has proven activity as 
assessed by cytotoxicity and DNA binding studies (Bose et al., 1992c; Puvvada et al., 
1993; 1997).  DC-81 was included in these studies to (i) allow comparison with a 
previously characterised PBD, (ii) to broaden the limited available knowledge for PBD 
compounds, and (iii) allow further structure-activity relationships to be elucidated.  
There are currently no existing analytical methods available for the study of such 
compounds. 
 
 
Figure 11.1  Structures of the PBD monomer compounds DC-81 (1), MMY-SJG 
(2), and SJG-303 (3). 
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11.1 Characterisation of compounds 
The PBD monomers DC-81, MMY-SJG, and SJG-303 were characterised to allow 
determination of optimal parameters for their detection via fluorescence, UV absorption 
and mass spectrometry. 
 
11.1.1 DC-81 
The UV absorbance spectrum of DC-81 was determined using a photodiode array 
detector, and showed peaks for detection at 222, 233, 260 and 311 nm (Figure 11.2).  
Optimal wavelengths for detection using fluorescence were determined by scanning for 
excitation (Figure 11.3) and emission (Figure 11.4) peaks, and were found to peak at 
230 and 400 nm, respectively, for excitation and emission. 
 
 
Figure 11.2  UV absorbance spectrum of DC-81.  Useful maxima for optical 
detection seen at 222, 233, 260 and 311 nm. 
 
Fluorescence detection was chosen over UV detection as it allowed a lower limit of 
detection for DC-81.  However, the optimal excitation wavelength was found to be 260 
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nm as this reduced interference caused by biological materials (versus 230 nm) without 
any appreciable loss of sensitivity. 
 
Figure 11.3  Fluorescent excitation spectral scan of DC-81 (emission wavelength 
420 nm).  Optimal sensitivity for excitation is seen at 230 nm. 
 
Figure 11.4  Fluorescent emission spectral scan of DC-81 (excitation wavelength 
230 nm).  Optimal sensitivity for emission is found at 400 nm. 
 
11.1.2 MMY-SJG 
The UV spectrum of MMY-SJG shows a similar pattern of absorbance to DC-81, with 
peaks at 223, 235, 262 and 324 nm (Figure 11.5).  Fluorescence scans for emission and 
excitation of MMY-SJG indicated peak emission at 410 nm (Figure 11.6) and excitation 
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at 230 nm (Figure 11.7).  As 260 nm was seen to give comparable intensity of signal, 
this was chosen for detection as it was less likely to be subject to interference from 
other materials at this higher wavelength.  Fluorescence proved to be the most sensitive 
mode of detection for MMY-SJG as it allowed a lower limit of detection for the 
compound compared to UV absorbance detection. 
 
 
Figure 11.5  UV absorbance spectrum of MMY-SJG.  Optimal peaks for detection 
seen at 223, 235, 262 and 324 nm. 
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Figure 11.6  Fluorescent emission spectral scan of MMY-SJG (excitation 
wavelength 230 nm).  Optimal sensitivity for emission is at 400 nm. 
 
Figure 11.7  Fluorescent excitation spectral scan of MMY-SJG derived from an 
emission wavelength of 890 nm.  Optimal sensitivity for excitation was 230 
nm; selectivity is enhanced using 260 nm, with negligible loss of sensitivity. 
 
11.1.3 SJG-303 
The UV absorbance spectrum for SJG-303 showed peaks at 231, 261, 287 and 332 nm 
(Figure 11.8).  Fluorescence spectra showed optimal emission and excitation 
wavelengths at 410 nm (Figure 11.9) and 260 nm (Figure 11.10), respectively.  SJG-303 
was less fluorescent than either DC-81 or MMY-SJG; it was found that UV absorbance 
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using a photodiode array detector offered the most sensitive mode of detection for this 
compound. 
 
Intensity of fluorescence of SJG-303 was found to be relatively lower than for either 
DC-81 or MMY-SJG; consequentially a lower limit of detection was achieved using 
UV absorbance detection, which was selected as the mode of detection.  Use of a 
photodiode array detector for SJG-303 detection allowed capture of wavelengths from 
200 – 400 nm and selection of the most appropriate wavelength (260 nm) for data 
processing. 
 
Figure 11.8  UV absorbance spectrum of SJG-303.  Optimal peaks for detection 
appear at 231, 261, 287 and 332 nm. 
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Figure 11.9  Fluorescent emission spectral scan of SJG-303 (excitation 
wavelength 230 nm).  Optimal sensitivity for emission was 410 nm. 
 
 
Figure 11.10  Fluorescent excitation spectral scan of SJG-303 (emission 
wavelength 410 nm).  Optimal sensitivity for excitation was determined at 
260 nm. 
 
11.2 HPLC method development 
 
11.2.1 Methanol-based method 
The initial development of a methanol/water-based analytical method gave a 
satisfactory HPLC method for the initial purposes of this study.  All three PBD 
11 PBD monomer compounds 
192 
monomer compounds gave highly reproducible peak retention times with good 
symmetrical peak shape (Figure 11.11, Figure 11.12 and Figure 11.13 for DC-81, 
MMY-SJG and SJG-303, respectively). 
 
 
Figure 11.11  Example trace of DC-81 using a methanol/water-based HPLC 
method; peak retention time of 7.9 min. 
 
Figure 11.12  Example trace of MMY-SJG using a methanol/water-based HPLC 
method; peak retention time of 8.6 min. 
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Figure 11.13  Example trace of SJG-303 using a methanol/water-based HPLC 
method; peak retention time of 10.2 min. 
 
11.2.2 Acetonitrile-based method 
In order to prevent formation of the carbinolamine methyl ether form of the PBD 
monomer compounds due to reaction with MeOH (see section 9.1.4.1), acetonitrile was 
substituted for MeOH.  Optimisation of mobile phase conditions gave a robust method 
with reproducible retention times for each compound (Figure 11.14, Figure 11.15 and 
Figure 11.16, respectively). 
 
 
Figure 11.14  Example trace of DC-81 using an acetonitrile/water-based HPLC 
method, showing a peak at a retention time of 6.6 min. 
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Figure 11.15  Example trace of MMY-SJG using an acetonitrile/water-based 
HPLC method, showing a peak at a retention time of 4.9 min. 
 
 
Figure 11.16  Example trace of SJG-303 using an acetonitrile/water-based HPLC 
method, showing a peak at a retention time of 8.2 min. 
 
11.3 Mass spectrometry of compounds 
Mass spectra for each of the three monomer compounds were obtained by direct 
infusion of compound into the mass spectrometer in order to (i) obtain optimal 
parameters for MS detection and (ii) identify the presence of alternate forms of the PBD 
monomer caused by the presence of water or methanol.  It is possible for PBD 
compounds to exist in three forms due to reactions between the imine C11-N10 position 
of the PBD and water or MeOH.  The forms present in solution will thus be the imine 
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(illustrated in Figure 11.17), the carbinolamine (hydrate) and the carbinolamine methyl 
ether (methanolate). 
 
Figure 11.17  The three forms of a PBD compound present in solution.  The imine 
(1) carbinolamine (2) and carbinolamine methyl ether (3) forms. 
 
11.3.1 DC-81 
DC-81 could be detected in both imine and carbinolamine methyl ether forms (Figure 
11.18) as [M + H]•+ (imine) or [M + MeOH + H]•+ (carbinolamine methyl ether).  
However, DC-81 could not be detected in its carbinolamine form. 
 
Figure 11.18  Mass spectrum of DC-81 showing the imine form (247.0; [M + 
H]•+) and carbinolamine methyl ether form (279.1; [M + MeOH + H]•+). 
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11.3.2 MMY-SJG 
 
 
Figure 11.19  Mass spectra of MMY-SJG.  a: Top trace; no methanol present, 
showing evidence of MMY-SJG in imine (273.3; [M + H]•+) and carbinolamine 
(291.2; [M + H2O+ H]•+) form.  b: Bottom trace; methanol present, showing 
additional evidence of carbinolamine methyl ether (305.2; [M + MeOH + H]•+). 
 
MMY-SJG could be detected in all three predicted forms.  In the presence of aqueous 
solvent both the imine and carbinolamine could be detected (Figure 11.19a).  In the 
presence of MeOH, the carbinolamine methyl ether could also be detected (Figure 
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11.19b).  It is of note that, in the presence of MeOH, the carbinolamine methyl ether 
form of the compound becomes the most intense species detected.  This has 
implications for mass spectral detection of the compounds, as the parent imine form is 
no longer the most intense ion, and therefore would not afford the most sensitive 
detection. 
 
11.3.3 SJG-303 
SJG-303 could be detected in all three forms.  In the presence of water, the imine and 
more intense carbinolamine forms were detected (Figure 11.20, top trace).  In the 
presence of methanol, the carbinolamine methyl ether could also be detected alongside 
the imine (Figure 11.20, bottom trace).  Further, there was also evidence for the 
presence of carbinolamine and carbinolamine methyl ether plus sodium adducts (i.e. 
+23 for [M + Na]•+ instead of [M +H]•+) in both traces. 
 
The formation of alternate forms of the monomer compounds was investigated as this 
influenced the choice of mobile phase for HPLC method development for this range of 
PBD compounds.  The findings from this preliminary study resulted in changing from 
the initial MeOH based method to MeCN for all method development of PBD 
compounds.  Ideally, working with one form of the compound is analytically 
favourable, but it was impractical to eliminate the aqueous element from the assay 
methods.  Furthermore, there was no evidence during HPLC method development that 
the different forms of the PBD compounds could be separated chromatographically; 
therefore, it was unlikely to be of great import unless using mass spectrometry as the 
primary mode of detection. 
 
11 PBD monomer compounds 
198 
 
 
Figure 11.20  Mass spectra of SJG-303.  Top trace; no methanol present, showing 
evidence of SJG-303 in imine (379.1; [M + H]•+) and carbinolamine (397.0; [M 
+ H2O + H]•+) form.  Bottom trace; methanol present, showing additional 
evidence of carbinolamine methyl ether (411.2; [M + MeOH + H]•+). 
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11.4 Stability in blood and plasma 
 
11.4.1 DC-81 
 
Figure 11.21  Stability of DC-81 in blood and plasma over 18 h.  50 µM 
compound incubated at 37°C (mean ± SD; n = 3). 
 
The data in Figure 11.21 show the stability of DC-81 over an 18 h period when 
incubated with either mouse whole blood or plasma.  DC-81 is relatively stable in 
plasma, with <5% loss of parent compound over 18 h.  However, DC81 appears to be 
less stable in blood, with <5% loss of compound over the first hour, rising to a 15% loss 
over the 18 h period.  These data indicate plasma and blood t½ in excess of 18 h, and 
demonstrate DC-81 to be relatively stable.  This indicates that it is unlikely that there 
will be extensive degradation of DC-81 in plasma or blood samples over this time 
period. 
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11.4.2 MMY-SJG 
The data in Figure 11.22 show the stability of MMY-SJG in blood and plasma over an 
18 h period.  MMY-SJG is stable in plasma over 18 h, with <1% loss of parent 
compound over 18 h.  However, MMY-SJG was less stable in blood showing a 21% 
loss of compound over the first hour, rising to 25% total loss of parent compound over 
18 h. 
 
These data indicate that MMY-SJG has a t½ in blood and plasma greater than 18 h.  
However, it is apparent that there is loss of compound in blood samples over the initial 
1 h period.  To maximise recovery of MMY-SJG from samples this would suggest that 
rapid sample processing (centrifugation to separate plasma) once a blood sample is 
obtained may help to maximise recovery of compound. 
 
Figure 11.22  Blood and plasma stability of MMY-SJG over 18 h.  50 µM 
compound incubated at 37 ºC (mean ± SD; n = 3). 
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11.4.3 SJG-303 
The PBD monomer SJG-303 was investigated in a similar fashion.  SJG-303 is fairly 
stable in plasma, showing a 5% loss of parent compound over the 18 h period (Figure 
11.23).  The compound is less stable in blood, with a loss of 28% parent compound over 
the first hour, rising to 35% loss over 18 h. 
 
As with both DC-81 and MMY-SJG, the SJG-303 compound shows plasma and blood 
t½ of greater than 18 h.  Similar to MMY-SJG though, there is appreciable loss of SJG-
303 in blood over the first hour, indicating the need to separate plasma from blood 
rapidly to maximise recovery of compound from samples. 
 
Figure 11.23  Blood and plasma stability of SJG-303 over 18 h.  50 µM 
compound incubated at 37 ºC (mean ± SD; n = 3). 
 
11.5 Extraction efficiency 
Efficiency of extraction of the PBD monomer compounds DC-81, MMY-SJG and SJG-
303 from blood and plasma was investigated using a MeCN protein precipitation 
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method (Table 11.1).  This method resulted in high levels of recovery for the PBD 
monomer compounds.  On this basis, alternate methods of extraction were not 
investigated as this method proved to be both simple and effective. 
 
High levels of extraction were seen from plasma samples for all compounds, and 
decreased levels of recovery were seen for extraction from blood.  Analytically, 
extraction from plasma is more relevant as plasma samples are more commonly studied. 
 
Extraction efficiency ( % ) Compound 
Plasma Blood 
DC-81 97.7 ± 13.9 46.8 ± 4.2 
MMY-SJG 79.8 ± 3.1 64.1 ± 2.4 
SJG-303 92.0 ± 7.3 70.0 ± 12.4 
Table 11.1  Extraction efficiencies determined for PBD monomer compounds 
from murine blood and plasma using MeCN protein precipitation method 
(mean ± SD; n = 6). 
 
11.6 Summary 
The aim of this investigation was to develop analytical methods for the three PBD 
monomer compounds, DC-81, MMY-SJG and SJG-303 along with extraction methods 
to enable analysis of compound levels in biological fluids.  DC-81 has been examined 
previously for cytotoxicity and DNA binding abilities (Bose et al., 1992c; Puvvada et 
al., 1993; 1997).  Although of less interest as a potential clinical agent, DC-81 was 
included in this study to act as a point of reference for comparison with the novel PBD 
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monomers, MMY-SJG and SJG-303, along with further comparison to the PBD dimer 
SJG-136 in glutathione reactivity studies (Chapter 12). 
 
This is the first study to demonstrate analytical methods and extraction procedures for 
DC-81, MMY-SJG and SJG-303.  The compounds have been characterised to allow 
their optimal modes of detection to be selected. The relative stabilities of the PBD 
monomers in blood and plasma have also been investigated.  Furthermore, the 
phenomenon observed with the other PBD compounds investigated, SJG-136 (chapter 
9.1.4) and D709119 (chapter 10.1.3), showing reactivity of the compounds with water 
and methanol to produce carbinolamine and carbinolamine methyl ether derivatives of 
the compounds, was also seen with these monomer agents.  This is an important issue to 
be considered for detection using mass spectrometry in future work. 
 
 
12 Glutathione reactivity of PBDs 
204 
12 Glutathione reactivity of PBDs 
Studies have suggested a reactivity of GSH with PBD-based compounds (Morris, 1992; 
Smellie et al., 1994; Zioga, 1999), both in cell-free and cell-based systems.  A range of 
PBD compounds were investigated in order to better characterise the reactivity seen in 
the earlier studies.  In order to put these data into a biologically relevant perspective, it 
is important to be aware that previously published work estimates the concentration of 
GSH in murine plasma to be in the range of 20-100 µM (Kim et al., 2003).  Intracellular 
concentrations of GSH are found to be approximately 1-20 mM, dependant on cell type 
(Liu & Hannun, 1997; Vahrmeijer et al., 1999; Zhang, 2000; Hogg, 2002). 
 
12.1 Reaction with GSH versus time 
 
12.1.1 DC-81 
Incubation of the PBD monomer DC-81 (50 µM in PBS) with 50 µM GSH over time 
showed an initial and immediate decrease in compound recovered, with little drop in 
recovery over the following 3 h.  This experiment was conducted twice: once injecting 
the GSH reaction mixture directly onto the HPLC system, and secondly using a MeCN 
protein precipitation extraction procedure (Figure 12.1) to assess impact of extraction on 
the reaction.  This study showed a lack of influence of time on the reaction of GSH with 
DC-81, indicating that the reaction occurs in t <5 min (estimated time required to handle 
and inject sample onto HPLC system), and the t½ of DC-81 after this point is > 3h.  
Extrapolation of the curve fit estimates this at 7.6 h (for extracted samples) and 30.1 h 
(without extraction) relative to initial recovery from GSH.  There is evidence of an 
effect of extraction on recovery of DC-81 as this increased drug recovered from 
approximately 60-80%, indicating possible disruption of binding of DC-81 to GSH by 
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MeCN.  Calculation of a half-life for the PBD with GSH incubation is unlikely to be 
valid as the initial drop in compound levels occurs rapidly (t <5 min), and accounts for 
the largest decrease in compound recovery seen during the course of the experiment. 
 
 
Figure 12.1  Reactivity of DC-81 (50 µM) over time with GSH (50 µM), relative 
to DC-81 control (0 µM GSH) (mean ± SD; n = 3).  Open circles indicate 
MeCN extraction method used to recover DC-81, closed circles indicate no 
extraction used. 
 
12.1.2 MMY-SJG 
Similar to DC-81 (section 12.1.1), MMY-SJG shows an immediate and rapid drop in 
recovery of compound (t < 5 min).  After the initial drop in compound level, there was 
only a small alteration in compound levels over the subsequent 3 h (Figure 12.2).  The 
data indicated a t½ > 3 h for both the extracted and non-extracted experiments (21.0 and 
10.9 h, respectively, by extrapolation of curve fit; values relative to t0 recovery of 
compound).  The trend seen with DC-81 is repeated with MMY-SJG; extraction appears 
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to influence recovery of compound after incubation with GSH, but time does not seem 
to exert great influence on MMY-SJG levels relative to the initial drop in recovery. 
 
Figure 12.2  Reactivity of MMY-SJG (50 µM) over time with GSH (50 µM), 
relative to MMY-SJG control (0 µM GSH) (mean ± SD; n = 3).  Open circle 
indicates MeCN extraction method used to recover DC-81, closed circle 
indicates no extraction used. 
 
12.1.3 SJG-303 
SJG-303 repeats the pattern of GSH reactivity seen with DC-81 and MMY-SJG, 
although it appears that time of incubation with GSH is more influential than with the 
other monomers, and almost 100% of SJG-303 could be recovered at the early time 
points (t = 0 and t = 0.5 h) compared to the other monomers when MeCN extraction is 
used (Figure 12.3).  SJG-303 shows shorter t½ (4.4 h in extracted samples, 6.1 h in non-
extracted samples) than both DC-81 and MMY-SJG, although it maintains the initial 
rapid disappearance of parent compound when GSH is present. 
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Figure 12.3  Reactivity of SJG-303 over time with GSH (50 µM), relative to 
SJG-303 control (0 µM GSH) (mean ± SD; n = 3).  Open circle indicates 
MeCN extraction method used to recover DC-81, closed circle indicates no 
extraction used. 
 
There is a clear trend across all three monomers investigated in this study.  
Disappearance of compound at t < 5 min (unfeasible to process and inject samples 
quicker than this onto the analytical system) is apparent in all three monomers 
(excepting SJG-303, where 100% recovery was achieved at early time-points with 
extraction).  The MeCN extraction procedure has a noticeable effect, increasing the 
recovery of the monomers by approximately 20-40%; this is variable between 
compounds.  All of the PBD monomers investigated had half-lives longer than the 
investigated period.  The 3 h period reflects a reasonable estimate of the time of 
exposure likely to be seen in vivo based on previous pharmacokinetic studies performed 
with the PBD dimer DSB-120 (Walton et al., 1996).  These data indicate that GSH 
binding to the PBD compounds is likely to occur rapidly; the effect of a range of 
concentrations of GSH on compound recovery is investigated below to attempt to 
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ascertain how the range of GSH concentrations in vivo may influence PBD availability 
(section 12.2). 
 
12.2 Concentration dependant reaction with GSH 
The effect of a range of concentrations on PBD recovery was examined to assess the 
influence of GSH.  The concentration range was selected to bracket physiologically 
relevant concentrations of GSH; plasma concentrations in the 20 – 100 µM range, and 
intracellular concentrations in the 1- 20 mM range.  Extraction procedures were not 
used in order to minimise disturbance of drug-GSH reactivity. 
 
12.2.1 DC-81 
 
Figure 12.4  DC-81 recovery in the presence of increasing concentrations of GSH 
relative to standard (no GSH present).  50 µM DC-81 with GSH concentrations 
ranging from 0.05 – 50 mM (n = 3; mean ± SD). 
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As the concentration of GSH increased, it was observed that recovery of DC-81 
decreased (Figure 12.4).  Assuming plasma levels of GSH at approximately 100 µM, it 
can be estimated that 30% of DC-81 loss may be attributed to GSH binding.  This 
decreased recovery increases as GSH levels approach intracellular concentrations (to 
approximately 80% DC-81 loss at 10 mM). 
 
12.2.2 MMY-SJG 
MMY-SJG recovery was observed to fall as levels of GSH were increased (Figure 
12.5).  At GSH levels approaching plasma concentrations, approximately >90% of 
compound was recovered.  As concentrations of GSH approached intracellular levels 
this drops to approximately 30%. 
 
Figure 12.5  MMY-SJG recovery in the presence of increasing concentrations of 
GSH relative to standard (no GSH present).  50 µM MMY-SJG with GSH 
concentrations ranging from 0.05 – 50 mM (n = 3; mean ± SD). 
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12.2.3 SJG-303 
Recovery of SJG-303 after incubation with GSH was >90% at plasma-relevant 
concentrations of GSH.  Recovery of the compound decreased rapidly as concentrations 
of GSH were increased (Figure 12.6).  Recovery of drug decreased to 40% at 
concentrations approximating intracellular levels. 
 
Figure 12.6  SJG-303 recovery in the presence of increasing concentrations of 
GSH relative to standard (no GSH present).  50 µM SJG-303 with GSH 
concentrations ranging from 0.05 – 50 mM (n = 3; mean ± SD). 
 
12.2.4 SJG-136 
Concentrations of SJG-136 were seen to decrease relative to increasing GSH 
concentration, as was found with the PBD monomer compounds.  This was seen at the 
same molar concentration of SJG-136 as the monomer compounds (Figure 12.7) and at 
a lower concentration of SJG-136 (Figure 12.8). 
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Figure 12.7  SJG-136 recovery in the presence of increasing concentrations of 
GSH relative to standard (no GSH present).  50 µM SJG-136 with GSH 
concentrations ranging from 0.05 – 50 mM (n = 3; mean ± SD). 
 
Figure 12.8  SJG-136 recovery in the presence of increasing concentrations of 
GSH relative to standard (no GSH present).  1 µM SJG-136 with GSH 
concentrations ranging from 0.1 – 30 mM (n = 3; mean ± SD). 
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12.3 GSH interference with metabolism 
The metabolism of SJG-136 in liver S9 fraction was investigated in section 9.6.1.  It 
was observed that the traces of SJG-136 (which appeared extensively and rapidly 
metabolised in S9 fraction; t½ < 5 min) after incubation with GSH appeared to closely 
correlate to those after incubation with murine liver S9 fraction.  Further investigation 
showed that these traces matched (Figure 12.9).  It is reported in the literature that 
typical intracellular concentrations of GSH are in the 1 - 20 mM range (Liu & Hannun, 
1997; Vahrmeijer et al., 1999; Zhang, 2000; Hogg, 2002).  The tissue processing 
involved in S9 fraction preparation is likely to result in the lysis of cells and subsequent 
release of intracellular contents, including GSH.  It is possible that this could increase 
the GSH content of the S9 fraction to the low mM range, although this has not been 
analytically confirmed.  Therefore it can be concluded from these data that the 
incubation of SJG-136 with S9 fraction results in reaction of GSH with SJG-136.  The 
appearance of metabolism in previous experiments is almost certainly due to reaction 
with glutathione.  This is supported by data shown in section 12.2, indicating that a 
concentration of GSH in the low mM range will result in the loss of up to 90% of parent 
compound. 
 
Attempts to identify a conjugate of SJG-136 and GSH were not successful, although the 
disappearance of the compound strongly suggests this is occurring.  Furthermore, time 
constraints prevented the mass spectral characterisation of peaks b and c (Figure 12.9). 
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Figure 12.9  HPLC trace showing (top) SJG-136 at t0 with 2 mM GSH and 
(bottom) SJG-136 incubated with S9 fraction (t0).  Traces show identical peak 
patterns despite no added GSH to S9 fraction experiment.  Peak a (RT 10.2 
min) present in SJG-136 standard also (possible impurity).  Peaks b (RT 13.9 
min) and c (RT 14.7 min) seen only when either GSH or S9 fraction present.  
SJG-136 seen at RT 17.5 min.  RT = retention time. 
 
12.4 Summary 
With all PBD compounds investigated, it was observed that increasing concentrations of 
GSH resulted in lower recovery of PBD across a biologically relevant range of 
concentrations.  These data have implications on the pharmacokinetics of PBD 
compounds within biological systems due to the high levels of GSH found in vivo.  It 
has also been proposed that PBD compounds react readily with any thiol containing 
molecule (Morris et al., 1990; Morris, 1992), further increasing the likelihood of 
reactivity of the compounds with endogenous molecules.  The reactivity of the PBD 
compounds with GSH appears to be biphasic in all cases.  It is possible that at higher 
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concentrations of GSH, the GSH molecules form dimers and thus the binding of GSH to 
itself acts as a competitive inhibitor of further reactions. 
 
At concentrations of GSH found in the plasma there was observed to be a high recovery 
of PBD compounds (70 – 100%).  Hence binding to GSH is not likely to influence 
plasma levels of PBD compounds, and therefore will not prevent distribution of the 
drug via the vasculature.  However, due to the high levels of GSH found in the 
intracellular environment, the amount of free drug is likely to be significantly 
diminished.  This effect was most marked with the clinical trial candidate molecule, 
SJG-136 (Figure 12.7), >90% recovery at plasma relevant concentrations and <10% 
recovery at intracellular relevant concentrations.  Despite this drop in recovered drug at 
the higher concentrations of GSH, SJG-136 is still highly potent, and NCI human 
tumour xenograft data in the NCR-Nu mouse have indicated efficacy (personal 
communication, Prof. D. E. Thurston). 
 
Relating specifically to SJG-136, it may be possible that, despite GSH binding, the 
inherent toxicity of the molecule is so potent that only a very small proportion of SJG-
136 needs to be in an unbound state to elicit cytotoxic effects.  It would be interesting to 
investigate this further in GSH-depleted cell lines, as one may expect increased toxicity 
of the compound with GSH-depleted cells if this suggestion is valid. 
13 Discussion and conclusions 
215 
13 Discussion and conclusions 
The pyrrolobenzodiazepine (PBD) class of compounds have been shown in several 
studies to have antitumour activity believed to result from cytotoxicity induced by 
interaction with cellular DNA.  Although the use of DNA as an antitumour target has 
largely fallen out of favour over recent years, many of the most effective anti-cancer 
agents currently in use in the clinic are DNA-targeting drugs.  This is due to the lack of 
specificity of current DNA-targeting agents and their associated toxicity.  The PBD 
class of compound aims to improve specificity and reduce toxicity by a sequence-
selective binding profile to cellular DNA (Puvvada et al., 1997).  Currently there are no 
PBD agents in the clinic, and agents that progressed to phase I trials were dropped due 
to high levels of toxicity (Fujita et al., 1982).  The main aim of this project was to 
characterise several PBD agents that have been flagged by the NCI 60-cell line screen 
as acting via a novel mechanism, and specifically to investigate the pharmacological 
actions of the PBD dimer SJG-136.  This compound is of special interest due to its rapid 
progression to phase I clinical trials. 
 
To enable accurate quantification of the PBD agents within the systems to be studied, 
sensitive and selective analytical methods were developed to enable extraction from the 
biological materials and HPLC analysis of the compounds.  While mass spectroscopy 
was not considered an optimal mode of detection for all the compounds, it was 
important to ensure that a mass spectrometer-compatible HPLC method was developed 
in order to enable use of this mode of detection at later points of the study for purposes 
such as metabolite identification.  As a consequence, mass spectrometer conditions for 
each compound were optimised.  During this process it was discovered that all of the 
PBD agents are affected by an inherent reactivity with water and/or methanol that 
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causes the agents to interconvert between different forms (imine, carbinolamine, or 
carbinolamine methyl ether), depending on the presence of the aforementioned solvents.  
This became an issue as initial method development focused on a methanol/water-based 
separation, and interaction of the PBD agents with methanol caused the appearance of 
mass spectral peaks at m/z ratios corresponding to the discrete imine, carbinolamine, 
and carbinolamine methyl ether forms.  While there was no evidence of 
chromatographic separation of these three forms, it posed a potential loss of sensitivity 
should single quadrupole mass spectral detection be used; the analytical sample of drug 
could potentially be split into three different masses each of lower intensity.  This 
prompted the use of an acetonitrile-based method to prevent this issue.  The 
carbinolamine (imine + water adduct) was still observed, but optimal tuning of the mass 
spectrometer enabled the imine form to be observed as the most intense ion, with 
elimination of the carbinolamine methyl ether (imine + methanol) form of the PBD 
compound.  Furthermore, avoidance of water from the experimental protocol was 
deemed highly impractical for biological studies. 
 
13.1 SJG-136 
A sensitive and selective method for the analytical detection of SJG-136 was developed.  
Characterisation of the compound revealed fluorescence detection of SJG-136 to 
provide a comparable limit of detection to tandem quadrupole (MS/MS) detection, but 
with a higher degree of portability due to the expense and availability of MS/MS 
detectors.  Consequentially, method development and analysis centred around HPLC 
separation and fluorescence detection, although MS and MS/MS detection methods 
were developed for further work.  A simple and efficient method was developed for the 
extraction of SJG-136 from murine samples, allowing 98% recovery of compound from 
13 Discussion and conclusions 
217 
plasma, and SJG-136 was found to be stable in plasma (t½ > 12 h) ex vivo.  The SJG-
136 analytical method was calibrated and was found to be linear over the range 5 – 1000 
nM, a range predicted to be appropriate for pre-clinical pharmacokinetic studies in view 
of the low MTD (0.2 mg kg-1 i.p., 0.3 mg kg-1 i.v.) for SJG-136 in the mouse. 
 
The pre-clinical pharmacokinetic studies of SJG-136 revealed the agent to be easily 
detectable in the mouse at the MTD and ⅓MTD following i.v. administration, with peak 
plasma concentrations in the µM range; 4.8 and 1.6 µM Cmax respectively, both at 2 min 
post-dose.  Importantly, the observed Cmax concentrations of SJG-136 demonstrate 
linear plasma pharmacokinetics for SJG-136 between the two doses, as the ⅓MTD Cmax 
is 33% of the MTD, at 33% of the dose.  Furthermore, using non-compartmental 
analysis (the linear trapezoidal method) to calculate the AUC0 - ∞ as a more accurate 
assessment of the linearity of the increase in detected SJG-136, the AUC of the ⅓MTD 
study showed as 31% of that of the value determined in the MTD study.  As SJG-136 
was dosed at the MTD, and linear pharmacokinetics were apparent over the 0.1 – 0.3 
mg kg-1 range, it is likely that pharmacokinetics will be linear up to the murine MTD.  
However, study of SJG-136 pharmacokinetics at lower doses may be desirable to 
confirm linearity. 
 
The low MTD determined for SJG-136 ensured that a highly sensitive analytical 
method could be developed, as it was expected that distribution of the agent within the 
mouse would result in low and difficult to detect plasma concentrations.  Surprisingly, 
SJG-136 was present at high concentrations within murine plasma, and it was necessary 
to dilute plasma samples in order to bring the detected concentrations back within the 
range of the calibration curve.  This arises from the low volume of distribution (Vss) of 
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the compound, averaging at approximately 242 ml kg-1, a volume lower than total body 
water (600 ml kg-1) (Davies & Morris, 1993).  The observed low volume of distribution 
indicates that the compound is not extensively distributed into tissues.. 
 
Parameter SJG-136 DSB-120a 
Structure 
 
Dose (mg kg-1) 
0.3 
(MTD) 
0.1 
(⅓MTD)
0.2b 
(MTD) 
5 (MTD) 
Vss  ( ml kg-1 ) 245 239  130 
t½ ( h ) 0.66 1.44 1.2 0.63 
% protein bound 80.3 96.6 
CL (ml min-1 kg-1) 11.8 12.9 17.7(12) 22 
F (%)   67 n/a 
Table 13.1  Comparison of SJG-136 (i.v. dose route) and DSB-120 (i.v dose 
route) pharmacokinetic properties.  a Data taken from Walton et al. 1996.  
b SJG-136 i.p. data for comparison; value in brackets is corrected for 
incomplete absorption of SJG-136 via i.p. route. 
 
A low volume of distribution may be the result of high plasma protein binding of SJG-
136 reducing distribution of the agent outside of the bloodstream.  However, protein 
binding studies show only a moderate level of protein binding of SJG-136.  Protein 
binding levels of SJG-136 were established using human sera in these studies, due to the 
volume of biological fluid needed to perform the ultracentrifugation step.  
Consequentially, it would be useful to define the level of plasma protein binding in 
murine plasma to determine if there is a species difference between mouse and man, as 
a discrepancy between binding in man and mouse may lead to altered pharmacokinetics 
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when translating the data to man.  More accurately, lower protein binding in man may 
result in a relatively higher proportion of free drug in plasma. 
 
Interestingly, SJG-136 shows very similar pharmacokinetic properties to the earlier 
PBD dimer, DSB-120 (Table 13.1).  Disappointingly, further development of DSB-120 
was discontinued due to evidence of poor in vivo antitumour activity, despite 
demonstrable in vitro cytotoxicity (Walton et al., 1996).  However, SJG-136 has been 
shown to offer good in vitro antitumour activity across a wide range of human tumour 
xenografts in vivo (personal communication, D. Thurston).  This is perhaps a result of 
the markedly increased cytotoxicity of SJG-136 compared to DSB-120; SJG-136 
averages as approximately 1800-fold more cytotoxic than DSB-120 as assayed using the 
96 h exposure MTT cytotoxicity assay (Gregson et al., 2001).  Consequentially, a much 
smaller concentration of SJG-136 would be required to elicit a cytotoxic effect; 
minimising the effect of the limited volume of distribution of SJG-136.  It is apparent 
from these data that the small structural change from DSB-120 to SJG-136 has resulted 
in a significant increase in cytotoxicity of the compound without an appreciable effect 
on pharmacokinetics. 
 
Plasma levels of SJG-136 were found to be well in excess of in vitro IC50 concentrations 
for 1 h exposure of tumour cell lines to SJG-136 for up to 2 h after dosing (section 9.5), 
indicating that SJG-136 is available in the systemic circulation at concentrations likely 
to be efficacious.  SJG-136 was also detected in brain and tumour tissue at 
concentrations above the 1 h in vitro IC50 values; levels of SJG-136 were seen in brain 
samples at concentrations higher than would be expected to result solely from the 
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volume of blood/plasma present in the vasculature of the brain, blood volumes were not 
quantifiable in the tumour so this could not be estimated for tumour samples. 
 
Intra-peritoneal pharmacokinetics of SJG-136 show a triphasic shape, indicating a rapid 
absorption phase, with subsequent distribution and elimination phases.  Comparing the 
AUC of the MTD i.p. study with the i.v. study and correcting for dose indicates 
incomplete absorption of SJG-136 from the peritoneal cavity; approximately 68% 
absorbed.  Values calculated for clearance and plasma half life were comparable to the 
i.v. dosed studies.  Despite the incomplete absorption of SJG-136, back extrapolation of 
the distribution and elimination phases of the fitted curve to approximate an equivalent 
to the i.v. C(0) results in the calculation of a Vi which is close to that calculated using 
i.v. data. 
 
Metabolic stability of SJG-136 was studied initially using a murine liver S9 fraction 
preparation, however the glutathione reactivity of the compound limited the usefulness 
of this model (discussed below), and no discrete metabolites were identifiable.  
Incubation of SJG-136 with liver microsomes indicated a rapid breakdown of SJG-136 
to several metabolites, with molecular weights identifiable using mass spectrometer 
analysis.  The most abundant metabolite appeared to be a mono-demethylated form of 
SJG-136 (M = 542.6); the structure of this metabolite was determined by matching 
predictive metabolism to the detected mass spectral ion rather than via empirical 
determination, NMR studies on the metabolite would be required to confirm the 
structure.  Other prospective metabolites were also detected that correspond to either 
ring hydroxylation of SJG-136 or breaking apart of the C8 linker into monomeric 
subunits. 
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To determine the relevance of the major metabolite determined in vitro, the 30 min 
plasma i.p. pharmacokinetic sample (corresponding to Cmax) was reanalysed using LC-
MS/MS.  The metabolite was detectable in vivo, although assuming identical MS 
response to the metabolite and SJG-136, the metabolite represents only 1.2% of SJG-
136 in plasma at this time point.  Time constraints prevented reanalysis of further time 
points to establish a full pharmacokinetic profile of the metabolite and attempts to 
investigate potential formation of phase II metabolism derived metabolites. 
 
Due to the fluorescence of SJG-136, it was possible to investigate cellular localisation 
of the agent.  SJG-136 was observed to localise in the nucleus of the cells studied.  
However, the length of time and concentration at which cells were treated in order to 
detect intracellular SJG-136 resulted in obvious morphological changes to the cells 
arising from toxicity.  While localisation in the nucleus is a desirable quality for SJG-
136, as its mechanism of action is proposed to be via interaction with DNA, the 
concentrations of SJG-136 used (1 mM) were well in excess of the highest levels likely 
to actually be achieved in vivo (Cmax in vivo from i.v. pharmacokinetic study = 4.8 µM).  
It is envisioned that further work using UV confocal microscopy may allow detection of 
SJG-136 and localisation at a more physiologically relevant concentration. 
 
Cytotoxicity studies showed a degree of cell-type selective cytotoxicity.  96 h exposure 
of cells to SJG-136 indicated IC50 values ranging from 120 pM to 2.5 nM, dependent on 
cell type; a 20-fold difference between the sensitive UACC-62 melanoma cell line and 
the less-sensitive SK-OV-3 ovarian cell line.  However, after 1 h exposure to SJG-136 
there was a less pronounced difference in sensitivity to SJG-136, with only a 7-fold 
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difference between the sensitive M14 melanoma cell line and the less sensitive 
SK-MEL-2 cell line.  These data are in line with previously published data indicating an 
IC50 value of 9.1 nM for 96 h exposure using the MTT assay with the SK-OV-3 cell line 
(found to be 2.5 nM in this study) (Gregson et al., 2001), and data from the NCI 60-cell-
line screen which found the GI50 of SJG-136 with SK-OV-3 to be 10 nM. 
 
The effects of SJG-136 on the cell cycle were investigated to characterise the effects of 
the compound on cell growth and compare the actions of SJG-136 to other DNA 
interstrand crosslinking agents.  The cells were treated at a concentration of SJG-136 
achievable in vivo and midway between the 1 h and 96 h IC50 values.  It was apparent 
that continuous exposure of cell lines to SJG-136 resulted in a decreased G1 peak and 
increased S and G2 peaks after 24 h exposure and loss of histogram definition after 48 h 
exposure with toxicity apparent due to the loss of adherence of the cell lines.  Following 
1 h exposure of the cells to SJG-136, a G2/M block of the cell cycle was seen in all cell 
lines investigated after 24 h, apparent as an increase in G2 peak area and a 
corresponding decrease in G1 peak area.  This effect persisted for up to 72 h post 
exposure in three of the five cell lines studied.  This effect has been reported as a 
characteristic of DNA minor groove-binding agents (Erba et al., 1995; Turner & Denny, 
1996; Yamori et al., 1999) and DNA crosslinking agents in general (Konopa, 1988).  
Furthermore, this study demonstrates a prolonged action of SJG-136 following a 
relatively short exposure of cells to SJG-136, perhaps indicative of evasion of DNA 
repair mechanisms by the agent arising from minimal distortion of the DNA double 
helix, previously proposed for the PBD dimer DSB-120 (Jenkins et al., 1994) and for 
SJG-136 itself (Gregson et al., 2001).  In addition, these data are consistent with 
previously published data for the structurally similar but considerably less active 
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compound, DSB-120.  Cell cycle analysis of DSB-120 revealed a dose-dependent block 
of the cell cycle in the G2/M phase, with effects persisting for up to 96 h post-exposure 
following a 1 h exposure of cells to agent (Smellie et al., 1994). 
 
Assessment of the crosslinking effects of SJG-136 in vivo allowed a unique assessment 
of a pharmacodynamic endpoint for the agent, as DNA interstrand crosslinking of SJG-
136 is the proposed mechanism by which SJG-136 elicits its cytotoxic effects.  SJG-136 
was shown to produce a high level of interstrand crosslinks in lymphocytes, as assessed 
using the Comet assay.  Comparison of the crosslinking induced in lymphocytes after 1 
h post dose to that present 24 h post dose revealed no significant decrease in the amount 
of crosslinking between the two time points; further evidence of a lack of cellular 
competency to repair SJG-136-induced lesions.  Furthermore, there was no significant 
dose-dependent difference in the amount of crosslinking arising from dosing at the 
MTD versus ⅓MTD, although there was an observable (not-significant) decrease in 
crosslinking at ⅓MTD in both the i.p. and i.v. dosed studies.  Detection of interstrand 
crosslinks within the HL-60 (acute myeloid leukaemia derived cell line) tumour was not 
possible, as there was a high level of DNA fragmentation observed in control tumour 
cells arising as a characteristic of the tumour therefore invalidating the assay for this 
tumour;  time constraints prevented study of an alternate tumour type. 
 
A point of note observed during the preparation of lymphocyte samples for Comet 
analysis is that there was appreciably less (approximately 20-fold) lymphocytes in 
samples from SJG-136 treated mice compared to control mice.  While the investigation 
was not designed to investigate this and thus these data are not conclusive, it was 
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thought appropriate to mention this as it may provide an indication of potential 
toxicities of SJG-136 upon translation of the drug into man. 
 
13.2 D709119 
This study has produced a sensitive and selective LC-MS analytical method for the 
analysis of D709119 in biological fluids.  D709119 was found to be relatively 
insensitive to detection via fluorescence or UV absorbance; consequentially, mass 
spectrometry was chosen as the mode of detection for use on the HPLC separation 
system.  A simple and efficient acetonitrile-based protein precipitation method was 
developed for recovery of D709119 from murine plasma (79% extraction efficiency).  
The HPLC method was calibrated and D709119 was found to be linear over the 10 – 
1000 nM range (10 nM limit of detection).  The determined MTD for pharmacokinetic 
studies of D709119 was 0.5 mg kg-1 and it was estimated that this range would be 
appropriate for detection of D709119 in vivo. 
 
Pre-clinical pharmacokinetic studies of D709119 at the MTD following i.p. dosing at 
the MTD (0.5 mg kg-1) showed D709119 to be detectable well within the calibration 
limits of the HPLC assay.  Peak plasma concentrations of D709119 were detected at 30 
min post-dose as 171 nM (62.4 ng ml-1).  D709119 was detectable until 4 h post-dose, 
and non-compartmental analysis (using the linear trapezoidal method) showed the 
AUC0 - ∞ to be 540 nM h (197.1 ng h ml-1).  While it is not possible to accurately 
calculate the volume of distribution of D709119 from an i.p. dose due to the possibility 
of incomplete absorption of the compound via this route and the slow release of agent 
into the circulatory system, based on the rapid absorption seen in the pharmacokinetics 
profile C(0) was estimated by back extrapolation of the distribution and elimination 
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portions of the fitted curve (fitted using a triphasic curve based on the two-compartment 
model; accounting for absorption, distribution and elimination phases) in order to allow 
an approximation of the initial volume of distribution for comparison to the PBD dimer 
compounds.  The calculated Vss of 3202 ml kg-1 tentatively indicates extensive 
distribution of the agent out of the central compartment, and is close to 8-fold higher 
that that seen for either DSB-120 (Walton et al., 1996) or SJG-136 (reported in chapter 
9).  There is little reported data relating to the pharmacokinetic behaviour of PBD 
monomer agents.  However, D709119 shows a much larger Vss than neothramycin 
(3202 ml kg-1 versus 410 ml kg-1), with a similar terminal t½  (0.29 h versus 0.24 h) 
(Fujita et al., 1982) (summarised in Table 13.2).  These data are not strictly comparable 
due to the choice of differing dose routes (i.p. versus i.v.) and the disadvantages 
involved in predicting Vss from non-i.v. data, so data should be treated with the 
appropriate caution.  Furthermore, the plasma concentration versus time profile for 
D709119 showed several points with a high degree of standard deviation.  Clearance of 
D709119 has likely been overestimated as calculation from i.p. data assumed complete 
absorption from the peritoneal cavity.  Despite a larger volume of distribution, D709119 
could not be detected in MAC29 tumour, MAC15A tumour or brain tissues in this 
study. 
 
The structural differences between D709119 and neothramycin (Table 13.2) appear to 
have resulted in little difference in the t½ between the compounds.  The most apparent 
difference caused by the minor structural modifications between the two agents is the 
large increase in the Vss of D709119 compared to neothramycin. 
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Parameter D709119 neothramycina 
Structure 
  
Dose (mg kg-1) 0.5 10 
Vss ( ml kg-1 ) 3202 410 
t½ ( h ) 0.29 0.24 
% protein bound 84.4 n / a 
CL (ml min-1 kg-1) 42.3 20.2 
Table 13.2  Comparison of D709119 (i.p. dose route) and neothramycin (i.v. dose 
route) pharmacokinetic properties.  a Data taken from Fujita and co-workers 
(Fujita et al., 1982). 
 
The plasma time course of D709119 in vivo demonstrated that the agent is present in the 
mouse at concentrations well in excess of the 1 h IC50 values determined in vitro for up 
to 4 h post-dose.  This indicates that D709119 is present in the circulatory system of the 
mouse at a concentration likely to produce a cytotoxic effect and for long enough to 
produce this effect.  Unfortunately as levels of D709119 were not detected in the 
tumour it cannot be confirmed that the agent reaches the tumour at levels required to 
produce a cytotoxic effect. 
 
13.3 PBD monomer compounds, MMY-SJG, SJG-303 and DC-81 
Analytical methods were developed for detection of the PBD monomer compounds 
MMY-SJG, SJG-303 and DC-81.  Characterisation of the compounds showed 
fluorescence detection to be the optimal mode of detection for MMY-SJG and DC-81, 
and UV absorbance detection using a photodiode array detector to be the optimal mode 
of detection for SJG-303.  HPLC was used to provide chromatographic separation.  An 
acetonitrile-based protein precipitation method was used to provide a straightforward 
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and efficient method for extraction of the agents from plasma and blood.  Blood and 
plasma stability studies showed all three PBD monomer agents to be stable in murine 
plasma for up to 18 h, but less stable in blood. 
 
Methods were developed for the analysis of these compounds to aid in future studies 
and to enable study of the glutathione reactivity of the PBD monomers.  This 
investigation developed the first HPLC analytical method and extraction procedure for 
quantification of these compounds. 
 
13.4 Reactivity of PBD compounds with glutathione 
Glutathione (GSH) is a well documented agent involved in detoxification mechanisms 
for removal of xenobiotic compounds, including carcinogens and anticancer agents.  
This often involves glutathione S-transferases which act to catalyse the conjugation of 
GSH to a broad range of compounds.  As a result of the major role of GSH in 
detoxification, its presence within biological systems is ubiquitous.  Earlier work 
investigating the PBD compounds have shown an inherent, non-enzyme mediated, 
reactivity of this class of agents with thiol-containing molecules such as GSH (Morris et 
al., 1990; Morris, 1992).  The level of intracellular GSH has also been reported to 
influence cellular resistance to DSB-120; higher levels of GSH result in increased 
resistance (Smellie et al., 1994).  Consequentially the GSH reactivity of the PBD agents 
studied here was investigated to characterise this phenomenon and to predict the 
behaviour of these agents in vivo. 
 
Study of the PBD monomer agents MMY-SJG, SJG-303 and DC-81 indicate that there 
is little influence of time on the reactivity of the compounds with GSH, as assessed by 
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recovery of the monomers after incubation with GSH.  There appears to be an 
immediate (<5 min) reaction of the agents with GSH, resulting in rapid loss of 
detectable compound.  Extraction using the acetonitrile precipitation method increased 
recovery of the compounds by 20-40%, indicating that this extraction procedure 
disrupts binding of the PBD monomers to GSH and that PBD-GSH binding is 
reversible.  It is possible that GSH and the PBD monomers reach equilibrium rapidly, 
hence there is no further decrease in recovered agent after initial reaction.  Further, 
acetonitrile may disturb binding sufficiently to increase recovery of agent by some 
small amount. 
 
To investigate the effect of GSH concentration on recovery of PBD agents, the 
compounds were incubated with different concentrations of GSH in order to build a 
concentration versus percentage free PBD curve over a physiologically relevant range 
of concentrations.  These data indicate that a higher concentration of GSH results in a 
lower recovery of PBD agent.  To put these data in context, at concentrations of GSH 
found in plasma (20–100 µM), there is high recovery of PBD representative of a high 
amount of unbound compound, whereas at intracellular GSH concentrations (1 – 20 
mM) there is a much lower recovery of PBD, representative of a lower amount of 
unbound compound. 
 
Potential implications of this GSH reactivity were apparent when metabolism of SJG-
136 was studied using the liver S9 fraction model.  It became clear that the rapid 
disappearance of SJG-136 indicated in the study was attributable to the reactivity of the 
agent with GSH, as peaks seen in the HPLC trace after extraction from the liver S9 
fraction matched exactly the peaks seen after incubation of SJG-136 with GSH alone.  
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GSH in the liver S9 fraction is likely to be in the mM range resulting from lysis of cells 
and subsequent release of intracellular GSH during preparation.  Study of the 
metabolism of SJG-136 in the liver microsomal fraction did not show similarities to the 
S9 metabolism data or to the GSH studies; preparation of the liver microsomal fraction 
removes GSH, consequentially there is no evidence of the GSH-PBD conjugate in these 
data. 
 
Thus, the innate reactivity of the PBD class of compounds is likely to affect unbound 
agent in vivo and therefore the distribution of the agents and free drug in tissue.  
Furthermore, this may have implications on the therapeutic usage of these compounds, 
as tumours expressing high levels of GSH may result in resistance. 
 
13.5 Conclusions 
The studies presented in this thesis have characterised several important factors for the 
progression of the PBD dimer SJG-136 into the clinic for use in man.  A sensitive and 
selective HPLC analytical method has been developed for the analysis of pre-clinical 
samples, and early method development for an appropriate extraction procedure from 
human samples has been performed.  Optimisation of the extraction procedure and full 
validation of the HPLC method should prove this method to be ideal for analysis of 
clinical samples. 
 
The pharmacokinetics of SJG-136 in the mouse have been examined, and SJG-136 has 
been shown to be available in vivo at concentrations that produce cytotoxic effects in 
vitro.  Furthermore, DNA crosslinking at these concentrations in vivo has been 
observed, demonstrating in vivo pharmacodynamic activity of SJG-136.  Metabolism 
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studies of SJG-136 have identified the production of several metabolites in vitro, and 
the major metabolite is detected in vivo, although at low levels.  Furthermore, SJG-136 
has been shown to localise within the nucleus of the cell, and to cause a G2/M block in 
the cell cycle, a feature characteristic of DNA-interactive agents. 
 
A sensitive and selective HPLC based analytical method for the PBD monomer 
D709119 has been developed, with an accompanying extraction method for pre-clinical 
analysis of the agent in vivo.  Pharmacokinetics of D709119 have shown the agent to be 
available following i.p. dosing at concentrations in excess of those required to elicit 
cytotoxic effects in vitro. 
 
Glutathione reactivity towards the PBD monomers MMY-SJG, SJG-303 and MMY-
SJG, and the dimer SJG-136 was investigated.  The PBD agents studied all showed an 
inherent, non-enzyme-mediated reactivity with reduced glutathione.  This is of 
particular interest as the agents showed highest levels of reactivity, as assessed by 
reduced recovery of compound, at concentrations of GSH in the intracellular range, and 
a markedly lower level of reactivity at levels of GSH found in plasma.  This GSH 
reactivity suggests that activity of PBD agents may be affected by increased levels of 
GSH found in some tumours. 
 
In summary, this study has shown that SJG-136 has favourable pharmacokinetics, with 
proven in vivo activity and is detectable in tumour tissue in vivo.  D709119 possesses 
favourable pharmacokinetics similar to those of SJG-136, but with a larger apparent 
volume of distribution (further work using i.v. dosed studies needs to be done to 
confirm this), and may be of future interest if it shows to have anti-tumour activity.  The 
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PBD compounds also have reactivity with GSH that may pose issues with tumours that 
over-express GSH. 
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14 Further work 
The work carried out in the course of these investigations has gone some way further 
towards the characterisation of the compounds investigated, but has prompted the need 
for further investigation that time constraints have not allowed in the time-frame 
allocated. 
 
Studies investigating the crosslinking of SJG-136 as assayed by Comet analysis in vivo 
in tumour were unsuccessful due to the characteristics of the tumour investigated.  As a 
pharmacodynamic endpoint, proof of crosslinking of SJG-136 in tumour in vivo would 
be a desirable assessment of in vivo activity for the agent.  Cell cycle analysis of the 
effects of SJG-136 showed a G2/M block produced by the agent after 1 h exposure of 
cells to the compound 24 h post-exposure.  Further characterisation of the rapidity of 
onset of the G2/M block by study of cell-cycle effects at earlier time-points may prove 
useful.  The identification of a major metabolite for SJG-136 in vivo is useful in 
predicting elimination of the compound from the body; however time did not allow a 
full pharmacokinetic profile to be generated for metabolite production from SJG-136 
after dosing, or for the investigation of further metabolism of the metabolite.  
Consequentially it is not possible to estimate the AUC for the compound and therefore 
the proportion of SJG-136 converted to the metabolite.  Synthesis of the metabolite and 
subsequent calibration and quantification along with full pharmacokinetic profiling 
would allow this to be assessed more accurately.  Molecular modelling studies of the 
major metabolite of SJG-136 may allow elucidation of the effect of the possible 
dealkylation on the DNA-binding characteristics of the molecule.  Combined with 
cytotoxicity studies, this would show the effect of the modification on the cytotoxic 
efficacy of the compound.  However, NMR studies to confirm the predicted structure of 
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the metabolite would be necessary prior to further investigation.  Additional sensitivity 
of detection provided by UV confocal microscopy may allow better visualisation of the 
subcellular localisation of SJG-136 at concentrations closer to those found in vivo.  
Furthermore, the use of cellular counter-stains to show the nucleus and/or other cellular 
organelles would allow a less subjective assessment of cellular localisation.  UV 
confocal microscopy may also allow characterisation of selective binding of SJG-136 to 
DNA as assessed by the use of chromosomal spreads. 
 
The pharmacokinetics of D709119 were investigated using an i.p. dosed in vivo model 
bearing murine tumours.  Ideally to accurately predict pharmacokinetic parameters, i.v. 
dosing regimens such as those employed for SJG-136 should be used to eliminate the 
absorption phase seen with i.p. dosing as well as the possibility of incomplete 
absorption.  Furthermore, additional studies of D709119 using two or more dose levels 
to establish whether or not the agent exhibits linear pharmacokinetics would be useful.  
Additional studies in i.v.-dosed mice bearing human tumour xenografts would allow a 
more accurate assessment of pharmacokinetic parameters and a closer approximation of 
tumour penetration to that which would be expected to be seen in man. 
 
Of the monomer compounds studied, MMY-SJG is the monomer subunit of the dimer, 
SJG-136.  It may be of interest to characterise this agent further to assess how the 
pharmacokinetics of the monomer vary compared to the dimer form. 
 
The glutathione studies performed failed to conclusively identify the PBD-GSH adducts 
that were suspected to be formed and the cause of loss of recovery of the agents.  
Further investigations may be able to identify this adduct to confirm or disprove the 
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formation of this adduct using mass spectrometry and chromatography.  If this adduct 
can be identified successfully, re-analysis of the SJG-136 pharmacokinetic samples 
would determine if this conjugate is seen in vivo.  Study of the cytotoxicity of SJG-136 
in GSH-depleted cell lines would also provide evidence to support GSH as a mechanism 
of cellular resistance to SJG-136 induced cytotoxicity. 
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Summary 
SJG-136 is a synthetic pyrrolobenzodiazepine (PBD) dimer in which two DNA-
alkylating subunits are linked through an inert propanedioxy tether. Biophysical and 
biochemical studies of SJG-136 have shown a remarkable affinity for DNA and potent 
cytotoxicity in vitro. On this basis, together with its unique sequence selectivity and 
interstrand DNA cross-linking activity, SJG-136 has been selected for clinical trials. 
This study examines the pharmacological characteristics of SJG-136 and provides the 
first report of pharmacokinetic properties for this agent. A sensitive, selective and 
reproducible reversed-phase gradient LC/MS assay has been developed for detection 
and analysis, where a molecular ion (m/z 557.2) is detectable for the SJG-136 parent 
imine. Fluorescence detection (260 nm excitation, 420 nm emission) gives a limit of 
sensitivity of 5 nM (2.5 ng ml–1) for analysis of SJG-136 in mouse plasma. Extraction 
efficiencies from plasma were >65% across a range of concentrations (5–1000 nM). 
Following administration to mice at the MTD (i.p., 0.2 mg kg–1), high peak plasma 
concentrations of SJG-136 were seen (Cmax = 336 nM) at 30 min after dosing. A 
calculated terminal t1/2 of 0.98 h and AUC of 0.34 µM·h resulted in a clearance rate of 
17.7 ml min–1 kg–1. The PBD dimer binds only moderately to proteins (65–75%), and in 
vitro cytotoxicity studies confirmed IC50 values of 4–30 nM with a panel of human cell 
lines. This finding demonstrates that plasma concentrations achieved in the mouse are 
substantially higher than those required to elicit an anti tumour response in vitro. This 
report forms an important phase in the pre-clinical characterization of the compound. 
 
Keywords: plasma, protein binding, DNA cross-linking, mass spectrometry, HPLC, 
PBD. 
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Introduction 
Many clinically useful anti-cancer agents produce their anti-tumour effects by targeting 
DNA (1). Thus, for example, classical intercalating agents such as the anthracyclines 
(e.g., mitoxantrone or daunomycin/doxorubicin) form “cleavable complexes” involving 
DNA topoisomerase II, whereas covalent modifiers such as cisplatin induce cross-links 
in double-stranded DNA. These mechanisms are intimately linked to their cytotoxic and 
biological potency. However, few drugs in current clinical use show sequence 
recognition for DNA tracts greater than 2–3 base pairs (bp) in length (2), and hence do 
not target defined gene sequences. Strategies for selective targeting of tumours with 
DNA-interactive agents generally exploit their rapid cell cycling rather than the 
targeting of any cellular flaw at a genomic level. Compounds should ideally be able to 
selectively recognise and inhibit stretches of DNA to prevent the transcription and 
subsequent translation of oncogenic DNA, and thereby inhibit tumour progression. 
However, for this level of selectivity to be feasible such agents must recognise 
individual sequences of duplex DNA to achieve inhibition at the gene level (2). 
 The pyrrolo[2,1-c][1,4]benzodiazepines (PBDs) are antitumour antibiotics where a 
large number of natural (e.g., anthramycin) and synthetic derivatives are known (2–4). 
PBD compounds form covalent adducts by alkylation at the exocyclic 2-NH2 positions 
of guanines via the minor groove of double-stranded DNA, and have been shown to 
span a 3-bp region of duplex DNA in a sequence-selective manner, with preferential 
binding to guanines flanked by purine bases, i.e. 5'-Pu-G-Pu (4–6). 
 While PBDs behave as monofunctional DNA alkylating agents, a dramatic increase 
in cytotoxicity and sequence selectivity can be achieved by linking two PBD units to 
form a PBD dimer that can cross-link appropriately separated guanines on opposite 
DNA strands (e.g., interstrand cross-links) (7–11). The first synthetic PBD dimer DSB-
120 offered selectivity toward embedded 5'-GATC target DNA sites that are 6–7 bp in 
length (9,11), although it is accepted that recognition of ~15 bp will be required for 
DNA sequences within the human genome (12). Molecular tailoring of PBD monomers 
and judicious linkage to form dimeric compounds has culminated in improved anti-
cancer efficacy and has recently enabled recognition of longer DNA sequences (e.g., 5'-
Pu-GATC-Pu in the case of SJG-136) [13]. 
 SJG-136 (Figure 1) is a synthetic PBD dimer that comprises two C2-exo-methylene-
substituted DC-81 subunits linked via their C8 positions through an inert –O(CH2)3O– 
diether bridge (13,14). DC-81 (for ring numbering and nomenclature, see Figure 1) is a 
simple, synthetic PBD monomer “building block” that has been used extensively to 
probe DNA-binding events for this unique class of agent. Biophysical and biochemical 
assay methods have shown that SJG-136 has remarkable affinity for DNA and acts as a 
highly efficient interstrand DNA cross-linking agent. Further, the dimer is a potent 
cytotoxic agent in vitro, with an IC50 of ~25 pM in sensitive cell lines (13,14). On the 
basis of this activity, SJG-136 has been selected for clinical trials. It is therefore 
essential to have an understanding of the pharmacokinetic (PK) and pharmacological 
characteristics of SJG-136 at likely therapeutic doses to enable prediction of PK 
parameters in man. This study examines the pharmacological characteristics of SJG-136 
and provides the first report of pharmacokinetic properties for this novel agent in mice. 
This forms an important phase in the pre-clinical characterisation of the compound. In 
vitro cytotoxicity has also been assessed in a panel of cells selected from data produced 
by the NCI 60-cell-line screen (15,16) in order to further investigate tumour selectivity 
and to confirm the likely exposure parameters required to produce an in vivo antitumour 
16 Publications 
256 
response. The cytotoxicity data obtained can also be used to assess the significance of 
plasma concentrations achieved in vivo. 
 
Materials and Methods 
Chemicals and reagents 
SJG-136 was synthesised as described previously (13,14) and supplied by the National 
Cancer Institute (Bethesda, Batch No Z/5) . The PBD dimer was supplied as an almost 
colourless powder. Stock solutions were shown to be stable when dissolved in dimethyl 
sulfoxide (DMSO) at 1.0 mg ml–1 and stored in polypropylene tubes at –80 °C. High-
purity HPLC-grade solvents (Fisher Scientific, Loughborough, UK), analytical-grade 
chemicals (Sigma-Aldrich Ltd, Poole, UK) and triple-distilled water were used 
throughout. Heparinised polypropylene tubes were used for collection of blood samples. 
Polypropylene microcentrifuge tubes (Sigma-Aldrich Ltd, Poole, UK) were used 
throughout for sample handling and storage, and polypropylene autosampler vials 
(Sigma-Aldrich Ltd, Poole, UK) were used to load samples for HPLC analysis. 
Following approval from the Local Ethical Review Committee human plasma was 
kindly donated by The National Blood Service, Leeds, UK.  
 
Animals 
Female NCR nude mice (NCR/nu) aged 6–8 weeks were obtained from the National 
Cancer Institute (NCI Bethesda, MD, USA) and were fed a CRM pellet diet (CRM, 
Special Diets Service, Witham, Essex, UK) and water ad libitum. Mice were kept in 
cages in an air-conditioned room with regular alternating cycles of light and darkness. 
All animal procedures were carried out under a project licence issued by the UK Home 
Office, and UKCCCR guidelines (17) were followed rigorously. 
 
Instrumentation 
The HPLC chromatographic system used consisted of a Waters Alliance 2690 
separations module (Waters, Manchester, UK), fitted with a Waters 996 photodiode 
array detector for absorbance monitoring and a Merck-Hitachi 4780 fluorescence 
detector. Data were collected and chromatograms processed using MassLynx 3.4 
software (Micromass, Manchester, UK). Fluorescence spectra for SJG-136 were 
obtained using a Varian-Cary Eclipse fluorimeter (Varian, Warrington, UK). 
 
Chromatography conditions 
The chromatographic separation of SJG-136 was performed using a binary gradient on a 
reversed-phase Hypersil phenyl column (150 mm × 4.6 mm i.d.; Sigma-Aldrich Ltd, 
Poole UK). A 0.5-µm pre-column filter was used to protect the column from any 
residual particulate matter. Mobile phase A consisted of 5% acetonitrile (MeCN) and 
95% aqueous 0.01 M ammonium formate buffer (HCO2NH4, pH 5.0); mobile phase B 
consisted of 50% MeCN and 50% 0.01 M HCO2NH4 buffer (pH 5.0). Gradient 
conditions (flow rate 1.8 ml min–1) were used with linear gradient changes between 
intervals: 0–5 min, 80→70% A; 5–26 min, 70→53% A; 26–30 min, 53→5% A; 30→45 
min, 5% A. The column was equilibrated with 80% A for 15 min before re-injection. 
The use of MeCN as eluting solvent was preferred to methanol to avoid MeOH-adduct 
formation with SJG-136 (see below). 
 
Mass spectrometry 
LC/MS analysis was carried out using a ZMD quadrupole mass spectrometer 
(Micromass, Manchester, UK) linked in series to the Waters Alliance 2690 
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chromatography system. The mass spectrometer was operated in positive-ion 
electrospray mode with an ionising voltage of +3.00 kV applied to the capillary. A 
solvent flow rate of 1.8 ml min–1 (1:10 volume split), a N2 gas flow of 400 l h–1 and a 
source temperature of 125 °C were employed to produce stable spray conditions. A cone 
voltage of 35 V resulted in clear mass spectra for the PBD dimer compound. Mass 
spectra were continuously scanned in the m/z 250–700 range at 3.5 s intervals 
throughout the HPLC separation. MassLynx 3.4 software (Micromass, Manchester, UK) 
was used to process the mass spectral data and to produce total ion chromatograms 
(TICs) for the separations. A single-ion recording (SIR) channel was established at m/z 
557.1 to monitor the [M + H]·+ molecular ion for the parent bis-imine form of SJG-136. 
All HPLC conditions, column, solvents and flow rates were as described earlier. 
 
Sample preparation and drug extraction 
Plasma was prepared immediately by centrifugation of a mouse blood sample at 5000 g 
for 3 min and removal of the plasma to a fresh tube. Plasma was stored at –80 °C prior 
to analysis. Drug was extracted from plasma (100 µl) by addition of MeCN (200 µl) at 4 
°C. Samples were briefly vortex-mixed, then centrifuged at 20,000 g for 20 min at room 
temperature. The supernatant was removed to a fresh microcentrifuge tube and 
transferred to a Jouan RC 10.10 centrifugal evaporator (Jouan Ltd, Ilkeston, UK), where 
the sample was evaporated to dryness under vacuum at room temperature. The dried 
sample was reconstituted in 100 µl of mobile phase, vortex-mixed briefly and 
centrifuged at 20,000 g for 10 min to remove any residual particulate matter; a 70 µl 
aliquot was used for HPLC analysis. Extraction efficiencies were calculated by 
comparing samples extracted from plasma (n = 6) to standards prepared in the same 
mobile phase. 
 
Calibration 
Calibration curves were generated by spiking drug-free mouse plasma (90 µl) with SJG-
136 (10 µl), diluted from stock in PBS to give final concentrations in plasma in the 0–
1000 nM range, and a final concentration of DMSO of <0.2%. Samples were then 
extracted as described. Calibration curves were determined by linear regression analysis 
of a plot of the peak areas obtained for the analyte versus concentration. Replicate 
samples (n = 6) at a midpoint of the calibration curve were examined to ensure 
reproducibility. 
 
In vivo pharmacokinetic studies 
For in vivo studies, SJG-136 was dissolved in DMSO and then diluted in physiological 
saline to give a final solution containing <1% v/v DMSO. The drug was administered 
via the intraperitoneal (ip) route at the maximum tolerated dose (MTD) of 0.2 mg kg–1 . 
Blood samples from three mice at each time point (5, 15, 30, 60, 120, 240 and 360 min) 
were taken by cardiac puncture under terminal anaesthesia using heparinised syringes, 
and placed into heparinised tubes on ice. Plasma was prepared immediately by 
centrifugation of a mouse blood sample at 5000 g for 3 min and removal of the plasma 
to a fresh tube. Plasma samples were stored at –80 °C prior to analysis. 
 
16.1.1.1.1 Pharmacokinetic analysis 
Pharmacokinetic parameters were calculated using the trapezoidal rule for area under 
the plasma concentration–time curve (AUC) to the final time point, and the remaining 
area to ∞ was calculated from Ct/kel (where Ct is the final time point at which 
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concentration can be determined, and kel is the elimination rate constant). Other 
parameters were calculated using standard techniques, as described previously (18). 
 
16.1.1.1.2 Stability in plasma and blood 
Stability of SJG-136 in plasma and blood was assessed at concentrations and times 
likely to be pharmacokinetically relevant. SJG-136 was spiked into pooled NCR/nu 
mouse blood or plasma to give a final concentration of 100 nM. The plasma or blood 
samples were incubated at 37 °C for up to 6 h, with aliquots removed at 2 h intervals for 
HPLC analysis. Drug was extracted from each sample as described previously. 
 
16.1.1.1.3 Plasma protein binding studies 
Initial plasma protein binding studies were performed using ultrafiltration; however, this 
method was discontinued as SJG-136 shows a high affinity for usual filter membranes. 
Subsequent plasma protein binding studies were carried out using ultracentrifugation 
and human plasma as multiple large volumes (>500 µl) were required. Pooled human 
plasma (990 µl) was spiked with SJG-136 (10 µl diluted from stock in PBS) to give 
final concentrations of 1 µM, 100 nM and 10 nM (n = 4) in plasma. Identical volumes 
of phosphate-buffered saline (PBS) in ultracentrifuge tubes were spiked with SJG-136 
to give the same final concentrations of SJG-136 to provide controls. Samples were then 
centrifuged at 20 °C for 18 h at 150,000 g (Beckman Optima TL ultracentrifuge) to 
pellet the plasma proteins. Supernatant was removed from the plasma or PBS samples 
and analysed using the HPLC method described. The percentage of SJG-136 bound to 
plasma proteins was calculated from the difference in drug levels present in plasma 
water and the PBS control. 
 
16.1.1.1.4 In vitro cytotoxicity studies 
All cell lines were grown under similar conditions to those used by the National Cancer 
Institute (NCI): RPMI 1640 medium containing 10% fetal calf serum supplemented 
with 2 mM L-glutamine, maintained at 37 °C with 5%:95% CO2/air and no added 
antibiotics. Drug-induced cytotoxicity was determined using a 96 h growth inhibition by 
the MTT dye conversion assay. Five cell lines were selected based on data from the NCI 
60-cell-line screen for relative sensitivity or resistance to SJG-136. The selected cell 
lines used were UACC-62 (melanoma), M-14 (melanoma), DU-145 (prostate), SK-OV-
3 (ovarian) and SK-MEL-2 (melanoma), and were obtained from NCI. Growth curves 
were generated for each cell line using the MTT dye conversion assay to establish 
exponential growth phase. Cells were seeded at 104 cells ml–1 into cell culture-treated 
96-well plates, and allowed to attach overnight. For in vitro studies, SJG-136 stock 
solution in DMSO was diluted to the required concentrations in cell culture growth 
medium immediately before use. SJG-136 solution was added to cells in medium, to 
give ≤0.1% v/v DMSO working concentrations. IC50 values were determined for SJG-
136 after 1 h and 96 h continuous exposure. 
 
Results 
Chromatographic analysis 
Initial chromatographic separation was attempted using a reversed-phase C18 column 
(HiChrom RPB) with a MeOH / 0.01 M HCO2NH4-based mobile phase. The organic 
solvent in the mobile phase was ultimately replaced with MeCN due to reactivity of the 
SJG-136 dimer with MeOH (Figure 2A), and analytical difficulties that arise from 
possible mixtures containing the parent bis-imine and possible dihydrate or bis-
carbinolamine methyl ether forms (Figure 2A). Peak shape was found to be optimal 
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using these mobile phase conditions in conjunction with a reversed-phase Hypersil 
phenyl column. Isocratic conditions were used in preliminary studies; however, optimal 
separation and peak shape were subsequently achieved using gradient elution. Gradient 
conditions were refined to include a strong organic phase at the end of the gradient as 
this significantly improves peak reproducibility by preventing accumulation of 
adsorbent particles on the column and ensures prompt elution of any potential late-
eluting peaks. The limit of detection on the column was found to be 39 pg of SJG-136 
(i.e., 70 µl injection of a 1 nM standard solution); the limit of quantitation for drug in 
plasma was found to be 5 nM. The PBD dimer compound was eluted after 17.8 min 
(Figure 3). Optimal conditions for fluorescence detection of SJG-136 were determined 
as 260 nm (excitation) and 420nm (emission), respectively, as shown by the excitation 
and emission spectra (Figure 4). 
 
Mass spectrometry 
PBD monomer compounds are reactive towards nucleophilic species due to the N10–
C11 imine moieties, and this reactivity is responsible for their biological efficacy. 
Dissolution of a PBD in water results in an equilibrium mixture (4) containing the imine 
and both R/S-carbinolamine (or hydrate) enantiomeric forms of the compound (Figure 
2B). Analogous reversible reaction with an anhydrous alcohol results in a mixture that 
contains the R/S-carbinolamine alkyl ether (or alcoholate) adduct forms (Figure 2B). 
The situation is more complex for alcohol solvents containing water (or mixed 
alcohol/water solutions), where the imine, hydrate and alcoholate can co-exist; the 
equilibrium composition for the PBD solute will be governed by the level of water 
present, the relative stabilisation afforded by the organic solvent, and (chiefly) the 
inherent reactivity of the PBD compound. However, this factor is unimportant for 
biological efficacy as interconversion to the DNA-reactive PBD imine (or protonated 
iminium) species is facile and not rate-limiting at low drug concentrations. 
Nevertheless, these solvent-mediated equilibria will have implications for the reliable 
detection and monitoring of PBD drug levels in analytical samples. 
 SJG-136 is supplied as a bis-imine (Figure 1), but the compound will react with the 
water present in most solvents to generate the bis-carbinolamine or dihydrate form 
(Figure 2A). Equivalent dual adduct formation in the presence of MeOH leads to the 
bis-carbinolamine methyl ether or dimethanolate form of the drug (Figure 2B). This was 
demonstrated by mass spectrometry to identify the signatures for the parent bis-imine at 
m/z 557.1 ([M + H]·+ in Figure 5.1), the dihydrate at m/z 615.1 ([M + 2H2O + Na]·+ in 
Figure 5.2) and the dimethanolate adduct at m/z 643.4 ([M + 2MeOH + Na]·+ in Figure 
5.3). 
 Avoidance of drug or sample contact with MeOH solvent at all stages prevents 
formation of the dimethanolate adduct of SJG-136 and hence possible complications for 
HPLC analysis. There was no apparent chromatographic separation of the possible 
discrete forms of the drug under the HPLC protocol used, presumably as a result of 
rapid equilibrium interconversion during elution. Use of a chiral column may enable 
separation of the R/S-enantiomeric species but was not investigated in this study. Switch 
of solvent from MeOH to acetonitrile (MeCN) resulted in a marked improvement in 
detection sensitivity. In MeCN solution, the majority of SJG-136 was detected as the 
imine form appearing at m/z 557.1 (i.e., [M + H]·+), and this molecular ion was chosen 
for detection using single-ion recording in our mass spectrometric assays. No mass 
spectral peaks of interest were seen outside the m/z 540–680 range. While appearance of 
the dihydrate species in mass spectra of samples is unavoidable due to water traces this 
has no significant effect upon the overall analysis. Use of MeCN serves to maximise 
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detection of SJG-136 as the parent bis-imine, presumably as equilibrium formation 
and/or stabilisation of the dihydrate is disfavoured compared to the more polar alcohol 
solvents. 
 Aqueous solutions of SJG-136 will contain both the bis-imine and the mono-/di-
hydrate (i.e., mono- and di-carbinolamine) species formed by reaction with water, 
although most drug is detected by MS in the unreacted parent form. Dimer reaction 
appears to favour equilibrium formation of the dihydrate rather than intermediate 
monohydrate, presumably due to the overwhelming concentration of water reactant 
(~55 M) in the solution. The dihydrate species can be detected by NMR analysis, albeit 
at higher concentration (unpublished data). Interconversion between the hydrate forms 
of SJG-136 and the biologically relevant bis-imine form is judged to be facile from 
kinetic studies of equilibrium processes for monomeric PBD compounds. The 
imine/hydrate balance in aqueous solution is governed by stereoelectronic factors 
involving the structural complexion of the 5-membered C-ring in the PBD. It is 
noteworthy that the C2-exo-methylene substitution in SJG-136 (Figure 1) appears to 
displace the equilibrium in favour of the imine species.  
 
Extraction from biological matrices and calibration 
Efficiency of recovery of SJG-136 from spiked plasma was reliably found to be 67.8 ± 
8.8%, 84.5 ± 2.1%, 115.1 ± 0.6% for 10, 100 and 1000nM respectively (n = 6, mean ± 
SEM). Calibration curves for SJG-136 in plasma were linear in the 0.01–1 µM range, 
where this spans the drug levels examined in the present study. Intra-day variation of 
extraction of SJG-136 from plasma was low, with a co-efficient of variation of 6.0% at 
100 nM. 
 
Plasma pharmacokinetics 
The plasma time-course of SJG-136 in NCR/Nu mice is shown in Figure 6. The 
pharmacokinetics show a tri-exponential behaviour, illustrating absorption, distribution 
and elimination phases following ip dosing. SJG-136 was detectable in mouse plasma 
up to 4 h after administration. Cmax was observed at 30 min after dosing, with a peak 
plasma concentration of 336 nM. The t1/2 of the elimination phase for SJG-136 was 
determined as 0.98 h, with a total clearance of 17.72 ml min–1 kg–1. The AUC0–∞ value 
was calculated as 0.34 µM h. 
 
Stability in plasma and blood 
The stability of SJG-136 was investigated in whole blood and plasma over a 6-h period 
at 37 °C (Figure 7). There was no significant loss of SJG-136 in plasma over this time. 
However, there was a progressive but slow loss of SJG-136 in blood during 6 h, 
resulting in a 31% loss of parent drug over this period. The t1/2 was >6 h for both whole 
blood and plasma. These data indicate that blood samples should be processed promptly 
in order to minimise degradative loss of SJG-136 ex vivo. To this end, all blood PK 
samples were immediately placed on ice and processed within 15 min of sample 
collection. 
 
Plasma protein binding 
Binding of SJG-136 to plasma proteins was examined by incubation of fresh human 
plasma with 10, 100 and 1000 nM drug for 10 min, followed by ultracentrifugation as 
described. Binding of drug to plasma proteins was found to be moderate at 65 ± 11% 
and 76 ± 5% for initial 100 and 1000 nM concentrations of SJG-136, respectively (mean 
± SEM, n = 4 at each concentration). SJG-136 was not detectable in the 10 nM samples. 
16 Publications 
261 
 
In vitro cytotoxicity 
Cytotoxicity data obtained for SJG-136 against the selected panel of cell lines are 
collected in Table 1. SJG-136 shows high in vitro potency, with IC50 values in the 4–30 
nM range. These values are still 100-fold higher than previously reported for the very 
sensitive A2780 cell line (13). However, IC50 values reported here for the SK-OV-3 
ovarian cell line are comparable to earlier reported data (13). There is evidence of cell 
type selectivity for the five cell lines examined, with 20-fold differences for the 96 h 
drug exposures. 
 
Discussion 
SJG-136 is a DNA-targeting cross-linking agent and the NCI 60-cell-line screen and 
COMPARE analysis have indicated a pattern of in vitro cell line sensitivity that differs 
markedly from that of established clinical agents (15,16). Reported work has shown 
SJG-136 to be an exceptionally cytotoxic compound achieving sub-nanomolar IC50 
values in four different cell lines (13,14). There is considerable interest in the compound 
due to its progress into phase I clinical trials in the UK during 2004; the compound is 
also under consideration for US trials with the NCI.  We describe here a sensitive and 
selective analytical method to enable the study of SJG-136 in the murine in vivo model 
prior to clinical trial.  SJG-136 represents a logical progression in the development of 
potent sequence-selective interstrand DNA cross-linking agents. 
 This is the first report of the mass spectral analysis of SJG-136 in aqueous, MeCN or 
MeOH solution and illustrates the predicted reactivity of the two imine groups present 
in this PBD dimer. The bis-imine form of SJG-136 can be detected when the compound 
is analysed in MeCN, with a predominant mass peak at m/z 557.1 ([M + H]·+) (Figure 
5.1). Additional peaks can be seen at m/z 615.1 and 631.1 when water is introduced that 
correspond to the hydrate or carbinolamine form of the drug on each PBD unit of the 
dimer (i.e., [M + 2H2O]·+), where the adduct further combines with either a sodium or 
potassium in the detected ion species. In this case, the [M + H]·+ ion for the agent is no 
longer seen (Figure 5.2). Further, the addition of MeOH results in the formation of 
mono- and di-methanolate forms of the drug, as evident from peaks at m/z 589.4 
([M+H+MeOH]·+), 611.1 ([M+Na+MeOH]·+), 643.4 ([M+Na+2MeOH]·+) and 659.1 
([M+K+2MeOH]·+[Figure 5.3]). As it proved possible to avoid use of MeOH in the 
HPLC method, this strategy was adopted to prevent loss of sensitivity due to untoward 
methanolate formation. No apparent chromatographic separation could be achieved for 
the three different forms of SJG-136 in solution (i.e., imine, hydrate or methanolate 
forms; see Figure 2B). Mass spectrometry (MS) was also investigated as an alternate 
means of HPLC detection, but was found to be less sensitive than fluorescence 
monitoring. 
 
The plasma time course of SJG-136 in the NCR-Nu mouse indicates the concentration 
of SJG-136 that can be achieved in vivo.  It is notable that the peak plasma 
concentrations reached (Cmax = 336 nM) are over 10-fold higher than the IC50 values 
necessary for anti tumour activity in vitro suggesting likely efficacy in vivo.  
Furthermore, no metabolites of the compound were detected in this study indicating a 
low metabolic potential of the compound and consequentially less chance of 
complications that may arise from metabolite production. 
 SJG-136 was surprisingly stable in plasma over 6 h at 37 °C, with <10% loss. 
However, it was less stable in blood during the same period. Comparison of the blood 
stability data for SJG-136 and the structurally similar PBD dimer DSB-120 (7) reveals a 
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marked difference in stability. Earlier reports showed an 80% loss of DSB-120 within 
10 min (19), whereas SJG-136 shows a loss of only ~30% over 6 h (Figure 6). SJG-136 
showed a t1/2 of > 6 h in both blood and plasma. This difference may reflect a lower 
level of plasma protein binding evident for SJG-136 compared to DSB-120 (i.e., ~70% 
and 97% bound, respectively). 
 
Based on the NCI data a panel of 5 cell lines were selected for relative sensitivity or 
resistance to SJG-136 and were assayed for in vitro IC50 values.  This study also 
suggests a  degree of selectivity of SJG-136 according to cell type, as there was a 20-
fold difference in sensitivity between the five cell lines examined.  The 1 h exposure 
regimen was chosen alongside the often studied 96 h exposure in an attempt to more 
accurately reflect the time of exposure likely to be seen in an in vivo environment 
following iv or ip bolus administration. It is of note that the IC50 value of 2.5 nM 
obtained for 96 h exposure of SJG-136 to the SKOV-3 cell line correlates closely to that 
previously reported for this cell line (9.1 nM, [13]). 
 
In summary, these preliminary studies are the first report of plasma concentrations 
achievable in animal models. Peak plasma concentrations are high, suggesting that a 
therapeutic index is achievable as plasma drug concentrations are over 10-fold greater 
than that needed for cytotoxicity in vitro. SJG-136 also shows potent in vitro 
cytotoxicity with evidence of cell-type selectivity. The pharmacokinetic parameters 
described will inform the forthcoming clinical trial. Further more detailed 
pharmacological studies are currently underway. 
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Table 1. In vitro cytotoxicity of SJG-136 toward selected cell lines 
Exposure 
time (h) IC50 (nM)
a by cell line and cell type 
 DU-145 prostate 
UACC-62 
melanoma 
SK-MEL-2 
melanoma 
SK-OV-3 
ovarian 
M14 
melanoma 
1 22 ± 3 17 ± 1 30 ± 6 18 ± 3 4 ± 0.7 
96 0.6 ± 1.1 0.12 ± 0.33 1.3 ± 1.0 2.5 ± 1.4 0.4 ± 0.1 
a Determined using the MTT dye conversion assay after exposure of cells to the PBD 
dimer for either 1 h or 96 h. 
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Figure Legends 
Figure 1. Structure of the PBD monomer DC-81 (left) and the synthetic dimer SJG-
136 (right) selected for anti-cancer clinical trials. The PBD ring numbering 
scheme used is indicated for DC-81. 
Figure 2. A: Illustration showing the reversible covalent reactions of a PBD imine 
with either water or an alcohol to form carbinolamine (hydrate) and 
carbinolamine alkyl ether (alkanolate) forms that can be detected in 
solutions. The equilibrium composition is influenced by the choice of 
solvent. R1 and R2 denote the PBD ring attachments, and ROH the reactive 
nucleophile species. B: The ions detected for each form of PBD dimer SJG 
detected by MS in solution are indicated (see text). 
Figure 3. Example HPLC trace showing detection of SJG-136 (peak at 17.8 min) after 
extraction from mouse plasma following ip dose at the MTD (0.2 mg kg–1), 
time-point shown is 30 min post-dose  
Figure 4. Fluorescence spectra of SJG-136. Excitation spectrum (left) with emission 
at λ 400 nm, showing peaks at 235, 260 and 313 nm. Emission spectrum 
(right) with excitation at 235 nm, showing an emission peak at 420 nm. 
Figure 5. Mass spectra for SJG-136: (1) parent imine form [m/z of 557.1]; (2) in 
aqueous solution as the bis-imine [m/z 557.1], dihydrate+Na adduct [m/z 
615.1], and dihydrate+K adduct [m/z 631.1] forms, and (3) in MeOH 
solution as the imine [m/z 557.1], monomethanolate [m/z 589.1] and its Na 
adduct [m/z 611.1], and dimethanolate+Na adduct [m/z 643.4] or +K adduct 
[m/z 659.1]. No spectral peaks of interest were seen outside the m/z 540–680 
range.  
Figure 6. Pharmacokinetic profile of SJG-136 in plasma in the NCR/Nu mouse after 
dosing at the MTD (0.2 mg kg–1) via the intraperitoneal (ip) route. Cmax = 
336 nM and the calculated terminal t1/2 = 0.84 h. 
Figure 7. Stability of SJG-136 in mouse plasma (open circles) and whole blood 
(closed circles) at 37 °C. 
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Pharmacokinetics of D709119 (DRH-417), a DNA minor groove-binding 
pyrrolobenzodiazepine monomer with a novel mechanism of action 
 
G.P. Wilkinson 1 , T.C. Jenkins 2, D.E. Thurston 3 , P.W. Howard 3 , J.A. Double 1 , 
M.C. Bibby 1 , P.M. Loadman 1. 
1University of Bradford, Cancer Research UK Cancer Research Unit, Bradford, United 
Kingdom; 2 University of Bradford, Yorkshire Cancer Research Laboratory of Drug 
Design, Bradford, United Kingdom; 3 University of London, Cancer Research UK Gene 
Targeted Drug Design Group, London, United Kingdom 
 
D709119 is a DNA minor groove-binding pyrrolobenzodiazepine derivative that shows 
significant in vitro cytotoxicity towards a select number of cell lines in the 60-cell line 
NCI screen. This activity translates into human tumour xenograft models where in vivo 
antitumour activity has been demonstrated for a number of models including melanoma, 
renal and ovarian. On the basis of this in vivo activity, together with the novel 
mechanism of action of D709119 as suggested by findings from an NCI COMPARE 
analysis, the compound is now in pre-clinical development with the EORTC. The aim 
of this study was to develop a highly selective LC/MS analytical method in order to 
investigate the pre-clinical pharmacokinetics of D709119 in mice. A further goal was to 
measure tumour concentrations of the drug, and also brain concentrations in order to 
assess the degree of CNS penetration. An LC/MS-based method has been developed 
using an acetonitrile/ammonium formate mobile phase with a Hypersil phenyl reversed-
phase HPLC column. Selective detection is achieved using electrospray MS analysis 
with a SIR of m/z 368.4 to detect the parent ion, the limit of detection is 50 nM. All in 
vivo studies have been approved by the UK Home Office. Pharmacokinetic studies have 
been carried out in NMRI mice bearing either MAC29 or MAC15A murine colon 
tumours. Although an extraction efficiency of ~50 % was achieved from plasma and 
brain homogenates, only ~15 % extraction was achieved from spiked tumour 
homogenate suggesting extensive binding to tumour proteins. After i.p. administration 
at the MTD of 0.5 mg/kg, D709119 was easily detectible in mouse plasma up to 4 h 
post-dose, with peak concentrations of 171 nM after 30 min and a tl/2 of 2.3 h. The 
AUC was calculated to be 0.54 uM h. D709119 levels were below the limit of detection 
in both brain and tumour homogenates. An IC50 value for D709119 was determined 
experimentally in the human ovarian adenocarcinoma cell line SK-OV-3 to be 2.75 nM. 
These studies suggest that D709119 is bioavailable following i.p. injection at plasma 
concentrations well in excess of those necessary to achieve in vitro cytotoxicity. Further 
studies are now underway to probe the extensive binding of D709119 in tumour tissue. 
 
Presented at the 14th EORTC/NCI/AACR Symposium on Molecular Targets and 
Cancer Therapeutics held in Frankfurt, November 2002. 
Published in European Journal Of Cancer 38: 77 Suppl. 7 (2002). 
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Intracellular and in vivo distribution of the pyrrolobenzodiazepine dimer SJG-136, 
a novel sequence-selective DNA minor groove cross-linking agent 
 
G.P. Wilkinson 1 , P.M. Loadman 1 , J.P. Taylor 1 , T.C. Jenkins 2, J.A. Double 1 , S.J. 
Gregson 3 , P.W. Howard 3 , D.E. Thurston 3. 
1University of Bradford, Cancer Research UK Cancer Research Unit, Bradford, United 
Kingdom; 2 University of Bradford, Yorkshire Cancer Research Laboratory of Drug 
Design, Bradford, United Kingdom; 3 University of London, Cancer Research UK Gene 
Targeted Drug Design Resear, London, United Kingdom 
 
The pyrrolobenzodiazepine dimer SJG-136 is a novel sequence-selective DNA minor 
groove cross-linking agent with potent DNA stabilising activity and remarkable in vitro 
cytotoxicity (e.g. IC50 value of 23 pM in A2780 cells). The aim of this study was to 
characterise the in vitro cellular distribution of the agent and to establish its in vivo 
preclinical pharmacokinetic properties. SJG-136 is highly fluorescent and this enables 
its in vitro visualisation. Cell lines selected from the NCI's 60-cell line panel were 
treated with SJG-136 and fluorescence microscopy was used to monitor cellular uptake. 
It was demonstrated to produce a high level of nuclear-specific staining in HCT-116, 
UACC62, SK-MEL-2, SK-OV-3 and M14 cell lines, indicating both cellular penetration 
of the drug and Iocalisation by covalent fixation within the nucleus, the proposed site of 
drug action. A sensitive and reproducible HPLC-based analytical method has been 
developed for SJG-136 that will be used to obtain pharmacokinetic data in forthcoming 
clinical trials. Using an acetonitrile/ammonium formate gradient with a reversed-phase 
phenyl column and fluorescence detection, a limit of detection for SJG-136 of 1 nM in 
serum has been achieved. Extraction efficiencies from serum were >60% across a range 
of concentrations (1-100 nM). All in vivostudies have been approved by the UK Home 
Office. In pilot pharmacokinetic studies where SJG-136 was administered i.p. to NMRI 
mice at the MTD of 0.2 mg/kg, the drug could be observed at detectible levels with a 
Cmax of 336 nM after 30 min in mouse plasma. A calculated terminal tl/2 of 0.98 h and 
an AUC of 0.34 uM h resulted in a clearance of 17.72 ml / min kg. Preliminary plasma 
protein-binding studies demonstrate that the agent is poorly bound to proteins (<20 %), 
suggesting that SJG-136 is readily bioavailable in the blood with peak plasma 
concentrations substantially higher than those needed for in vitro cytotoxicity. Studies 
are currently in progress to establish the levels of SJG-136 that can be achieved in 
tumours. 
 
Presented at the 14th EORTC/NCI/AACR Symposium on Molecular Targets and 
Cancer Therapeutics held in Frankfurt, November 2002. 
Published in European Journal Of Cancer 38: 78 Suppl. 7 (2002). 
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Pharmacokinetics, Metabolism & Glutathione Reactivity Of SJG-136 
 
Gary P. Wilkinson*, Paul M. Loadman, Terence C. Jenkins, James Taylor, Steve D. 
Shnyder, Patricia A. Cooper & David E. Thurston 
Tom Connors Cancer Research Centre, University of Bradford, All Saints Road, 
Bradford, West Yorkshire, BD7 3AY 
 
   SJG-136 is a novel DNA-crosslinking agent with sequence selective properties. The 
PBD dimer shows potent in vitro cytotoxicity and DNA-stabilising activity, and has 
been selected for clinical development on the basis of impressive preclinical activity. 
 
   The aim of this study was to investigate the in vitro & in vivo pharmacological 
characteristics of SJG-136 and to identify any potential metabolites. The proposed 
reactivity of PBDs with thiol containing macromolecules (e.g. GSH) was also 
investigated due to the potential influence of this on the pharmacology of SJG-136. 
 
   An HPLC method was developed using fluorescence and MS/MS detection. 
Intraperitoneal administration of SJG-136 to NMRI mice at the MTD (0.2 mg/kg) gave 
peak plasma concentrations of 336 nM after 30 min and an AUC of 0.34 uM. In vitro 
metabolism studies of SJG-136 in the mouse liver S9 fraction showed rapid drug 
depletion (< 10% at t0) likely to be due to GSH conjugation. SJG-136 is freely 
metabolised to a demethylated form in mouse liver microsomes & this metabolite was 
detected in in vivo samples at low concentrations. This metabolite is not detectible in 
the S9 fraction suggesting that GSH reactivity inhibits metabolic degradation of the 
drug. SJG-136 reacts with GSH in a concentration-dependant manner, suggesting 
increased adduct formation at higher GSH levels. Analytically, these adducts appear to 
be identical to those found in the S9 fraction. 
 
   Such low metabolic potential in vivo simplifies the pharmacology of the compound 
and enhances its therapeutic potential. 
 
   All in vivo studies complied with UK home office regulations. 
 
Presented at the BACR British Cancer Research Meeting held in Bournemouth, 
July 2003. 
Published in British Journal Of Cancer 88: S29 Suppl. 1 (2003). 
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Pharmacokinetics and intracellular pharmacological characteristics of the novel 
pyrrolobenzodiazepine (PBD) dimer SJG-136. 
 
Wilkinson G. P.1 , Loadman P. M.1 , Taylor J.1, Swaine D.1, Jenkins T. C.2 , Double J. 
A.1 , Spanswick V. J.3, Hartley J. A.3, Gregson S. J.4 , Howard P. W.4 , Thurston D. E.4 
 
1 Cancer Research UK Cancer Research Unit, University of Bradford, All Saints Road, 
Bradford, West Yorkshire, BD7 3AY, UK; 2 Yorkshire Cancer Research Laboratory of 
Drug Design, University of Bradford, All Saints Road, Bradford, West Yorkshire, BD7 
3AY, UK; 3 Cancer Research UK Drug-DNA Interactions Group, Dept of Oncology, 
UCL, London, W1W 7BS, UK; 4 Cancer Research UK Gene Targeted Drug Design 
Research Group, School of Pharmacy, University of London, 29/39 Brunswick Square, 
London, WC1N 1AX, UK 
 
SJG-136 is a novel sequence-selective DNA minor-groove binding 
pyrrolobenzodiazepine (PBD) dimer that spans six DNA base pairs forming interstrand 
cross-links at Pu-GATC-Py sites. It is remarkably cytotoxic in vitro and has significant 
antitumour activity with a clear therapeutic index in a large number of human tumour 
xenograft models. As a result of these pre-clinical data, SJG-136 has been selected for 
Phase I clinical trials in the UK (Cancer Research UK) and the USA (NCI). The aim of 
this study was to characterise the pre-clinical pharmacokinetics and cellular 
pharmacological properties of SJG-136. 
A gradient reversed-phase HPLC method using ES+-mass spectrometry and 
fluorescence detection has been developed to enable the analysis of SJG-136 in 
biological samples.  The assay has limits of detection of 10 nM and 0.5 nM for mouse 
and human plasma, respectively. Following ip administration to NMRI mice at the 
MTD of 0.2 mg/kg, SJG-136 was easily detectable with a Cmax of 336 nM after 30 min. 
A calculated terminal t½ of 0.98 h and an AUC of 0.34 µM h resulted in a clearance of 
17.72 ml/min/kg. During these pharmacokinetic studies, DNA interstrand crosslinks 
were measured in mouse lymphocytes using a modification of the Comet assay. 
Crosslinks could be detected at 1 h following ip drug administration and remained at the 
same level for 18 h. 
The fluorescence of SJG-136 enabled studies of its intracellular distribution in living 
cells using fluorescence microscopy. Cell lines (UACC-62, DU-145, SK-MEL-2, SK-
OV-3 and M14) showing a range of sensitivities to SJG-136 were selected from the 
NCI’s 60-cell line panel and exposed to SJG-136 at concentrations close to peak plasma 
concentrations in the mouse.  Nuclear-specific staining was observed in all cell lines 
demonstrating cellular penetration and localisation within the nucleus, the proposed site 
of drug action. IC50 concentrations for selected cell lines were determined using the 
MTT dye conversion assay. These ranged from 4.2 - 29.8 nM for a 1 h drug exposure. 
FACS studies indicated that at these concentrations, SJG-136 caused a G2/M block in 
the cell cycle for all selected cell lines. 
Further pharmacokinetic and pharmacodynamic studies are in progress to monitor drug 
concentrations and DNA crosslinking in solid tumours in in vivo models using 
therapeutic concentrations. These data will help in the clinical development of SJG-136. 
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Pyrrolobenzodiazepine-polyamide libraries: synthesis and DNA binding selectivity 
 
G. Wells*, T. Gale*†, A. Hardy*†, A. Hamaguchi†, J. A. Hartley†‡, G. P. Wilkinson§, 
P. M. Loadman§, T. Jenkins§, P. W. Howard*† and D. E. Thurston*† 
*CRUK Gene Targeted Drug Design Research Group, The School of Pharmacy, 29–39 
Brunswick Square, London, WC1N 1AX; †Spirogen Ltd, 29–39 Brunswick Square, 
London, WC1N 1AX; ‡CRUK Drug-DNA Interactions Research Group, Department of 
Oncology, University College London, London, W1W 7BS and §CRUK Cancer 
Research Unit & Yorkshire Cancer Research Laboratory of Drug Design, University of 
Bradford, All Saints Road, Bradford, UK 
 
The ability to modify gene transcription by inhibiting the activity of specific 
transcription factors or blocking transcription in the coding region of a gene has 
potential applications in the treatment of cancer. A sufficient number of base pairs must 
be recognised in order to obtain a specific effect. At the molecular level the minor-
groove binding pyrrolobenzodiazepine (PBDs) recognise and covalently bind to Pu-G-
Pu sequences (Thurston 1993; Hardy et al 2003), whereas heterocyclic polyamide 
(HPAs) interact reversibly with a variety of sequences depending on the nature of the 
heterocycle and the binding stoichiometry. The aim of this work is to synthesise hybrid 
molecules that combine the recognition characteristics of both molecules. Solution 
phase peptide coupling methods have been used to synthesise a series of PBD-HPA 
hybrids with polyamide components (N-methylpyrroles) of varying length with a long-
term view of studying the effect of polyamide length on DNA binding-site size and 
selectivity, binding affinity, cellular penetration and in-vitro cytotoxicity. GW6 consists 
of a PBD attached to three N-methylpyrrole heterocycles. Footprinting studies have 
shown that the molecule binds to a GATAATC sequence suggesting that it possesses 
DNA-recognition properties characteristic of both the PBD and HPA portions of the 
molecule. Using fluorescence microscopy we have shown that, unlike Dervan hairpin 
polyamides (Belitsky et al 2002) that bind to a similar number of base pairs, GW6 
penetrates the nucleus of cultured MCF-7 cells. It also has in-vitro cytotoxic properties 
with a mean GI50 of 5 10 n M in the NCI’s 60 cell line screen. Synthesis of the PBD-
HPA conjugates has been successfully transferred to solid phase methodology using a 
variety of heterocyclic building blocks, and has been extended to the preparation of 
PBD-heterocycle combinatorial libraries. These libraries have been synthesised in 
conjunction with a peptide coding strand to enable identification of an individual DNA-
binding molecule. A 100 000 member library has been screened against a number of 
rhodamine labelled gene fragments including one taken form bcr-abl and a number of 
hits have been obtained. Edman degradation of the tag sequences has revealed the 
structures of 10 lead molecules which are currently being resynthesized for further 
biological evaluation.  
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